Document:

Lease Agreement for Aventis Northern NJ Building

 EXHIBIT 10.104 
  
 LEASE AGREEMENT FOR AVENTIS NORTHERN NJ BUILDING 

 MEMORANDUM OF LEASE 
  
 Prepared by: 
 Ted Zangari, Esq. 
 Sills Cummis Radin Tischman Epstein & Gross, PA. 
 One Riverfront Plaza 
 Newark, New Jersey 07102 
  
 (The
Above Space for Recorder’s Use Only) 
  
 MEMORANDUM OF
LEASE 
  
 THIS MEMORANDUM OF LEASE, made as of
December 22, 2000, by and between BRIDGEWATER HINES DEVELOPMENT LLC whose address is c/o Hines Interests Limited Partnership, 885 Third Avenue, Suite 2700, New York, NY 10022 (“Landlord”) and AVENTIS PHARMACEUTICALS INC., whose
address is Route 202-206, Post Office Box 6800, Bridgewater, New Jersey 08807-0800 (“Tenant”). 
  
 1. Landlord has leased to Tenant pursuant to the terms and conditions of an Agreement of Lease dated as of December     , 2000
(the “Lease”) a portion (the “Premises”) of that certain office building known as Bridgewater Crossing 1, to be constructed on that certain parcel of land (the “Land”) designated as Lot 4 in Block 552 on the Tax
Map of Bridgewater Township, Somerset County, New Jersey, together with all easements and appurtenances thereto, and located at 200-400 Crossing Boulevard, Bridgewater, New Jersey, as described on Exhibit A-1 attached hereto.

  
 2. The terms and conditions of the Lease are incorporated
herein as though set forth in full, whereby Tenant may have and hold the Premises together with any and all rights, benefits, privileges and easements, now or hereafter appurtenant thereto, at the rental and upon the terms and conditions therein
stated, for an initial term of approximately ten (10) years (the “Initial Term”). 
  
 3. Under the terms of the Lease, the Initial Term may be extended for two (2) separate and additional periods of five (5) years each after the expiration of the Initial Term (each such additional five-year period is
hereinafter referred to as a “Renewal Term”). Each Renewal Term shall be subject to all the terms and conditions of the Lease as if the Initial Term originally included such Renewal Term. 
  

 1 

 4. This Memorandum of Lease is executed for the purpose of recordation in order to give notice of all of
the terms, provisions and conditions of the Lease (including, without limitation, provisions set forth therein regarding Tenant’s right to use [and to permit Tenant’s employees, agents and contractors to use] certain common areas of the
Land [such as, without limitation, the parking facilities appurtenant to the said office building] as well as certain other common areas of the Land. 
  
 5. In addition to those terms referred to hereinabove, the Lease contains numerous other terms, covenants and conditions which likewise affect not only
the Premises but also the Land, and notice is hereby given that reference should be had to the Lease directly with respect to the details of such terms, covenants and conditions. The Lease and exhibits thereto are hereby incorporated by reference in
this Memorandum of Lease and the parties hereby ratify and confirm the Lease as if said Lease were being re-executed by them and recorded. In the event of any conflict between the provisions of this instrument and the Lease, the provisions of the
Lease shall control. 
  
 6. Capitalized terms not defined herein
shall have the same meaning as set forth in the Lease. 
  
 7. This
Memorandum of Lease may be executed in counterparts, each of which shall be deemed an original and all of which shall he considered one and the same agreement. 
  

IN WITNESS WHEREOF, the parties hereto have executed this Memorandum of Lease as of the day and year first above written. 
  

	 	 	 	 	 LANDLORD:

			
	WITNESS:	 	 	 	 BRIDGEWATER HINES DEVELOPMENT LLC

				
	 /s/ Renee Khan

	 	 	 	 By:
	 	 /s/ Tom (Illegible)

	 	 	 	 	 	 	 Name:
	 	 
	 	 	 	 	 	 	 Title:
	 	 

  

			
	 	 	 	 	 TENANT:

			
	ATTEST:	 	 	 	 AVENTIS PHARMACEUTICALS INC.

				
	  

	 	 	 	 By:
	 	  

	 	 	 	 	 	 	 Name:
	 	 
	 	 	 	 	 	 	 Title:
	 	 

  
  

 2 

 IN WITNESS WHEREOF, the parties hereto have executed this Memorandum of Lease as of the day and
year first above written. 
  

	 	 	 	 	 LANDLORD:

			
	WITNESS:	 	 	 	 BRIDGEWATER HINES DEVELOPMENT LLC

				
	  

	 	 	 	 By:
	 	  

	 	 	 	 	 	 	 Name:
	 	 
	 	 	 	 	 	 	 Title:
	 	 

  

			
	 	 	 	 	 TENANT:

			
	ATTEST:	 	 	 	 AVENTIS PHARMACEUTICALS INC.

				
	 /s/ Owen K. Ball, Jr.

	 	 	 	 By:
	 	 /s/ Gerald P. Belle

	 	 	 	 	 	 	 Name: Gerald P. Belle

	 	 	 	 	 	 	 Title: President

  
  
  

 3 

 AGREEMENT OF LEASE 
  
 BRIDGEWATER HINES DEVELOPMENT LLC 
  

as Landlord 
  
 - and - 
  
 AVENTIS PHARMACEUTICALS INC. 
  
 as Tenant 
  
  

	 Premises:
	  	 BRIDGEWATER CROSSING 1

	 	  	 200 Crossing Boulevard

	 	  	 Bridgewater, New Jersey

 TABLE OF CONTENTS 
  

	 	  	 	  	Page

	 ARTICLE 1. DEFINITIONS
	  	1
	 ARTICLE 2. DEMISED PREMISES
	  	5
	 2.1.
	  	 Leasing of Demised Premises
	  	5
	 2.2.
	  	 Remeasurement of Demised Premises
	  	6
	 ARTICLE 3. USE
	  	6
	 3.1.
	  	 Permitted Use
	  	6
	 3.2.
	  	 Zoning, Etc.
	  	7
	 ARTICLE 4. TERM AND POSSESSION
	  	7
	 4.1.
	  	 Term
	  	7
	 4.2.
	  	 Late Delivery
	  	7
	 4.3.
	  	 Commencement Date Memorandum; Memorandum of Lease
	  	8
	 4.4.
	  	 Condition of Demised Premises
	  	8
	 ARTICLE 5. RENT
	  	8
	 5.1.
	  	 Net Base Rent
	  	8
	 5.2.
	  	 Additional Rent
	  	9
	 5.3.
	  	 Operating Expenses
	  	9
	 5.4.
	  	 Management Fee
	  	10
	 5.5.
	  	 Taxes
	  	11
	 5.6.
	  	 Tenant’s Proportionate Share
	  	12
	 5.7.
	  	 Occupancy Adjustment
	  	13
	 5.8.
	  	 Complex Allocation
	  	13
	 5.9.
	  	 Survival of Additional Rent Obligations
	  	14
	 5.10.
	  	 Time of Payment: Late Fee; Default Interest
	  	14
	 5.11.
	  	 Rent Tax
	  	15
	 5.12.
	  	 Landlord’s Remedies
	  	15
	 5.13.
	  	 Payment of Rent
	  	15
	ARTICLE 6. LANDLORD’S BASE BUILDING WORK; TENANT IMPROVEMENTS AND EARLY ACCESS, MAINTENANCE AND REPAIRS	  	15
	 6.1.
	  	 Landlord’s Base Building Work
	  	15
	 6.2.
	  	 Tenant Improvements
	  	15
	 6.3.
	  	 Tenant’s Early Access
	  	16
	 6.4.
	  	 Maintenance and Repairs by Tenant
	  	16
	 6.5.
	  	 Maintenance and Repairs by Landlord
	  	17
	 6.6.
	  	 Landlord’s Warranty
	  	17
	 6.7.
	  	 Compliance with Laws; Americans with Disabilities Act of 1990
	  	17
	 6.8.
	  	 Cafeteria
	  	17
	 ARTICLE 7. ALTERATIONS BY TENANT AND TRADE FIXTURES
	  	18
	 7.1.
	  	 Alterations
	  	18
	 7.2.
	  	 No Liens
	  	18
	 7.3.
	  	 Labor Harmony
	  	19
	 7.4.
	  	 Expiration of Term
	  	19

  

 i 

	 7.5.
	  	 Trade Fixtures
	  	19
	 ARTICLE 8. LANDLORD’S SERVICES
	  	19
	 8.1.
	  	 Landlord’s Services
	  	19
	 8.2.
	  	 Tenant’s Access
	  	22
	 8.3.
	  	 Tenant’s Security System
	  	22
	 8.4.
	  	 Intentionally Omitted
	  	22
	 8.5.
	  	 Building Management
	  	22
	 8.6.
	  	 Designated Providers of Certain Building Services
	  	22
	 8.7.
	  	 Service Providers for Tenant’s Systems
	  	22
	 ARTICLE 9. ELECTRICITY
	  	23
	 9.1.
	  	 Intentionally Omitted.
	  	23
	 9.2.
	  	 Electrical Usage
	  	23
	 9.3.
	  	 Tenant Electrical Installations
	  	23
	 ARTICLE 10. INTENTIONALLY OMITTED
	  	 23

	 ARTICLE 11. RIGHTS RESERVED TO LANDLORD
	  	23
	 11.1.
	  	 Reserved Rights
	  	23
	 ARTICLE 12. COVENANT OF QUIET ENJOYMENT
	  	24
	 12.1.
	  	 Quiet Enjoyment
	  	24
	 ARTICLE 13. WAIVER OF SUBROGATION, INDEMNIFICATION AND INSURANCE
	  	24
	 13.1.
	  	 Tenant’s Indemnity
	  	24
	 13.2.
	  	 Tenant’s Insurance
	  	24
	 13.3.
	  	 Landlord’s Indemnity
	  	25
	 13.4.
	  	 Landlord’s Insurance
	  	25
	 13.5.
	  	 Waiver of Subrogation
	  	26
	 13.6.
	  	 Limitations on Indemnities
	  	26
	 13.7.
	  	 Survival
	  	27
	 ARTICLE 14. MUTUAL RELEASES
	  	27
	 14.1.
	  	 Limitation of Liability of Landlord
	  	27
	 14.2.
	  	 Limitation on Liability of Tenant
	  	27
	 ARTICLE 15. CONDEMNATION
	  	28
	 15.1.
	  	 Waiver of Claims
	  	28
	 15.2.
	  	 Whole or Partial Condemnation
	  	28
	 ARTICLE 16. DAMAGE OR DESTRUCTION
	  	28
	 16.1.
	  	 Casualty
	  	28
	 16.2.
	  	 Waiver of Statutory Remedies
	  	29
	 16.3.
	  	 Governmental Approvals
	  	30
	 ARTICLE 17. SUBORDINATION
	  	30
	 17.1.
	  	 Subordination of Lease
	  	30
	 17.2.
	  	 Attornment
	  	30
	 17.3.
	  	 Acknowledgement by Tenant
	  	30
	 17.4
	  	 Non-Disturbance Protection
	  	30
	 ARTICLE 18. ASSIGNMENT AND SUBLETTING
	  	31
	 18.1.
	  	 Restrictions Upon Transfer
	  	31
	 18.2.
	  	 Landlord’s Consent Recapture
	  	32
	 18.3.
	  	 Approval of Sublease or Assignment Requiring Consent
	  	33
	 18.4
	  	 Transfers to Related/Successor Entities
	  	34

  

 ii 

	 18.5.
	  	 Continuing Liability
	  	35
	 18.6.
	  	 No Waiver
	  	35
	 18.7.
	  	 Intentionally Omitted
	  	36
	 18.8.
	  	 Restrictions upon Rental Arrangements
	  	36
	 18.9.
	  	 Intentionally Omitted
	  	36
	 18.10.
	  	 Further Subletting and Assignment
	  	36
	 ARTICLE 19. RULES AND REGULATIONS
	  	36
	 19.1.
	  	 Rules and Regulations
	  	36
	 ARTICLE 20. PERFORMANCE OF OTHER PARTY’S COVENANTS
	  	36
	 20.1.
	  	 Landlord’s Right to Perform
	  	36
	 20.2.
	  	 Tenant’s Right to Perform
	  	37
	 ARTICLE 21. AIR AND LIGHT
	  	37
	 21.1.
	  	 Air and Light Rights
	  	37
	 ARTICLE 22. NOTICES
	  	37
	 22.1.
	  	 Notices to Tenant
	  	37
	 22.2.
	  	 Notices to Landlord
	  	38
	 22.3.
	  	 Effectiveness of Notices
	  	39
	 ARTICLE 23. INTENTIONALLY OMITTED
	  	39
	 ARTICLE 24. EVENTS OF DEFAULT
	  	39
	 24.1
	  	 Matters Constituting a Default
	  	39
	 ARTICLE 25. RIGHTS OF LANDLORD UPON DEFAULT BY TENANT
	  	40
	 25.1.
	  	 Landlord’s Remedies
	  	40
	 25.2.
	  	 Remedies Cumulative
	  	42
	 25.3.
	  	 No Waiver
	  	42
	 25.4.
	  	 Payments to Landlord After Default
	  	42
	 25.5.
	  	 Tenant’s Waivers
	  	42
	 25.6
	  	 Mitigation of Damages
	  	43
	 ARTICLE 26. ACCESS
	  	43
	 26.1.
	  	 Landlord’s Entry
	  	43
	 ARTICLE 27. CUSTOM AND USAGE PRESUMPTION OF CONSTRUCTION
	  	44
	 27.1.
	  	 Enforcement of Lease Provisions
	  	44
	 27.2.
	  	 Presumption of Construction
	  	44
	 ARTICLE 28. SCOPE AND INTERPRETATION OF AGREEMENT
	  	44
	 28.1.
	  	 Sole Agreement: Governing Law
	  	44
	 ARTICLE 29. CAPTIONS
	  	44
	 29.1.
	  	 Captions
	  	44
	 ARTICLE 30. SEVERABILITY
	  	44
	 30.1.
	  	 Enforcement of Remaining Provisions
	  	44
	 ARTICLE 31. PARTIES, SUCCESSORS AND ASSIGNS
	  	44
	 31.1.
	  	 Definition Tenant
	  	44
	 31.2.
	  	 Definition of Landlord
	  	45
	 31.3.
	  	 Extent of Landlord’s Liability
	  	45
	 31.4.
	  	 Successors and Assigns
	  	45
	 31.5
	  	 No Personal Liability
	  	45
	 ARTICLE 32. PARKING PRIVILEGES
	  	45
	 32.1.
	  	 Parking Allocation
	  	45

  

 iii 

	 32.2.
	  	 Designation of Visitor Parking
	  	46
	 ARTICLE 33. SURRENDER OF DEMISED PREMISES
	  	46
	 33.1.
	  	 Tenant’s Obligations upon Surrender
	  	46
	 3.2
	  	 Holdover
	  	46
	 ARTICLE 34. BROKERS
	  	47
	 34.1.
	  	 Tenant’s Representation
	  	47
	 34.2.
	  	 Landlord’s Representation
	  	47
	 34.3.
	  	 Commissions
	  	47
	 ARTICLE 35. SIGNAGE AND FIXTURES
	  	47
	 35.1.
	  	 Signs
	  	47
	 35.2.
	  	 Tenant’s Equipment and Fixtures
	  	48
	 ARTICLE 36. FORCE MAJEURE
	  	49
	 36.1.
	  	 Effect of Excusable Delay
	  	49
	 ARTICLE 37. COMPLIANCE WITH ENVIRONMENTAL LAWS
	  	49
	 37.1.
	  	 Tenant’s Compliance
	  	49
	 37.2.
	  	 Obligations under ISRA
	  	49
	 37.3.
	  	 No Hazardous Substances
	  	49
	 37.4.
	  	 Indemnity for Environmental Matters
	  	50
	 37.5
	  	 Existing Environmental Conditions
	  	50
	 ARTICLE 38. ESTOPPEL CERTIFICATES
	  	50
	 38.1.
	  	 Delivery of Estoppel Certificates to Tenant
	  	50
	 38.2.
	  	 Delivery of Estoppel Certificates by Landlord
	  	50
	 ARTICLE 39. WAIVER OF JURY TRIAL
	  	51
	 39.1.
	  	 Waiver by Landlord and Tenant
	  	51
	 ARTICLE 40. TENANT’S ACCESS RIGHTS
	  	51
	 40.1
	  	 Roof Rights
	  	51
	 40.2
	  	 Conduit Rights
	  	51
	 40.3
	  	 Loading Dock Rights
	  	51
	 ARTICLE 41. SUBMISSION TO TENANT; LEASE COUNTERPARTS
	  	52
	 41.1.
	  	 Non-Binding Nature
	  	52
	 41.2.
	  	 Tenant’s Option to Renew
	  	52
	 ARTICLE 42. RENEWAL OPTION
	  	52
	 42.1.
	  	 Tenant’s Option to Review
	  	52
	 ARTICLE 43. SALE OF BUILDING
	  	53
	 43.1.
	  	 Sale of Building
	  	53
	 ARTICLE 44. LEASE GUARANTY
	  	54
	 44.1.
	  	 Lease Guaranty
	  	54
	 ARTICLE 45. ARBITRATION
	  	54

  
  

 iv 

 AGREEMENT OF LEASE 
  
 THIS LEASE, made this 22nd day of December, 2000, by and between BRIDGEWATER HINES DEVELOPMENT LLC whose address is c/o
Hines Interests Limited Partnership, 885 Third Avenue, Suite 2700, New York, New York 10022 (“Landlord”) and AVENTIS PHARMACEUTICALS INC., whose address is Route 202-206, Post Office Box 6800, Bridgewater, New Jersey 08807-0800
(“Tenant”). 
  
 ARTICLE 1. DEFINITIONS 

 
 For all purposes of this Lease and all agreements supplemental thereto or
modifying this Lease, the following terms shall have the meanings herein specified: 
  
 “Additional Rent” shall mean all amounts payable by Tenant under this Lease, other than the payment of Net Base Rent, including without limitation, the Recurring Additional Rent Items set forth in
Section 5.2 of this Lease. 
  
 “Adjacent
Building” shall mean the office building known as Bridgewater Crossing II, to be constructed on the Land (other than the Property) at 400 Crossing Boulevard, Bridgewater, New Jersey. 
  
 “Affiliate” shall mean with respect to any person or entity
any other person or entity that controls, is controlled by or under common control with the first such person or entity (with “control” meaning the ownership of more than fifty percent (50%) of the voting securities or equity interests of
an entity or the power to otherwise direct an entity’s business affairs). 
  
 “Brokers” shall mean Landlord’s Broker and Tenant’s Broker. 
  
 “Building” shall mean the office building known as Bridgewater Crossing I to be constructed on the Land at 200 Crossing Boulevard,
Bridgewater, New Jersey. 
  
 “Building Holidays”
shall mean New Year’s Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and Christmas Day, as each of said holidays are celebrated in the State of New Jersey. In addition to the above denominated days, holidays shall also include
days prior or subsequent to the enumerated holidays such as the Friday after Thanksgiving; Friday, when Christmas falls on a Thursday; etc. In addition, if any holiday falls on a weekend and is celebrated by the State of New Jersey or Federal
Government on a weekday, such weekday shall also be deemed a holiday hereunder. 
  
 “Business Hours” shall mean 7:00 am. to 6:00 p.m. on Mondays through Fridays and 9:00 am to 1:00 p.m. on Saturdays, excluding Building Holidays. 
  
 “Commencement Date” shall mean the earlier of (i)
Substantial Completion of the Demised Premises or (ii) such earlier date as Tenant takes possession or commences use of the Demised Premises for any purpose, other than Tenant’s Early Access, as set forth in Section 6.3 hereof. 
  

 1 

 “Common Area” or “Common Areas” shall mean the Interior Common Areas
and the Exterior Common Areas. 
  
 “Complex”
shall mean the Land, Common Areas and improvements thereon on which has been approved the development of a two (2) building office complex. In the event Landlord subdivides the Land following the execution of this Lease, then, at Landlord’s
option, “Complex” shall have the same meaning as “Property.” 
  
 “Default” shall have the meaning given such term in Section 24.1 of this Lease. 
  
 “Default Rate” shall have the meaning given such term in Section 25.4 of this Lease. 
  
 “Demised Premises” shall mean all of the rentable area of
the Building, which the Landlord and Tenant have agreed shall consist of approximately 297,379 rentable square feet of office space as shown on the floor plans of the Building annexed hereto as Exhibit “A” and made a part hereof,
subject, however, to a confirmatory adjustment of such rentable square footage as provided in Section 2.2 below. 
  
 “Designated Provider” shall have the meaning given such term in Section 8.6 of this Lease. 
  
 “Excusable Delay” shall mean a delay actually caused by
governmental action or lack thereof, shortages or unavailability of materials and/or supplies, labor disputes, strikes, slowdowns, job actions, picketing, secondary boycotts, fire or other casualty, delays in transportation, acts of God, requests of
any governmental agencies or authorities, acts of declared or undeclared war, public disorder, riot or civil commotion, or by anything else beyond the reasonable control of Landlord (when applied to an obligation of Landlord) or of Tenant (when
applied to an obligation of Tenant); provided, however, in order for a party to claim an Excusable Delay delayed the timely fulfillment of such party’s obligations hereunder, such party must provide notice to the other party within five (5)
business days after discovering the Excusable Delay, which notice shall specify the delay and the anticipated impact on the fulfillment of such party’s obligations. 
  
 “Exterior Common Area” or Exterior Common Areas” shall mean all areas, structures, parking areas,
access driveways, roadways, sidewalks, plazas, landscaped areas, traffic lights, storm drainage facilities, sanitary sewer, domestic and fire water systems, fire protection installations, electric power and telephone cables and lines and other
utility connections, facilities and other improvements (above and below ground) including, without limitation, the helipad to be constructed by Landlord, which now exist or hereafter are constructed on the Complex for use in common by Landlord,
Tenant and other tenants located in the Complex. 
  
 “Hazardous Substances” shall mean any “hazardous chemical,” “hazardous substance,” waste or similar term as defined, listed, regulated, classified or identified in the Comprehensive Environmental
Responsibility Compensation and Liability Act, as amended (42 U.S.C. 9601, et seq.), the New Jersey Industrial Site Recovery Act, as amended (N.J.S.A. l3:lK-6 et seq.), the New Jersey Spill Compensation and Control
Act, as amended (N.J.S.A. 58:l0-23.11b, et seq.), any rules or regulations promulgated thereunder, or in any other present or future applicable Federal, State or local law, rule, regulation or ordinance dealing with the protection of
human 

  

 2 

 
health and safety or the environment. “Hazardous Substances” shall include, without limitation, petroleum and petroleum-based products and waste or
any mixture thereof. 
  
 “Interior Common Area” or
“Interior Common Areas” shall mean those areas of the Building devoted to corridors, elevator foyers, rest rooms, mechanical rooms, janitorial closets, electrical and telephone closets, vending areas, and lobby areas (whether at ground
level or otherwise), the property management office (consisting of not more than one thousand (l,000) rentable square feet), and other similar facilities provided for the common use or benefit of tenants generally and/or the public. 
  
 “Land” shall mean the parcel of land designated as Lot 4 in
Block 552 on the Tax Map of Bridgewater Township, Somerset County, New Jersey, together with all easements and appurtenances thereto, and located at 200-400 Crossing Boulevard, Bridgewater, New Jersey, as described on Exhibit A-1 attached
hereto. In the event Landlord subdivides the Land following the execution of this Lease, then, at Landlord’s option, “Land” shall mean only the subdivided portion thereof on which the Building is located. Any such subdivision of the
Land shall be substantially as depicted on Exhibit A-2 attached hereto. 
  
 “Landlord’s Broker” shall mean Insignia/ESG. 
  
 “Landlord’s Base Building Work” shall have the meaning given such term in the Work Letter attached hereto as Exhibit
“B”. 
  
 “Lease” or “this
Lease” consists of this Agreement of Lease and Exhibits “A” through “G” attached hereto and made a part hereof. 
  
 “Lease Year” shall mean each calendar year during the Term hereof, subject to Section 5.6(a) hereof. 
  
 “Landlord’s Estimate” shall have the meaning given such
term in Section 5.6 of this Lease. 
  
 “Legal
Requirements” shall mean all federal, state and municipal laws, ordinances, rules, regulations, orders and recommendations issued by any governmental authority, permits or statements of occupancy, all requirements and recommendations of the
Board of Fire Underwriters and any insurance organizations or associations and/or companies, and all covenants, conditions and restrictions of record (collectively, “Legal Requirements”). With respect to the covenants, conditions and
restrictions of record as of the date hereof, Landlord agrees that it shall not amend or modify same (or cause same to be amended or modified), to the extent Landlord has discretion under applicable Legal Requirements, such that Tenant’s use or
occupancy of the Demised Premises as provided in this Lease is materially and adversely impaired thereby or such that Tenant’s monetary obligations are increased thereby. In addition, Landlord agrees that it shall not enter into a future
restriction of record, to the extent Landlord has discretion under applicable Legal Requirements, which would have the effect of materially and adversely impairing Tenant’s use or occupancy of the Demised Premises or which would have the effect
of increasing Tenant’s monetary obligations hereunder. 
  

 3 

 “Net Base Rent” shall mean the fixed rental payable pursuant to Section 5.1 of this
Lease. 
  
 “Operating Expenses” shall have the
meaning given such term in Section 5.3 of this Lease. 
  
 “Property” shall mean collectively the Land attributable to 200 Crossing Boulevard (initially, as depicted on Exhibit A-2 attached hereto) only, and the Building, the Interior Common Areas of the Building, the
Exterior Common Areas thereon, and all other improvements now or hereafter located thereon. 
  
 “Qualified Appraiser” shall have the meaning given such term in Section 42.1 of this Lease. 
  
 “Recurring Additional Rent Items” shall have the meaning given such term in Section 5.2 of this Lease. 
  
 “Related Entity” shall have the meaning given such term in
Section 18.4 of this Lease. 
  
 “Related Lease”
shall mean that certain Agreement of Lease dated of even date herewith, by and between Landlord and Tenant for 400 Crossing Boulevard, Bridgewater, New Jersey. 
  

“Rent” shall mean Net Base Rent and Additional Rent (including, without limitation, Recurring Additional Rent Items). 
  
 “Severe Excusable Delay” shall mean a delay actually caused
by (i) any event of Excusable Delay caused by acts of God which hinders the performance of Landlord’s Base Building Work and/or the Tenant Improvements for more than thirty (30) days, (ii) any event of Excusable Delay caused by labor strikes,
labor shortages, labor slowdowns, job actions, picketing or secondary boycotts which hinders the performance of Landlord’s Base Building Work and/or the Tenant Improvements for more than forty-five (45) days, or (iii) any other event of
Excusable Delay (regardless of how long same hinders the performance of Landlord’s Base Building Work and/or the Tenant Improvements); provided, however, in order for Landlord to claim a Severe Excusable Delay delayed the timely fulfillment of
Landlord’s obligations hereunder, Landlord must provide notice to Tenant within five (5) business days after discovering the Excusable Delay, which notice shall specify the delay and the anticipated impact on the fulfillment of Landlord’s
obligations. 
  
 “Substantial Completion” shall
mean the later of: (i) the date upon which Landlord’s Base Building Work and the Tenant Improvements are Substantially Completed in conformity with the Work Letter, and (ii) the date upon which Landlord has obtained a temporary or permanent
certificate of occupancy (or local equivalent) in connection with such work. As used herein, “Substantially Completed” shall mean with respect to the Demised Premises when the Landlord’s Base Building Work and Tenant Improvements are
substantially completed except for details or construction, decoration and mechanical adjustments which are minor in character, the non-completion of which will not interfere (other than to a de minimis extent) with Tenant’s occupancy of the
Demised Premises for the Permitted Use. 
  

 4 

 “Successor Entity” shall have the inclining given such term in Section 18.4 of this
Lease. 
  
 “Taxes” shall have the meaning given
such term in Section 5.5 of this Lease. 
  
 “Tenant
Delay” shall mean any act or omission of any nature by Tenant or Tenant’s Visitors which actually delays the Substantial Completion of Landlord’s Base Building Work or Tenant Improvements, actually delays the construction of any
other improvements in the Building or Complex necessary for Tenant’s occupancy of the Demised Premises, or actually delays the issuance of a temporary or permanent certificate of occupancy for the Demised Premises including without limitation,
any failure by Tenant to submit plans when due, any failure or delay by Tenant in supplying information or giving authorizations or approvals, any delays resulting from changes requested by Tenant to the Landlord’s Base Building Work or the
Tenant Improvements; provided, however, in order for Landlord to claim a Tenant Delay delayed the Substantial Completion of Landlord’s Base Building Work or Tenant Improvements. Landlord must provide notice to Tenant within five (5) business
days after discovering the Tenant Delay, which notice shall specify the delay and the anticipated impact on the Substantial Completion of Landlord’s Base Building Work or Tenant Improvements. 
  
 “Tenant Improvements” shall have the meaning set forth in
the Work Letter attached hereto as Exhibit “B”. 
  
 “Tenant’s Allowance” shall have the meaning given such term in Section 6.2 of this Lease. 
  
 “Tenant’s Broker” shall mean The Staubach Company of New Jersey, LLC 
  
 “Tenant’s Proportionate Share” shall mean 100%. 
  
 “Tenant’s Visitors” shall mean persons invited by
Tenant into the Demised Premises as guests or doing lawful business with Tenant including, without limitation, Tenant’s agents, servants, employees, contractors, invitees and licensees. 
  
 “Term”, sometimes also referred to as the “Lease
Term”, shall mean the time period commencing on the Commencement Date and terminating on the Termination Date. 
  
 “Termination Date” shall mean the earlier to occur of (i) the last day of the month in which the eleventh (11th) anniversary of the
Commencement Date occurs or (ii) the last day of the month in which the tenth (10th) anniversary of the “Stage III Commencement Date” under the Related Lease occurs, subject to extension pursuant to Section 33.2 hereof. 
  
 “Work Letter” shall mean the document which governs the
Landlord’s Base Building Work and the Tenant Improvements referred to in Article 6 of this Lease and attached to this Lease as Exhibit “B”. 
  
 ARTICLE 2. DEMISED PREMISES 
  

2.1. Leasing of Demised Premises. Landlord hereby leases to Tenant and Tenant hereby leases from Landlord, for the Term and upon the terms,
conditions, covenants and 

  

 5 

 
agreements herein provided, the Demised Premises to be used by Tenant solely for those uses permitted under Article 3 hereof. Tenant and Tenant’s
Visitors shall have the right to use, in common with Landlord and any other tenants of the Building, at no additional charge, the Common Areas and shall have the right to use, at no additional charge, on an exclusive basis, the parking spaces
located on the Property, as more particularly described in Article 32. 
  
 2.2. Remeasurement of Demised Premises. (a) Within sixty (60) days after Substantial Completion of the Demised Premises, Tenant may determine whether the “as built” rentable square footage of the Demised Premises
dìffers from that set forth in the definition of “Demised Premises.” Tenant shall give Landlord written notice of this calculation and, if Landlord disagrees with Tenant’s measurement, Landlord and Tenant shall mutually agree
on the selection of an engineer or architect who will make a final determination thereof, whose cost shall be shared equally between Landlord and Tenant. If the “as built” rentable square footage of the Demised Premises is less than or
more than that set forth in the definition of “Demised Premises,” (a) Rent and any other calculations based upon the rentable square footage of the Demised Premises shall be adjusted accordingly, and (b) Landlord and Tenant shall execute
and deliver an amendment to this Lease reflecting this decrease or increase, as applicable. 
  
 (b) In computing the rentable square footage of the Demised Premises, the following shall apply: 
  
 (i) With respect to an entire floor demised to a single tenant, the rentable area thereof shall be equal to the product of the usable square
footage of the entire floor multiplied by 1.111. No deduction shall be made for columns in the Building; 
  
 (ii) With respect to any portion of the Building which is less than an entire floor, the rentable square footage thereof shall be equal to the usable
square footage of such portion of the Building, multiplied by 1.111. No deduction shall he made for columns in the Building; and 
  
 (iii) The usable square footage of any portion of the Building shall be computed by using the “Standard Method for Measuring Floor Area in Office
Buildings,” promulgated by the Building owners and Managers Association International (ANSI Z65.1-1996). 
  
 ARTICLE 3. USE 
  
 3.1. Permitted Use. The Demised Premises shall be used and occupied only for the Permitted Use (as hereinafter defined) and for no other purposes. For purposes hereof, the term “Permitted Use” shall
mean general, executive and administrative offices in keeping with the standards and practices customarily applied to similar first class office buildings in the Somerset County, New Jersey area, which may include, on an incidental basis,
non-laboratory or so-called “dry” research and development as well as all uses customarily ancillary and incidental thereto, including without limitation for a cafeteria with general and private dining rooms and for a fitness center,
credit union branch, automatic teller machine kiosk, company store, nurse’s office and travel agency office, each for the exclusive use by Tenant’s employees (subject to Section 7.1 in the event any such items are not part of
Landlord’s Base Building Work or the Tenant 

  

 6 

 
Improvements); provided, however, that “Permitted Use” shall not include: (i) offices of any agency or bureau of the United States or any state or
political subdivision thereof; (ii) offices or agencies of any foreign government or political subdivision thereof; (iii) offices of any health care professionals or service organization, except for administrative offices where no diagnostic,
treatment or laboratory services are performed, except as otherwise provided in the last sentence of this Section 3.1; (iv) schools or other training facilities that are not ancillary to executive, professional or corporate administrative office
use; (v) retail or restaurant uses, other than the aforementioned cafeteria; (vi) intentionally omitted; (vii) offices at which deposits or bills are regularly paid in person by customers, other than the aforementioned credit union branch; and
(viii) personnel agencies, except offices of executive search firms. Notwithstanding the foregoing proviso, in the event that Landlord leases any portion of the Building to a tenant or tenants for any of the uses described in (i) through (viii)
above, such uses shall thereafter be included in the “Permitted Use.” 
  
 3.2. Zoning, Etc. Landlord represents that the zoning district in which the Property is located is the Bridgewater Regional Center Zone and that the Permitted Use for general, executive and administrative
offices is lawfully permitted in such district, but nothing contained herein shall be construed as any representation or warranty by Landlord as to whether the ancillary and incidental uses set forth in Section 3.1 are lawfully permitted in such
district. Landlord represents that, as of the date hereof, it is unaware (without having conducted any inquiry or investigation) of any covenants, conditions or restrictions of record (other than those shown on Schedule B of its title insurance
policy dated May 24, 2000, a copy of which has heretofore been provided to Tenant) that would adversely affect the use of the Building for the Permitted Use and that it has not entered into any such covenant, condition or restriction since May 24,
2000 which would adversely affect the use of the Building for the Permitted Use. 
  
 ARTICLE 4. TERM AND POSSESSION 
  
 4.1. Term. The Lease Term shall commence on the Commencement Date and shall continue until the Termination Date. 
  
 4.2. Late Delivery. (a) If the Commencement Date is delayed because of a Tenant Delay, Tenant shall pay to Landlord on the Commencement Date, as
Additional Rent, the amount of Net Base Rent and Recurring Additional Rent Items for the period that the Commencement Date was delayed due solely to the Tenant Delay. In the event of any dispute between Landlord and Tenant regarding the length of
any alleged Tenant Delay which has not been resolved by the parties prior to the Commencement Date, Landlord’s determination shall be utilized for purposes of calculating the amount of such Additional Rent due on the Commencement Date (subject,
however, to a readjustment by Landlord and Tenant at such time as said dispute is finally resolved, whereupon the amount of any overpayment shall be taken by Tenant as a credit against Net Base Rent and Recurring Additional Rent Items, or if it is
determined that Tenant has underpaid such Additional Rent, then the amount of the underpayment shall be paid to Landlord by Tenant within thirty (30) days after such amount has been so determined). 
  
 (b) Landlord shall exercise its good faith and diligent efforts to cause the
Commencement Date to occur by February 1, 2002. If, despite such good faith and diligent 

  

 7 

 
efforts, the Commencement Date does not occur by May 1, 2002, as such date is extended by one (1) day for each day of Tenant Delay or Excusable Delay, then,
as Tenant’s sole and exclusive remedy for such late delivery, Tenant shall be entitled to an abatement in Net Base Rent commencing on the Commencement Date equal to one (1) day for each one (1) day that the Commencement Date is delayed beyond
May 1, 2002 (extended by Tenant Delay or Excusable Delay as aforesaid), but in no event shall such rent abatement exceed One Million Eight Hundred Twenty-One Thousand Four Hundred Forty-Six and 38/100 ($1,821,446.38) Dollars (i.e., three (3)
months’ Net Base Rent). Furthermore, if the Commencement Date does not occur by July 31, 2002, as such date is extended by one (l) day for each day of Tenant Delay or a Severe Excusable Delay, then, as Tenant’s sole and exclusive remedy
for such late delivery, Tenant may terminate this Lease and the Related Lease upon twenty (20) days’ notice to Landlord, which notice may be given at any time between August 1, 2002 and August 31, 2002 (as such dates may he extended by Tenant
Delay or Severe Excusable Delay as aforesaid), TIME BEING STRICTLY OF THE ESSENCE, and unless the Commencement Date occurs within the aforesaid twenty (20) days, this Lease and the Related Lease shall terminate upon the expiration of said twenty
(20) day period and the parties shall be released from all liabilities or obligations hereunder and under the Related Lease. In the event Tenant elects to terminate this Lease as provided herein, Tenant shall not also be entitled to the rent
abatement (or cash equivalent thereof) provided in the first sentence of this sub-paragraph (b). 
  
 4.3. Commencement Date Memorandum; Memorandum of Lease. The actual Commencement Date shall he evidenced by a “Commencement Date
Memorandum” to be executed by Landlord and Tenant in substantially the form attached hereto as Exhibit “C”. Upon the request of either party following the execution and delivery of this Lease, Landlord and Tenant shall
execute a short form lease or memorandum for recording, which shall be in the form attached as Exhibit G hereto. In no event shall the amount of Net Ease Rent reserved hereunder or other business terms of this Lease be included in any such
short form lease or memorandum. The party requesting such short form or memorandum shall bear the cost and expense of recording same. 
  
 4.4. Condition of Demised Premises. Except as expressly set forth herein, neither Landlord nor Landlord’s agents have made any
representations or promises with respect to the physical condition of the Building, the Land upon which it is erected or the Demised Premises, the leases, expenses of operation or any other matter or thing affecting or related to the Demised
Premises, and no rights, easements or licenses are acquired by Tenant by implication or otherwise except as expressly set forth in the provisions of this Lease. 
  

ARTICLE 5. RENT 
  
 5.1. Net Base Rent. During the Lease Term, Tenant shall pay to Landlord “Net Base Rent” as follows: 
  
 (i) Commencing on the Commencement Date and continuing through and including
the day immediately preceding the fifth (5th) anniversary of the Commencement Date, Tenant shall pay to Landlord Net Base Rent equal to Seven Million, Two Hundred Eighty-Five Thousand Seven Hundred Eighty Five and 50/100 DOLLARS ($7,285,785.50),
which shall be payable in advance in equal monthly installments of Six 

  

 8 

 
Hundred Seven Thousand, One Hundred Forty-Eight and 79/100 DOLLARS ($607,148.79). 
  
 (ii) Commencing on the fifth (5th) anniversary of the Commencement Date and continuing through and including the Termination Date, Tenant shall pay to Landlord Net Base Rent equal to Eight Million, Two Hundred Fifty Two Thousand Two
Hundred Sixty-Seven and 25/100 DOLLARS ($8,252,267.25), which shall be payable in advance in equal monthly installments of Six Hundred Eighty-Seven Thousand, Six Hundred Eighty-Eight and 94/100 DOLLARS ($687,688.94). 
  
 5.2. Additional Rent. In addition to the Net Base Rent to be paid as
herein provided, Tenant shall pay, as Additional Rent, the following “Recurring Additional Rent Items”: (i) the cost of electrical energy consumed by Tenant as provided for in Article 9 herein; (ii) Tenant’s Proportionate Share of
Operating Expenses; and (iii) the Management Fee. 
  
 5.3.
Operating Expenses. Landlord shall be entitled to collect from Tenant as Additional Rent Tenant’s Proportionate Share of Operating Expenses in the manner more particularly set forth in Section 5.6. The term “Operating
Expenses” shall include, without limitation, those costs or expenses paid or incurred by Landlord for operating, maintaining and repairing the Property and the Exterior Common Areas of the Complex, including, by way of example and without
limitation, the cost of electricity for Common Areas including outside and garage lighting, the cost of heating, ventilating and air-conditioning the Building, water, sewer, fuel, window cleaning, janitorial service, elevator maintenance, security,
refuse removal, Taxes (as defined in Section 5.5 below), insurance of all kinds carried by Landlord and applicable to the Property and the Exterior Common Areas of the Complex (including without limitation, fire and extended coverage insurance,
public liability, elevator, workmen’s compensation, boiler and machinery, use and occupancy, health, accident and group life insurance of all employees, and casualty rent insurance), snow removal, maintenance and cleaning of the parking lot,
garage, site driveways and adjacent roadways, all landscape maintenance costs for the Complex, repairs of any kind for which Landlord is not reimbursed, pest control, painting, replacement of worn out mechanical or damaged equipment, uniforms,
equipment rentals or other operating costs paid pursuant to such rentals, building and janitorial supplies, sundries, sales or use tax on supplies or services, wages and salaries of all persons engaged by Landlord in the operation of the Complex,
all costs associated with operating and maintaining a property management office(s) in the Complex, expenses incurred by Landlord, legal and accounting expenses, and any other expense or cost, which, in accordance with generally accepted accounting
principles and the standard management practices for office buildings comparable to the Complex would be considered as an expense of operating, maintaining or repairing the Property and the Exterior Common Areas of the Complex. Landlord agrees to
use commercially reasonable efforts to obtain commercially competitive rates (with respect to the Somerset County, New Jersey market) for the goods and services included within Operating Expenses. 
  
 Operating Expenses may include certain costs or expenditures regarded as
capital costs or expenditures under generally accepted accounting principles, but only to the extent that the same are (i) to install a labor saving, energy saving or other equipment, device or improvement intended by Landlord to reduce Operating
Expenses, but only to the extent that the equipment, device or improvement reduces Operating Expenses, (ii) required to comply with Legal 

  

 9 

 
Requirements that were not applicable to the Property or the Exterior Common Areas of the Complex (as the case may be) as of the Commencement Date, or (iii)
incurred by Landlord for repairs or replacements required or permitted to be made by Landlord hereunder. All capital costs and expenditures permitted to be included in Operating Expenses by the immediately preceding sentence shall be amortized on a
straight time basis (with a per annum interest factor equal to the prime or base rate of Citibank, N.A. or its successor in effect on the date of the expenditure) over the useful life thereof calculated in accordance with generally accepted
accounting principles, as reasonably determined by Landlord, with only the annual amortization amount of such items included in Operating Expenses for each Lease Year (or portion thereof) of such useful life within the Term. 
  
 Notwithstanding the foregoing, Operating Expenses shall not include the
following: (a) depreciation or amortization of the Building, the Landlord’s Base Building Work, the Tenant Improvements or any other improvements made to the Property (except for the amortization of the capital costs and expenses described in
the immediately preceding paragraph of this Section); (b) the cost of performing any item contemplated as part of the Tenant Improvements or otherwise identified as a Landlord obligation under the Work Letter, including, without limitation, the cost
of repairing or replacing any defective or improperly installed item of such work within any applicable warranty period; (c) lease commissions or other costs incurred in leasing or procuring tenants for the Building; (d) principal, interest and
other debt service payments on any indebtedness of Landlord; (e) Taxes assessed during the Term but relating to a period prior to the Commencement Date or after the Termination Date; (f) expenses which are actually reimbursed by insurance or other
tenants; (g) the amount of any refundable deposits; (h) salaries and benefits of executive officers of Landlord, any Affiliate of Landlord or any third party management personnel above the level of building manager; (i) the cost of any work or
service performed for any particular tenant at such tenant’s cost and expense; (j) legal expenses incurred in the preparation of the leases or enforcing the terms of any lease; (k) management fees of any kind (it being understood that Tenant is
paying the Management Fee separately); (i) ground rental payments; (m) any costs or expenditures regarded as capital costs or expenditures under generally accepted accounting principles, excepting only to the extent provided in the immediately
preceding paragraph of this Section; (n) advertising, promotional and marketing fees or expenses for the Building; (o) Landlord’s limited liability company overhead not related to management of the Building; (p) costs of compliance with Legal
Requirements if and to the extent such compliance item was required with respect to the Complex as of the Commencement Date (including, without limitation, compliance costs associated with that certain No Further Action letter described in Section
37.3 below); (q) fines and penalties not as a result of Tenant’s Default under this Lease; (r) tort claims and expenses of the investigation and defense thereof other than as a result of the negligence or willful acts or omissions of Tenant or
Tenant’s Visitors; (s) amounts in excess of fair market rates (with respect to the Somerset County, New Jersey market) in respect of any transaction with, or provision of any item or service by, Landlord or any Affiliate of Landlord; (t) costs
associated with withdrawal from a “multi-employer plan;” (u) personal property or equipment rental costs if the purchase of same would not be includable in Operating Expenses; or (v) the cost of Tenant’s audit pursuant to Section
5.6(e). 
  
 5.4. Management Fee. Landlord shall be entitled
to collect front Tenant as Additional Rent, in the same manner as more particularly set forth in Section 5.6 below, a fixed 

  

 10 

 
management cost recovery charge equal to (a) three percent (3%) of the Tenant’s Net Base Rent for such calendar year, and (b) three percent (3%) of the
Tenant’s Proportionate Share of Operating Expenses allocable to the Property and payable by Tenant as a Recurring Additional Rent Item pursuant to this Article 5 (the sum of which shall be the “Management Fee”). 
  
 5.5. Taxes. (a) Landlord shall he entitled to collect from
Tenant as Additional Rent Tenant’s Proportionate Share of Taxes (as a component of Operating Expenses) in the manner more particularly set forth in Section 5.6. The term “Taxes” shall mean the amount of real estate taxes (or
tax impositions in substitution for real estate taxes), assessments, and any other governmental real estate or ad valorem charge, fee or payment, whether general, special, ordinary or extraordinary which may now or hereafter be levied or
assessed against the Complex (including the Buildings and related improvements). Landlord shall take the benefit of the provisions of any statute or ordinance permitting any assessment to be paid over a period of time, and Tenant shall be obliged to
pay only Tenant’s Proportionate Share of the installments of any such assessment applicable and payable during the Term of this Lease or any renewal hereof, plus any carrying costs or other charges levied by the taxing authority for the
privilege of so paying such assessment over period of time. Taxes shall not include any federal, state or local income, revenue or excise taxes imposed on Landlord or any inheritance, estate, succession, gift, capital stock, franchise, excise,
realty transfer or excess profit taxes (unless, only to the extent, imposed in lieu of Taxes) or any interest or penalties imposed as a result of Landlord’s lateness or failure to pay Taxes when due. 
  
 (b) If Landlord shall receive any tax refund in respect of any tax year,
Landlord shall deduct from such tax refund any expenses incurred in obtaining such tax refund, and out of the remaining balance of such tax refund, Landlord shall credit to Tenant’s Proportionate Share of such refund. Any expenses incurred by
Landlord in contesting the validity or the amount of the assessed valuation of the Complex or of any Taxes for any year to the extent not offset by a tax refund, shall be included as an item of Taxes for the tax year in which such contest shall be
finally determined for the purpose of computing the Additional Rent due Landlord or any credit due to Tenant hereunder. 
  
 (c) If the tax year for real estate taxes shall he changed then an appropriate adjustment shall be made in the computation of the Additional Rent due to
Landlord or any credit due to Tenant, in accordance with sound accounting principles to effectuate the changeover to any New tax year adopted by any taxing authority; and 
  
 (d) Landlord shall pay all Taxes prior to any delinquency, subject, however, to Landlord’s right to contest same.
Tenant hereby acknowledges and agrees that Landlord may contest and appeal Taxes from time to time and at any time when Landlord, in its commercially reasonable judgment, determines that it is prudent to do so (provided that such contest would not
constitute a default under any mortgage or underlying lease affecting the Land, the Buildings or the Demised Premises, or cause the Land, the Buildings or the Demised Premises to be in danger of being subject to a tax sale or being foreclosed upon).
Tenant may request from time to time that Landlord consider the potential for contesting any real estate tax assessment of the Complex by the taxing authority. Upon such request, Landlord will consult with Tenant regarding the appropriateness of
instituting an appeal of such assessment, but Landlord shall ultimately be guided by its own commercially reasonable determination. 
  

 11 

 5.6. Tenant’s Proportionate Share. Tenant shall be responsible for Tenant’s
Proportionate Share of the Operating Expenses for each Lease Year, or pro rata portion thereof, during the Term as hereinafter provided: 
  
 (a) Landlord shall send to Tenant a statement (“Landlord’s Estimate”) prior to the Commencement Date of projected Operating Expenses for
the Lease Year in which the Commencement Date occurs, and thereafter on or about December 15 of each Lease Year of projected Operating Expenses for the following applicable Lease Year. Notwithstanding the foregoing, the calculation of Operating
Expenses may be performed, at Landlord’s sole option, based on the annual anniversary of the Commencement Date (or another accounting period) rather than on a calendar year. Landlord shall indicate, as part of Landlord’s Estimate, what
Tenant’s Proportionate Share of the Operating Expenses shall be, said amount to be paid in equal monthly installments (rounded up to the nearest whole dollar) in advance by Tenant as a Recurring Additional Rent Item commencing on the
Commencement Date as may be adjusted on January 1 of each applicable Lease Year. 
  
 (b) If, during the course of any Lease Year, Landlord shall have reason to believe that the Operating Expenses shall be higher than Landlord’s Estimate, then Landlord shall have the right, but not the obligation,
on one occasion to adjust Landlord’s Estimate by a lump sum invoice for the months of the Lease Year which precede the revised projections, and in addition, to advise Tenant of any adjustment in future monthly amounts with the end result that
Operating Expenses shall be on a reasonably current basis each Lease Year. 
  
 (c) Within one hundred twenty (120) days following the end of each Lease Year, or as soon thereafter as reasonably feasible, Landlord shall send to Tenant: (i) a statement of actual expenses incurred for the prior
Lease Year showing the pro rata share of the Operating Expenses due from Tenant based on Tenant’s Proportionate Share; and (ii) copies of any and all invoices theretofore received by Landlord pertaining to Taxes for the prior Lease Year, as
well as evidence of payment by Landlord (prior to delinquency) of such Taxes for the prior Lease Year. For each Lease Year, in the event that the amount prepaid by Tenant for the Operating Expenses exceeds the amount that was actually due based upon
actual year end Operating Expenses, then Landlord shall issue a credit to Tenant in an amount equal to the overcharge, which credit Tenant may apply to future Operating Expense payments until Tenant has been fully credited with the overcharge. If
the credit due to Tenant is more than the aggregate total of future Operating Expense payments (as reasonably estimated by Landlord), or if the credit pertains to the last Lease Year of the Term, Landlord shall pay to Tenant, along with the
statement regarding same, the difference between the credit and such aggregate total or the full amount of such credit, as the case may be. In the event landlord has undercharged Tenant, then Landlord shall send Tenant an invoice for the amount due,
along with the statement regarding same, which amount shall constitute Additional Rent and shall he paid in full by Tenant within thirty (30) days of receipt of such invoice. 
  
 (d) Landlord shall maintain at all times during the Term of this Lease, at a location in the New York City metropolitan
area, full, complete and accurate books of account and records for all Operating Expenses prepared in accordance with generally accepted accounting principles. Landlord shall keep such books and records, as well as contracts, bills, vouchers, checks
and such other documents as are reasonably necessary to properly audit 

  

 12 

 
Operating Expenses, for a sufficient period of time alter the Lease Year to which they are applicable to allow Tenant to perform an audit, if Tenant so
elects, pursuant to paragraph (e) below. 
  
 (e) Tenant shall have
the right, one (l) time with respect to each Lease Year, at Tenant’s expense, to examine the books and records pertaining to Operating Expenses so that Tenant can determine that Operating Expenses have, in fact, been correctly calculated by
Landlord; provided that if Tenant fails to exercise such right within twelve (12) months following the expiration of the Lease Year for which Landlord’s calculation of Operating Expenses pertains (or within three (3) months following
Tenant’s receipt of Landlord’s statement (delivered pursuant to paragraph (c) above) for such Lease Year if such statement is delivered later than nine (9) months after the end of such Lease Year) and/or fails to so complete such
examination within twelve(12) months following Tenant’s receipt of Landlord’s statement delivered pursuant to paragraph (c) above, Tenant shall be deemed to have waived its right to audit and contest Landlord’s determination of
Operating Expenses for such period, and, in such event, Landlord’s determination of Operating Expenses shall become final and binding on Landlord and Tenant for all purposes under this Lease automatically upon such failure to exercise or
failure to complete, as the case may be. If Tenant makes a timely action to review Landlord’s determination of Operating Expenses, Landlord’s books and records relating thereto shall he open for copying (at Tenant’s cost) or
inspection (which shall he conducted on a strictly confidential basis) upon reasonable notice and at reasonable times during Business Hours by Tenant and its duly authorized representatives (other than a person or firm who would be compensated by
Tenant on a contingency fee basis, unless such firm is a national accounting firm such as PriceWaterhouseCoopers), who shall have reasonable access to the same and the right to require of Landlord, its agents and employees such information or
explanation with respect to the same as may reasonably be necessary for a proper examination thereof. If Tenant disputes any Operating Expense statement as a result of an audit, Tenant shall nonetheless pay all Operating Expenses set forth herein
until such dispute is resolved. In the event that it is finally determined as a result of any audit by Tenant that the actual Operating Expenses for any period are less than the sum paid by Tenant for such period, then the amount of the excess shall
be taken by Tenant as a credit against the Operating Expense payments next due or, if the credit pertains to the last Lease Year of the Term, refunded to Tenant by lump sum payment. If, on the other hand, Tenant’s audit reveals that Tenant has
underpaid Operating Expenses for any period, then the amount of the underpayment shall he paid to Landlord by Tenant within thirty (30) days after the amount Tenant owes has been determined. Landlord shall, within thirty (30) days after receipt of
notice from Tenant, reimburse Tenant for the commercially reasonable out-of-pocket costs incurred by Tenant in performing the audit. 
  
 5.7. Occupancy Adjustment. Notwithstanding any other provision herein to the contrary, if the Building is not filly occupied during any year
of the Term or the entire Building is not provided Landlord’s Services (as hereinafter defined), then Operating Expenses that vary as to occupancy shall be computed for such year as though the Building had been fully occupied and had been
provided with Landlord’s Services during such year. 
  
 5.8.
Complex Allocation. For so long as the Complex is operated under common management. Operating Expenses shall include all costs and expenses for the operating, maintaining (including without limitation snow removal, landscaping, street
maintenance and 

  

 13 

 
retention basin maintenance), repairing, making replacements to, managing, insuring and any utility charges (including without limitation, electricity and
the cost of Landlord’s Services) with respect to the Exterior Common Areas of the entire Complex, and Landlord, prior to calculating Tenant’s Proportionate Share of Operating Expenses, shall make an allocation of such Operating Expenses
attributable to the Exterior Common Areas between the Property and the other portion of the Complex, which allocation shall be determined solely by Landlord during such period as Landlord is the owner of the entire Complex, or as agreed upon by
Landlord and the owner(s) of the balance of the Complex at any time at the entire Complex is not owned by Landlord, but in all events in accordance with sound commercial real estate management practices. Operating Expenses shall only include those
costs and expenses attributable to the Exterior Common Areas of the Property. Similarly, for so long as the Complex is operated under common management, Operating Expenses shall include all Taxes with respect to the entire Complex, and Landlord,
prior to calculating Tenant’s Proportionate Share of Operating Expenses, shall make an allocation of the Taxes component of Operating Expenses between the Property and the other portion of the Complex, which allocation shall be determined
solely by Landlord during such period as Landlord is the owner of the entire Complex, or as agreed upon by Landlord and the owner(s) of the balance of the Complex at any time that the entire Complex is not owned by Landlord, but in all events in
accordance with sound commercial real estate management practices. If the Complex is not operated under common management or if Landlord otherwise choose to have the Property separately assessed, then Operating Expenses shall only include those
Taxes pertaining to the Property. 
  
 5.9. Survival of
Additional Rent Obligations. Tenant’s obligations to make the payments required by this Article 5 as Additional Rent shall survive any termination of this Lease by lapse of time or otherwise. 
  
 5.10. Time of Payment: Late Fee; Default Interest. Commencing on the
Commencement Date, all payments of Net Base Rent and Recurring Additional Rent items shall be paid to Landlord without demand and without deduction1 set-off or counterclaim, except as expressly set forth in this Lease, on the lust (1st) day of every month during the Lease Term. If the Commencement Date shall be a day other than the first day of the
month, the rental payment shall be pro rated for said month. Without waiving any of Landlord’s other remedies for Tenant’s failure to pay Rent as in this Lease contained, Tenant agrees that (i) any Net Base Rent or Recurring Additional
Rent item not paid by the fifth (5th) business day of any month, and (ii) any other item of Additional Rent not paid by the fifth (5th) business day following the due date hereunder, shall require payment by Tenant of a late charge to compensate
Landlord for the additional administrative costs resulting from such failure (and not as a penalty) equal to the lesser of (a) five percent (5%) of the amount unpaid, or (b) $500.00 for the first time in each Lease Year that such item of Rent is not
paid within such five (5) day period and, thereafter, for the balance of such Lease Year, Tenant shall pay a late charge equal to the lesser of (x) ten percent (10%) of the amount unpaid, or (y) $l,000 for each such late payment in addition, any
installment or installments of Net Base Rent or any Recurring Additional Rent item accruing hereunder, and all other sums payable by Tenant hereunder (other than the late charge set forth in the preceding sentence), which are not paid within thirty
(30) days following the date when due, shall bear interest from and after the thirtieth (30th) day following the due
date until the date paid at the Default Rate. Anything hereinabove contained to the contrary notwithstanding, it is expressly understood and agreed that any late payment of Rent or other charges, despite 

  

 14 

 
Landlord’s invoice for or collection of such late fees or interest, shall be a Default hereunder (so long as the giving of any required notices and the
expiration of any applicable grace periods has occurred), for which Landlord shall have such rights or remedies as provided in this Lease. 
  
 5.11. Rent Tax. In the event that any business, rent or other taxes that are now or hereafter levied upon Tenant’s use or occupancy of the
Demised Premises are enacted, changed or altered so that any of such taxes are levied against Landlord, or the mode of collection of such taxes is changed so that Landlord is responsible for collection or payment of such taxes, Tenant shall pay any
and all such taxes to Landlord upon thirty (30) days’ of Landlord’s demand, as Additional Rent, so long as Landlord provides an invoice or other reasonable evidence of the payment thereof. 
  
 5.12. Landlord’s Remedies. Landlord shall have all the rights and
remedies for the collection of Additional Rent as are available to Landlord for the collection of (the Net Base Rent pursuant to the terms of this Lease and as permitted by law. 
  
 5.13. Payment of Rent. Rent and all sums payable hereunder by Tenant to Landlord shall be paid in the legal tender of
the United States of America for the payment of public and private debts to: 
  
 Bridgewater Hines Development LLC 
 c/o Hines Interests Limited Partnership 
 885 Third Avenue, Suite 2700 
 New York, NY 10022 
  
 or to such other person or
place as Landlord shall from time to time designate by written notice to Tenant. Net Base Rent and Additional Rent may be paid by wire transfer using wiring instructions that will be supplied by Landlord. 
  
 ARTICLE 6. LANDLORD’S BASE BUILDING WORK; TENANT IMPROVEMENTS

 AND EARLY ACCESS, MAINTENANCE AND REPAIRS 
  
 6.1. Landlord’s Base Building Work. Landlord shall, at us sole cost and expense, construct the Landlord’s
Base Building Work in accordance with that certain work letter attached hereto as Exhibit “B” (the “Work Letter”), which Landlord agrees will be in keeping with the standards customarily applied to similar first-class
office buildings in the Somerset County, New Jersey area. If Landlord has not obtained a building permit (or equivalent legal authorization) which would permit Landlord to commence construction of Landlord’s Base Building Work by August 31,
2001, as such date is extended by one (l) day for each day of Tenant Delay or Excusable Delay, then Tenant may terminate this Lease upon twenty (20) days’ notice to Landlord, which notice shall be given no later than September 15, 2001 (as such
dates may be extended by Tenant Delay or Excusable Delay as aforesaid), TIME BEING STRICTLY OF THE ESSENCE, and unless, within said twenty (20) day period, landlord obtains said building permit (or equivalent authorization), this Lease shall
terminate upon the expiration of said twenty (20) day period and the parties shall be released from all liability and obligation hereunder. 
  
 6.2. Tenant Improvements. Landlord shall also construct the Tenant Improvements in accordance with the Work Letter, which Landlord agrees will be
in keeping with the standards 

  

 15 

 
customarily applied to similar first-class office buildings in the Somerset County, New Jersey area. Landlord shall be responsible for the Cost of the Tenant
Improvements (as defined in the Work Letter) up to $8,921,370.00 (based upon $30.00 per rentable square foot of the Demised Premises) plus $225,000.00 with respect to the cafeteria (“Tenant’s Allowance”), and Tenant shall be
responsible for any Additional Costs (as defined in the Work Letter). Tenant shall have no obligation to remove any of the Tenant improvements upon the expiration or earlier termination of the Term, except for any of the Tenant Improvements that is
not typically performed for office tenants such as bank vaults, internal staircases and the like (other than the cafeteria), and provided that with respect to such Tenant Improvements Landlord has advised Tenant of the requirement to remove such
Tenant Improvements at the time of the approval of the Space Plans in accordance with the Work Letter, in which event Tenant shall remove same and restore the Demised Premises to the condition which existed prior to the installation thereof.

  
 6.3. Tenant’s Early Access. Landlord shall
exercise its commercially reasonable efforts to provide Tenant access to the Demised Premises at least thirty (30) days prior to the Commencement Date (which as of the date hereof is expected to be February 1, 2002), but in no event later than
twenty (20) days prior to the Commencement Date (and the Commencement Date shall be postponed accordingly if Landlord fails to make the Demised Premises available for Tenant’s early access rights, subject to the following proviso), for
the limited purpose of installing its furniture, fixtures, equipment, and phone and computer wiring and for performing any other work to prepare the Demised Premises for its occupancy (other than actual move-in of personalty), all without any
obligation to pay Rent therefor, provided: (i) such work shall not interfere with or delay Landlord in completion of Landlord’s Base Building Work or the Tenant Improvements, or any other work that Landlord may be performing in the Demised
Premises, the Building or the Complex; (ii) such work shall be performed for Tenant so as not to cause or create any labor dispute for Landlord; and (iii) Tenant complies with all of the other terms and conditions of this Lease during such early
access period. In addition, Tenant shall indemnify and hold Landlord harmless from any and all causes of action occurring as a result of Tenant’s activities in the Demised Premises during the early access period. Tenant acknowledges and agrees
that such early access will be granted with respect to differing portions of the Demised Premises at different times, in Landlord’s discretion, in order to minimize the interference of Tenant’s activities with the performance of
Landlord’s Base Building Work or the Tenant Improvements, or any other work that Landlord may be performing in the Demised Premises. 
  
 6.4. Maintenance and Repairs by Tenant. Tenant shall take good care of the interior of Demised Premises throughout the Term, maintain and preserve
same in good repair, except for normal wear and tear and damage by fire or other casualty, and be responsible for all necessary repairs and replacements thereto. Tenant shall also be responsible for the repair, maintenance and replacement of those
structural components of the Building or the Building’s mechanical, electrical and plumbing systems to the extent that such components and/or systems were installed and/or modified by or for Tenant. Tenant shall not injure, deface or commit
waste of the Demised Premises. Except to the extent waived or released pursuant to Section 13.5, Tenant shall be responsible for any damage of any kind or character to the Building or Complex caused by the negligence or willful misconduct of Tenant
or Tenant’s Visitors or alterations performed by or for Tenant (excluding alterations performed by Landlord on Tenant’s behalf). All repairs that affect the Building’s structural components or the Building’s mechanical, heating,
air-conditioning, electrical and plumbing systems, shall be made solely by Landlord or 

  

 16 

 
its contractor, and Tenant shall pay the actual out-of-pocket costs incurred therefor to Landlord within thirty (30) days of Landlord’s demand, as
Additional Rent. 
  
 6.5. Maintenance and Repairs by
Landlord. Landlord shall maintain the Property and the Complex at all times in good repair and operating condition and in order and appearance in keeping with the standards customarily applied to similar first-class office buildings in the
Somerset County, New Jersey area, other than those which it is Tenant’s express obligation to make under Section 6.4 or elsewhere in this Lease, the cost of all of which, to the extent permitted under Article 5, shall be included in Operating
Expenses. Landlord shall maintain, repair and replace the Building’s structural components and the plumbing, heating air-conditioning, electrical and mechanical fixtures (exclusive of plumbing, heating, air-conditioning, electrical and
mechanical fixtures installed by or for Tenant) when required, and maintain and make repairs to the Common Areas, the roof of the Building and the exterior of the Building, the cost of all of which, to the extent permitted under Article 5, shall be
included in Operating Expenses; provided, however, that, except to the extent waived or released pursuant to Section 13.5, Tenant shall pay as Additional Rent the cost of all such repairs or replacements arising from the negligence or willful
misconduct of Tenant or Tenant’s Visitors or alterations performed by or for Tenant (excluding alterations performed by Landlord on Tenant’s behalf). 
  

6.6. Landlord’s Warranty. In addition to Landlord’s repair and maintenance obligations set forth in Section 6.5 above, Landlord hereby
warrants and guarantees Landlord’s Base Building Work and the Tenant Improvements against any defects in workmanship or materials for a period of two (2) years after the Commencement Date. In the event any repairs or replacements are required
pursuant to the foregoing warranty and guaranty, the cost thereof shall be borne by Landlord and shall not be included as an Operating Expense. 
  
 6.7. Compliance with Laws; Americans with Disabilities Act of 1990. The Demised Premises shall, upon the Commencement Date, comply with all
applicable Legal Requirements including, without limitation, the Americans with Disabilities Act of 1990, as amended (the “ADA”). Following the Commencement Date, Landlord hereby also agrees to be responsible for the compliance of the
Property and the complex (including the Common Areas and Demised Premises), to the extent same is not the responsibility of Tenant pursuant to the next sentence, with all such Legal Requirements, the cost of all of which, to the extent permitted
under Article 5, shall be included in Operating Expenses. Notwithstanding the foregoing, during the Term of this Lease, Tenant shall comply with all Legal Requirements pertaining to Tenant’s manner of use of the Demised Premises or any
alterations or improvements to the Demised Premises made by or on behalf of Tenant, including any alterations or improvements to the Properly or the Complex (including the Common Areas) required by any provision of the ADA not applicable to
Landlord’s Base Building Work or Tenant’s Improvements, or to the Property or the Complex (as applicable) as of the Commencement Date. 
  
 6.8. Cafeteria. Tenant shall, at its sole risk, cost and expense, be responsible for the control, management, operation, and maintenance of the
cafeteria. 
  

 17 

 ARTICLE 7. ALTERATIONS BY TENANT AND TRADE FIXTURES 
  
 7.1. Alterations. Tenant shall not do any work in or about the Demised
Premises or make any alterations or additions thereto which would affect the Building structure, the exterior of the Building, any mechanical plumbing, electrical or other systems in the Building, or which would be visible from the exterior of the
Demised Premises, without in each instance obtaining the prior written consent of Landlord, which consent shall not be unreasonably withheld or delayed. At the time Tenant requests Landlord’s consent to any such proposed alterations or
additions, Tenant shall submit to Landlord detailed drawings and specifications for such proposed alterations or additions. If Landlord grants its consent thereto, Landlord shall advise Tenant, at the time Landlord so grants its consent, whether,
upon the expiration or earlier termination of this Lease, Tenant will be requited to remove such alteration(s). Subject to the foregoing, Tenant shall have the right, without Landlord’s consent, to make interior, non-structural alterations Mid
additions to the Demised Premises, provided that prior to commencing any alterations to the Demised Premises, Tenant shall provide Landlord with at least ten (10) days’ advance notice thereof setting forth the scope of such proposed
alterations, All such work to which Landlord consents, or which is permitted hereunder without Landlord’s consent, shall be performed and installed at Tenant’s sole cost and expense in a good and workmanlike manner and in compliance with
all applicable Legal Requirements. Notwithstanding anything contained herein, any alterations which affect the Building’s structural components or the plumbing, heating, air conditioning, electrical or mechanical systems shall be performed by
Landlord or by contractor(s) designated by Landlord, the cost of which shall be commercially competitive in the Somerset County, New Jersey area, and Tenant shall pay the costs incurred therefor to Landlord, within thirty (30) days after
Landlord’s demand, as Additional Rent. In addition, Tenant agrees that in all instances where Tenant invites bids for the performance of any such alteration(s) or for any repair work pursuant to Section 6.4 above, whether or not same require
Landlord’s consent, Tenant will permit Landlord to submit a hid therefor on behalf of itself or an Affiliate of landlord, and Tenant shall consider such bid, in good faith, along with any other bid(s) it obtains with respect to same. During the
work, Tenant shall maintain such insurance as Landlord may reasonably require for the benefit of Landlord or such other parties as Landlord shall designate. Landlord may require that Tenant furnish a guarantee by each of Tenant’s prime
contractors and materialmen for the benefit of Landlord, Tenant and such other parties as Landlord shall designate, that all work, materials and equipment will be in accordance with the plans and specifications and that they will promptly, upon
notice, correct and repair at their own cost and expense any deficiency, defect, fault or imperfection of materials, equipment or workmanship which appears within one (1) year after completion of their work or installation. Within 30 days of
completion of any alterations or improvements that materially change the configuration of the Demised Premises or affect the Building structure, the exterior of the Building, or any mechanical, plumbing, electrical or other systems in the Building,
whether or not Landlord’s consent therefor was required, Tenant shall furnish Landlord with complete as-built sepia and CAD drawings thereof. 
  
 7.2. No Liens. No work or installation by Tenant at the Demised Premises or elsewhere in the Complex shall be done except after providing to
Landlord appropriate assurances in connection with the possible filing of any construction items and/or notice of unpaid balance (commonly known as a “construction lien”) in the local office, as provided by 

  

 18 

 
law. If any such lien is filed, Tenant shall cause it to be discharged, satisfied or bonded within thirty (30) days of filing. 
  
 7.3. Labor Harmony. No work, services or installation by Tenant in or
about the Demised Premises or elsewhere in the Complex shall be performed or installed except by workmen and mechanics working in harmony and not unreasonably interfering with labor employed by Landlord, Land lord’s mechanics or their
contractors or by any other tenant or their contractors. Any violation hereof shall automatically constitute a permitted cancellation by Landlord of any prior Landlord’s consent to or permission for such work or installation. 
  
 7.4. Expiration of Term. The Tenant Improvements, as well as any
alterations, improvements or additions thereafter made by or on behalf of Tenant with Landlord’s permission or as permitted herein shall remain upon the Demised Premises at the expiration or earlier termination of this Lease and shall become
the property of Landlord, except for those Tenant improvements and/or alterations, improvements and additions theretofore required by Landlord to be removed by Tenant at the expiration or earlier termination of this Lease pursuant to Section 6.2 or
Section 7.1 above, which Tenant shall remove and restore the Demised Premises to the condition which existed prior to the installation thereof. Should Tenant fail to so remove any such items so required to be removed, or should Tenant fail to
restore the Demised Premises as required pursuant to Section 6.2 or 7.1 above or Section 7.5 below, Landlord may do same, and Tenant shall pay the cost and expense thereof to Landlord as Additional Rent with thirty (30) days of demand. The
obligations set forth in this Section 7.4 shall survive the expiration or earlier termination of this Lease. 
  
 7.5. Trade Fixtures. All trade fixtures installed by Tenant in the Demised Premises, except lighting fixtures, heating and air-conditioning
equipment, mechanical, plumbing and electrical systems and fixtures, and floor coverings, shall remain the property of Tenant and shall be removed on or before the Termination Dale or earlier termination of this Lease. At Landlord’s option, any
trade fixture not removed on or before the Termination Date or earlier termination of this Lease shall either become Landlord’s property, or Landlord may remove and dispose of them, and in such event Tenant shall pay the cost and expense
thereof to Landlord as Additional Rent within thirty (30) days of demand. Tenant shall promptly restore the Demised Premises to the original order and condition upon removal of trade fixtures and shall repair any and all damage caused by said
removal. The obligations set forth in this Section 7.5 shall Survive the expiration or earlier termination of this Lease. 
  
 ARTICLE 8. LANDLORD’S SERVICES 
  
 8.1. Landlord’s Services. Landlord shall provide the following services (“Landlord’s Services”): 
  

	 	(a)	 	Air heating and air cooling during Business Hours, subject to curtailment as required by Legal Requirements, at such temperatures and in such amounts as are in keeping with similar
first-class office buildings in the Somerset County, New Jersey area. 

  

 19 

	 	(b)	 	Sufficient electrical capacity at all times, subject to the terms of the last paragraph of this Section 8.1 and Article 9 below, to operate (i) incandescent lights, persona)
computers and printers, photocopying machines and other machines of similar low voltage electrical consumption (l20/208 volts), provided that the total rated electrical design load or said lighting and machines of low electrical voltage shall not
exceed four (4) watts per square foot of the Demised Promises; and (ii) lighting and equipment of high voltage electrical consumption (277/480 volts), provided that the total rated electrical design load for said lighting and equipment of high
electrical voltage shall not exceed two (2) watts per square foot of the Demised Premises. 

  

	 	(c)	 	Cleaning services to the Demised Premises and the Complex as set forth in Exhibit “D” annexed hereto. Tenant shall have the right to select the janitorial
contractor for the Demised Premises, and may also be entitled to select the janitorial contractor for the Building as and to the extent set forth in Section 8.6 below. Tenant shall pay to Landlord the cost of removal from the Building of any of
Tenant1s refuse and rubbish which materially exceeds the refuse and rubbish usually attendant upon the use of such
premises for general office purposes. 

  

	 	(d)	 	Hot and cold water at all times (subject to the last paragraph of this Section 8.1) for use in lavatories in common with oilier tenants from the regular supply of the Complex.

  

	 	(e)	 	Non-exclusive multiple cab passenger elevator service to the Demised Premises during Business flours and at least one (1) cab passenger service to the Demised Premises twenty-four
(24) hours per day (subject to the last paragraph of this Section 8.1); non-exclusive freight elevator service daring Business Hours (all subject to temporary cessation for ordinary repair and maintenance and during times when life safety
systems override normal building operating systems) with such freight elevator service available at other times upon reasonable prior notice and the payment by Tenant to Landlord of any additional expense actually incurred by Landlord in connection
therewith; and non-exclusive passenger and freight elevator service during construction of the Tenant Improvements and Tenant’s move into the Demised Premises, which use shall be scheduled in advance with Landlord. 

  

	 	(f)	 	Electric lighting Service at all limes (subject to the last paragraph of this Section 8.1) for all Common Areas of the Complex in the manna and to the extent as are in keeping with
similar first-class office buildings in the Somerset County, New Jersey area. 

  

	 	(g)	 	 Access control for the Complex comparable as to coverage, control and responsiveness (but not necessarily as to means for accomplishing same) to other similar
first-class office buildings in the Somerset County New Jersey area; PROVIDED, HOWEVER, LANDLORD SHALL HAVE NO RESPONSIBILITY TO PREVENT, AND SHALL NOT BE LIABLE TO TENANT FOR LIABILITY OR LOSS TO TENANT OR TENANT’S VISITORS ARISING 

  

 20 

	 	 
OUT OF LOSSES DUE TO THEFT, BURGLARY OR DAMAGE OR INJURY TO PERSONS OR PROPERTY CAUSED BY PERSONS GAINING UNAUTHORIZED ACCESS TO THE COMPLEX OR THE DEM1SED
PREMISES (E.G., EXCLUDING LANDLORD’S AGENTS, CONTRACTORS, EMPLOYEES AND MEMBERS), AND TENANT HEREBY RELEASES LANDLORD FROM ALL LIABILITY RELATING THERETO, EXCEPT TO THE EXTENT SUCH LOSSES ARE CAUSED IN WHOLE OR IN PART BY THE NEGLIGENCE OR
WILLFUL MISCONDUCT OF LANDLORD OR LANDLORD’S AGENTS, CONTRACTORS, EMPLOYEES AND MEMBERS. 

  

	 	(h)	 	All building standard fluorescent bulb replacement in all areas and alt incandescent bulb replacement in the Common Areas. 

  

	 	(i)	 	Gas at all times (subject to the lust paragraph of this Section 8.1) for use in Common with other tenants, from the regular supply of the Complex. 

  
 If Tenant requires air conditioning or heat beyond Business Hours, Landlord will furnish such
air-conditioning or heat, provided Tenant gives Landlord’s agent sufficient advance notice of such requirement and Tenant agrees to pay for the, costs actually incurred by Landlord in connection therewith. Landlord shall provide this service at
actual cost, without mark-up to Tenant, which cost shall include, but not be limited to, the utility consumed, chemical treatment, Landlord’s staff, and costs allocated to preventative maintenance of the equipment providing such service.

  
 To the extent the services described above require electricity, gas and/or
water supplied by the public utilities, Landlord’s covenants thereunder shall only impose on Landlord the obligation to use its good faith, reasonable efforts to cause the applicable public utilities to furnish the same. Failure by Landlord to
furnish the services described in this Article 8, or any cessation thereof, shall not render Landlord liable for damages to either person or property (except to the extent caused by the act, omission or neglect of Landlord or Landlord’s agents
or employees), nor to be construed as an eviction of Tenant, nor work an abatement of Rent (subject to the last sentence of this paragraph), nor relieve Tenant from fulfillment of any covenant or agreement hereof. In addition, should any of the
equipment or machinery, for any cause, fail to operate, or function properly, Tenant shall have no claim for abatement or rebate of Rent (subject to the last sentence of tins paragraph) or damages on account of an interruption in service occasioned
thereby or resulting therefrom. Landlord shall have the right temporarily to interrupt services in order to make any necessary repairs or replacements to, or to otherwise service, the Building’s systems. In all of the foregoing instances,
however, Landlord shall exercise commercially reasonable efforts to minimize interference with Tenant’s operations, to eliminate the cause of the interruption and to effect restoration of service as expeditiously as possible. Notwithstanding
the foregoing or anything else to the contrary contained in this Lease, if any failure to provide any service or utility required of Landlord under this Lease shall continue for more than two (2) consecutive business days after notice from Tenant to
Landlord of such failure, and provided such failure to provide the required service renders all or any portion of the Demised Premises untenantable, then as Tenant’s sole remedy with respect thereto, Net Base Rent shall be proportionately
abated hereunder commencing on the third (3rd) business day after notice of such interruption, retroactive to the commencement of the interruption, to the extent, if any, that 
  

 21 

 
the amount of such abatement is actually reimbursed to Landlord under policies of rent interruption insurance maintained by Landlord as an Operating Expense
for the Property. 
  
 8.2. Tenant’s Access. Subject to
applicable Legal Requirements, Tenant shall have the right of twenty-four (24) hour, three hundred sixty-five (365) day access to the Demised Premises, the Building and the parking area, 
  
 8.3. Tenant’s Security System. Subject to the provisions of Article 7, Tenant shall be permitted to install, at
its sole cost and expense, a security surveillance system in the Demised Premises and elsewhere on the Property (including the parking areas). Additionally, provided that Tenant (including its permitted assignee and/or subtenants) are, taken
together, in possession of the entire Building, Tenant shall be permitted to install, at its solo cost and expense and subject to the provisions of Article 7, an access control system (bribe parking garage serving (he Building, Tenant shall
coordinate the installation of its security system(s) with Landlord in order to provide Landlord with continued access to the Demised Premises and the parking areas. 
  
 8.4. Intentionally Omitted. 
  

8.5. Building Management. During the Term of this Lease, Landlord shall have the right to control and direct the management of the Building.
Notwithstanding the foregoing, in the event in Tenant’s reasonable opinion, Landlord’s management of the Building is not commensurate with industry standards for the management of similar first-class office buildings in the Somerset
County, New Jersey area, Tenant shall notify Landlord in writing and allow Landlord sixty (60) days to cure any such alleged deficiency and bring the Building management into compliance with industry standards. In the event Landlord fails to cure
any deficiency alleged by Tenant within such sixty (60) day period, Tenant shall have the right to require Landlord to retain a property manager that will operate the Building in accordance with industry standards for similar properties in the
Somerset County, New Jersey area. In the event a dispute arises as to whether the Building is operated in accordance with industry standards, any such dispute will be resolved by arbitration in accordance with the provisions of Article 45.

  
 8.6. Designated Providers of Certain Building Services.
Provided that: (i) Tenant is Aventis Pharmaceuticals Inc. or any Related Entity or Successor Entity thereto; (ii) no Default by Tenant has occurred and is continuing; and (iii) Aventis Pharmaceuticals inc., any Related Entity or any Successor Entity
thereto, taken together, are in possession of the entire Building, Tenant shall have the right to require that Landlord utilize the services of Tenant’s designated contractors for the provision of security services and janitorial services to
the Demised Premises (individually a “Designated Provider” and collectively the “Designated Providers”), subject to the terms and conditions of this Section 8.6. Notwithstanding anything herein, Landlord shall only be obligated
to utilize a particular Designated Provider if: (x) the cost of such Designated Provider is commercially competitive with other providers of comparable reputation performing a similar service in the Somerset County, New Jersey area; and (y) such
Designated Provider performs its services in a first-class manner. 
  
 8.7. Service Providers for Tenant’s Systems. Tenant shall have the right to select the contractors Tenant will engage to service Tenant’s so-called “critical systems”, including but not limited to Tenant’s
emergency generator, supplemental HVAC unit, and uninterrupted power 

  

 22 

 
supply, subject to Landlord’s approval, which approval shall not be unreasonably withheld, conditioned or delayed, provided that Tenant selects
reputable contractors with an established reputation of providing first-class services. 
  
 ARTICLE 9. ELECTRICITY 
  
 9.1. Intentionally Omitted. 
  
 9.2. Electrical
Usage. Landlord shall arrange for the provision of electric current to the Demised Premises or any building systems servicing solely the Demised Premises on a direct meter or on a submetering basis, from utility providers and/or suppliers
selected by Landlord in its sole discretion, provided that the rates of such providers and suppliers are commercially competitive with other providers and suppliers of comparable reputation servicing the Somerset County, New Jersey area, and further
provided that the quality of such service(s) so provided satisfies the electrical requirements of Tenant set forth herein, so as to permit the normal operation of the Demised Premises. The Building “master” meter shall be installed as part
of Landlord’s Base Building Work and any submeters which measure consumption for the Demised Premises (whether on a per floor or other basis) shall be installed as part of the Tenant Improvements. Bills therefor shall be rendered at such times
as Landlord may elect on a monthly basis and the amount, as computed from such submeter(s), shall be deemed to he, and he paid as, a Recurring Additional Rent Item. If any tax is imposed by any governmental authorities upon Landlord’s receipts
from the sale or resale of electric current to Tenant, Tenant covenants and agrees that, where permitted by law, Tenant shall pay the portion of such taxes attributable to Tenant’s electrical usage. 
  
 9.3. Tenant Electrical Installations. Tenant agrees that it will not
use electricity in the Demised Premises in excess of the capacity of any of the electrical conductors and equipment otherwise serving the Demised Premises, and that it will not make any electrical installations, alterations or additions except in
accordance with Article 7. Tenant will at all times comply with the rules, regulations, terms and conditions applicable to service, equipment, wiring and requirements of the public utility supplying electric current to the Property or Complex,
provided Tenant is provided a copy of such rules, regulations, terms and conditions. In the event that, in Landlord’s reasonable judgment, Tenant’s electrical requirements necessitate installation of art additional riser, risers or other
proper and necessary equipment, the same shall be installed by Landlord at Tenant’s sole expense, which actual, out-of-pocket costs and expenses shall be chargeable and collectible as Additional Rent and paid within thirty (30) days after the
rendition of a bill to Tenant therefor. 
  
 ARTICLE 10.
INTENTIONALLY OMITTED 
  
 ARTICLE 11. RIGIITS RESERVED TO
LANDLORD 
  
 11.1. Reserved Rights. Landlord shall have
the right, but shall be under no obligation, to do the following things (at any time or times and from time to time) in or about the Demised Premises and Complex. 
  

 23 

 (a) discontinue any facility or service not expressly covenanted for herein, as they constitute no part
of the consideration for this Lease; 
  
 (b) control and prevent
access to any pan of the Building or Complex, provided such action does not materially interfere with Tenant’s ingress and egress to the Demised Premises; 
  

(c) prevent access to the Building by any person during any invasion, mob riot, public excitement or other commotion by closing the doors or otherwise;
and 
  
 (d) install, place upon or affix to the roof or exterior
walls of the Demised Premises and/or the Building, equipment, antennae and any other object or structure provided it does not interfere with Tenant’s use and occupancy of the Demised Premises. 
  
 Notwithstanding anything contained herein, for so long as Aventis Pharmaceuticals Inc., any
Related Entity or any Successor Entity thereto, taken together, are in possession of the entire Building. Landlord shall not, without Tenant’s prior consent, which consent shall not be unreasonably withheld, conditioned or delayed, make any
changes to the parking area in the portion of the Complex which is shaded on Exhibit A-2 annexed hereto (i.e., within the parking area located on the Property). 
  
 ARTICLE 12. COVENANT OF QUIET ENJOYMENT 
  
 12.1. Quiet Enjoyment. Landlord covenants that (a) it has the power and authority to enter into this Lease and (b) so
long as Tenant performs every obligation of Tenant under this Lease, Tenant shall quietly enjoy the Demised Premises without hindrance by Landlord or anyone claiming under Landlord, subject however, to all of the provisions of this Lease and the
instruments referred to in Section 17.1. 
  
 ARTICLE 13. WAIVER
OF SUBROGATION, INDEMNIFICATION AND INSURANCE 
  
 13.1.
Tenant’s Indemnity. Tenant shall be responsible for and shall relieve, indemnify and save Landlord harmless from and against all ex4enses, costs (including reasonable attorney fees and disbursements), loss, liability and claims based on,
arising out of or resulting from: (1) any set, omission or neglect or Tenant or Tenant’s Visitors or the use of the Demised Premises, Common Areas (or any part thereof) by Tenant, or (ii) any alteration or other work performed by Tenant in a
about the Demised Premises. 
  
 13.2. Tenant’s
Insurance. Tenant, at its own expense, will maintain with solvent insurers of good financial standing authorized to do business in the State of New Jersey the following: 
  

	 	(a)	 	Commercial general liability insurance policies in the broadest form then available in New Jersey, against claims for bodily injury, personal injury, death or property damage
occurring on, in or about the Demised Premises or as a result of ownership of facilities located on the Demised Premises, with Landlord as an additional insured, and at Landlord’s request with any property manager, ground lessor and/or
mortgagee as additional insured(s), in amounts not less than FIVE 

  

 24 

	 	 
MILLION AND 00/100 ($5,000,000.00) DOLLARS each occurrence combined single limit for bodily injury, personal injury, death, or property damage. Tenant’s
liability insurance required in this Lease shall be written to be primary, with any other insurance available to Landlord being excess. 

  

	 	(b)	 	All-Risk property insurance governing Tenant’s stock in trade, trade fixtures, furniture, furnishings, removable floor coverings, equipment, signs and all other property of
Tenant in the Demised Premises (including, but not limited to, all items in the Demised Premises not paid for by Landlord) in amounts not less than 100% of the full insurable value of the property covered and not less than the amount sufficient to
avoid the effect of the co-insurance provisions of the applicable policy or policies. Landlord shall have the right from time to time during the Term to require that the commercial general liability insurance policy limits be increased to the
prevailing level customarily carried with respect to similar properties in Somerset County, New Jersey, and the surrounding area. Tenant’s commercial general liability insurance shall contain a broad form contractual liability endorsement. Upon
commencement of this Lease and upon renewal of all insurance required hereunder, Tenant shall provide Landlord a certificate of insurance as evidence of the insurance required of Tenant hereunder. Landlord shall be provided thirty (30) days’
advance written notice of any cancellation or non-renewal of the insurance required herein. All insurance required to be maintained under this Section 13.2 may be provided under: (i) an individual policy covering this location; (ii) a blanket policy
or policies which includes other liabilities, properties and locations of Tenant, (iii) with respect to the all-risk property insurance only, a plan of self-insurance; or (iv) a combination of any of the foregoing insurance programs. To the extent
any deductible is permitted or allowed as a part of any insurance policy carried by Tenant in compliance with this Section 13.2, then Tenant shall he deemed to be covering the amount thereof under an informal plan of self-insurance; provided,
however, that in no event shall any deductible exceed One Hundred Thousand Dollars ($100,000). 

  
 13.3. Landlord’s Indemnity. Landlord shall be responsible for and shall relieve, indemnify and save Tenant harmless from and against all
expenses, costs (including reasonable attorney fees and disbursements), loss, liability and claims based on, arising out of or resulting from any act, omission or neglect of Landlord, or Landlord’s agents or employees. 
  
 13.4. Landlord’s Insurance. Landlord, as an item of Operating
Expenses: 
  
 (a) shall maintain, or cause to be maintained, a
policy or policies of insurance with the premiums thereon fully paid in advance, issued by and binding upon an insurance company of good financial standing, insuring the Property and Exterior Common Areas of the Complex against loss or damage by
fire or other insurable hazards (including earthquake loss if Landlord elects to maintain such coverage) and contingencies for the full insurable value thereof or, in the alternative, insuring for one hundred percent (100%) of the replacement cost
thereof as determined by Landlord’s insurer from time to time (or such other amount as shall be required to eliminate operation of coinsurance provisions), exclusive of excavations and foundations or such 
  

 25 

 
other coverage as Landlord deems appropriate for the Project. Landlord shall not be obligated to insure any of Tenant’s furniture, equipment, machinery,
trade-fixtures, personal property, goods or supplies (“Tenant’s Personal Property”), or any alterations that Tenant may make upon the Demised Premises. If the annual premiums paid by Landlord for such casualty insurance exceed the
standard premium rates because the nature of Tenant’s operations result in extra-hazardous or higher than normal risk exposure, then Tenant shall, within thirty (30) days after receipt of appropriate premium invoices, reimburse Landlord for
such increases premium. All insurance proceeds payable under Landlord’s insurance carried hereunder shall he payable solely to Landlord and Tenant shall have no interest therein. 
  
 (b) with respect to the Complex, shall maintain or cause to be maintained a policy or policies of commercial general
liability insurance with the premiums thereon fully paid in advance, issued by and binding upon an insurance company of good financial standing such insurance to afford minimum protection of not less than Five Million Dollars ($5,000,000) per
occurrence, combined single limit, for bodily injury (including death) and property damage. The coverages required to be carried shall be extended to include, but not to be limited to, blanket contractual liability, personal injury liability (libel,
slander, false arrest and wrongful eviction), and broad form property damage liability. Upon request of Tenant, landlord shall provide Tenant reasonable evidence that the insurance required to be maintained hereunder by Landlord is in full force and
effect. 
  
 13.5. Waiver of Subrogation. Any provision of
this Lease to the contrary notwithstanding, Landlord and Tenant hereby release the other from any and all liability or responsibility to the other or anyone claiming through or under them by way of subrogation or otherwise (a) from any and all
liability for any loss or damage to the property of the releasing party, (b) for any loss or damage that may result, directly or indirectly, from the loss or damage to such property and (c) from legal liability for any loss or damage to property (no
matter who the Owner of the property may be), all to the extent (and only to the extent) that the releasing party’s loss or damage is insured or, if not insured, was insurable under standard “all risk” property insurance policies
generally available to landlords and tenants of commercial properties, even if such loss or damage or legal liability shall be caused by or result from the fault or negligence of the other party or anyone for whom such party may be responsible and
even if the releasing party is sell-insured or the amount of the releasing party’s insurance is inadequate to cover the loss or damage or legal liability. It is the intention of the parties that Landlord and Tenant shall look solely to their
respective insurance carriers for recovery against any such loss or damage or legal liability with respect to its properly, without such insurance carriers having any rights or subrogation against the other party. Landlord and Tenant each shall be
responsible for obtaining whatever endorsements to their respective policies of insurance as may be necessary to permit the foregoing waivers and releases. 
  
 13.6. Limitations on Indemnities. All indemnity obligations of Landlord and Tenant arising under this Lease, and all claims, demands, damages and
losses assertable by Landlord and Tenant against the other in any suit or cause of action arising out of or relating to this Lease, the Demised Premises, the Building, the Property or the complex, or the use and occupancy thereof, are limited as
follows: 
  

 26 

 (a) By the releases and waivers expressed herein, including, without limitation, the mutual releases and
waivers of rights set forth in Section 13.5; 
  
 (b) All claims
for indemnification and other recoveries shall be limited to direct, proximately caused damages and exclude all consequential or indirect damages, including, but not limited to, business loss or interruption, suffered by the party asserting the
claim or seeking the recovery, except with respect to Tenant’s indemnity obligation set forth in Section 33.2; 
  
 (c) In the case of Landlord, the limitations expressed in Section 31.3; and 
  
 (d) In the event that Landlord and Tenant (or the persons for whom they are liable as expressly set forth herein) are
determined to be contributorily responsible for the indemnified injury or loss, each indemnitors obligation is limited to the indemnitor’s equitable share of the losses, costs or expenses to be indemnified against based on the relative
culpability of each indemnifying person whose negligence or willful acts or omissions contributed to the injury or loss. 
  
 13.7. Survival. The indemnities and limitations set forth in this Article 13 shall survive the expiration or termination of this Lease. 

 
 ARTICLE 14. MUTUAL RELEASES 
  
 14.1. Limitation of Liability of Landlord. (a) Tenant agrees that
Landlord and its agents, contractors, employees, and members shall not be liable to Tenant, and Tenant hereby releases said parties from any liability, for any personal injury, toss of income or damage to or loss of persons or property, or loss of
use of any property, in or about the Complex from any cause whatsoever unless such damage, loss or injury results from the negligence or willful misconduct of Landlord, its agents, contractors, employees, or members, or the breach by Landlord of any
outs covenants or obligations hereunder. 
  
 (b) Notwithstanding
any provisions of this Lease to the contrary, Tenant agrees that any goods, personal property or personal effects, including removable trade fixtures used or placed by the Tenant or its employees in or about the Demised Premises or Property, shall
be at the sole risk of Tenant, and Landlord shall not in any manner be held responsible or liable therefor. 
  
 (c) Notwithstanding any provisions of this Lease to the contrary, in no event shall Landlord have any liability to Tenant for any claims based on the
interruption of, or loss to, Tenant’s business. 
  
 14.2.
Limitation on Liability of Tenant. Landlord agrees that Tenant and its agents, contractors, employees, officers, directors, shareholders and partners shall not be liable to Landlord, and Landlord hereby releases said parties from any
liability, for any personal injury, loss of income (other than payment of Rent) or damage to or loss of persons or property or loss of use of any property in or about the corridors, lobbies and other untenanted portions of the Property or the
Complex from any cause whatsoever unless such damage, loss or injury results from the negligence or willful misconduct of Tenant and its agents, contractors, employees, 

  

 27 

 
officers, directors, shareholders, partners or Tenant’s Visitors, or the breach by Tenant of any of its covenants or obligations hereunder. 

 
 ARTICLE 15. CONDEMNATION 
  
 15.1. Waiver of Claims. Tenant hereby waives any injury, loss or
damage, or claim therefor, resulting from any exercise of a power of eminent domain affecting all or any part of the Demised Premises or the air rights, Land or Building, except that Tenant reserves against the condemning authority Tenant’s
right to, and separate claim for, any damages for loss of good will, machinery and moving expenses payable to tenants or lessees under the appropriate State code as well as any other claim to which Tenant may be entitled under law at the time of
condemnation provided there would be no reduction in the award to Landlord. In no event, however, shall Tenant have or make any claim against Landlord, or the condemning authority or any party having an interest in the air rights, Land or Building,
which would diminish or reduce the award for the air rights, Land or Building. 
  
 15.2. Whole or Partial Condemnation. In the event the whole or a substantial part (as hereinafter defined) of the Demised Premises, or the use or occupancy of the Demised Premises, shall be taken as a result of
the exercise of a power of eminent domain, this Lease shall terminate as of the date the right to possession vests in the condemning authority and Rent shall be apportioned as of that date. If less than a substantial part of the Demised Premises, or
the use or occupancy thereof, is taken or condemned by any governmental or quasi-governmental authority for any public or quasi-public use or purpose (including a sale thereof under threat of such a taking), and this Lease is not terminated by
Landlord as hereinafter provided, this Lease shall continue in full force and effect, but the Rent thereafter payable hereunder shall he equitably adjusted as of the date the right to possession vests in the condemning authority. For purposes of
this Section 15.2, a substantial part of the Demised Premises shall be considered to have been taken if more than ten percent (10%) of the Demised Premises is rendered unusable as a result of such taking or if access to the Demised Premises is
materially adversely affected as a result of such taking. If a significant portion of the Building (but not the Demised Premises) or the Property shall be taken or condemned by any governmental or quasi-governmental authority for any public or
quasi-public use or purpose (including a sale thereof under threat of such a taking), then Landlord may, at its option, terminate this Lease by notifying Tenant in writing of such termination within ninety (90) days after the date title thereto
vests in such governmental or quasi-governmental authority. 
  
 ARTICLE 16. DAMAGE OR DESTRUCTION 
  
 16.1.
Casualty. (a) In the event of any tire or other casualty to the Building, Landlord shall provide Tenant with a written notice (the “Landlord’s Notice”) of its intention to repair the fire or other casualty or terminate this
Lease in accordance with this Article 12 within thirty (30) days of such fire or other casualty, which thirty (30) day period shall in addition to Excusable Delay, be expressly subject to extension in an amount of time equal to the amount of time
during which Landlord is adjusting insurance proceeds with its insurance carrier. If the Building shall be so damaged that substantial alteration or reconstruction of the Building shall, in Landlord’s sole opinion, be required (whether or not
the Demised Premises shall have been damaged by such casualty), or in the event of any substantial uninsured loss to the Building or the mortgagee 

  

 28 

 
of any mortgage affecting the Demised Premises does not make insurance proceeds available, Landlord may at its option terminate the Lease by so notifying
Tenant as part of Landlord’s Notice. If Landlord does not elect to terminate the Lease, Landlord’s Notice shall specify the number of days following the occurrence of such fire or other casualty that would be required, in Landlord’s
judgment, in order to reconstruct the Demised Premises or those portions of the Building affecting the use and enjoyment of the Demised Premises. If Landlord’s Notice indicates that such reconstruction of the Demised Premises or those portions
of the Building affecting the use and enjoyment of the Demised Premises shall exceed three hundred sixty-five (365) days (or during the last twenty-four (24) months of the Term, two hundred forty (240) days) from the date of the fire or other
casualty, and Landlord does not elect to terminate the Lease as provided in Landlord’s Notice, Tenant shall have the right, to be exercised within fifteen (15) days after receipt of Landlord’s Notice, to elect, by notice to Landlord, to
cancel this Lease (hereinafter called “Tenant’s Notice”). If the Lease is terminated by either Landlord or Tenant as above permitted, Landlord and Tenant thereafter shall have no further obligation or claim, one to the other, and this
Lease shall be deemed null and void and of no further force and effect. 
  
 (b) In the event the Lease is not terminated by either Landlord or Tenant as hereinabove permitted, Landlord shall, subject to Excusable Delay, commence and proceed with reasonable diligence to restore the portion of
the Building affecting the use and occupancy of the Demised Premises. If Landlord indicates in Landlord’s Notice (i) that the Demised Premises and/or the Building can be repaired within the applicable time period giving rise to Tenant’s
termination right, but such repairs are not completed within such time period (as such time period may be extended for Excusable Delay, but in no event more than one hundred eighty (180) days, or (ii) that it will take longer than the applicable
time period giving rise to Tenant’s termination right to repair the Demised Premises and/or the Building and Tenant does not elect to terminate this Lease, but such repairs are not completed within such time period (as such time period may he
extended for Excusable Delay, but in no event more than one hundred eighty (180) days), then in either case this Lease and the Term hereof may at the election of Tenant be terminated by notice in writing from Tenant to Landlord, within thirty (30)
days thereafter, TIME BEING STRICTLY OF THE ESSENCE, which termination shall be effective thirty (30) days after such notice unless the Demised Premises and/or Building have been fully restored within said thirty (30) day period, in which case this
Lease shall continue in full force and effect. Landlord shall not be liable for any inconvenience, loss of business or annoyance to Tenant or damage to the business of Tenant resulting in any way from such damage or the repair thereof, except that,
as Tenant’s sole and exclusive remedy with respect thereto, Landlord shall allow Tenant a fair diminution of Net Base Rent and Recurring Additional Rent Items during the time and to the extent that the Demised Premises is unfit for occupancy.
During the period of any reconstruction undertaken by Landlord, Tenant shall be responsible to remove its personal properly, fixtures and equipment from the damaged area prior to Landlord’s institution of reconstruction work. Landlord shall
have no liability to Tenant with respect to any damage, loss or theft of any such personal property, fixtures and equipment not so removed. 
  
 16.2. Waiver of Statutory Remedies. Tenant waives the benefit of New Jersey Revised Statutes, Title 46, chapter 8, Sections 6 and 7, and agrees
that Tenant will not be relieved of the obligations to pay the Net Base Rent or any Additional Rent in cast of damage to or destruction of the Building, except as provided by this Lease. 
  

 29 

 16.3. Governmental Approvals. Notwithstanding any of the foregoing provisions to the contrary,
Landlord’s obligation to repair the damage and restore and rebuild the Building and/or the Demised Premises pursuant to this Article shall be conditioned on such restoration being then lawfully permitted and Landlord being granted all necessary
approvals from governmental authorities having jurisdiction. 
  
 ARTICLE 17. SUBORDINATION 
  
 17.1.
Subordination of Lease. Subject to the provisions of Section 17.4 below, Tenant acknowledges that this Lease and Tenant’s rights hereunder are subject and subordinate to all mortgages hereafter placed upon Landlord’s estate in the
Land, the Building and the Demised Premises (Landlord hereby representing that no mortgages, judgments or liens affect the Land, the Building or the Demised Premises as of the date hereof). 
  
 17.2. Attornment. Subject to the provisions of Section 17.4 below, if
any mortgagee or other person shall acquire title to Landlord’s estate in the Demised Premises, the Land or Building by foreclosure, deed in lieu thereof, or otherwise, or, at any time during the Term of this Lease, the landlord of the Demised
Premises shall be the holder of a leasehold estate covering premises which include the Demised Premises, and if such leasehold estate shall terminate or be terminated for any reason, Tenant agrees, at the election and upon written notice of any
owner of the premises which include the Demised Premises, or, of any mortgagee in possession thereof; or of any holder of a leasehold thereafter affecting premises which include the Demised Premises, to attorn, from time to time, to any such owner,
mortgagee or holder, upon the terms and could it ions set forth herein for the remainder of the Term demised in this lease. 
  
 17.3. Acknowledgement by Tenant. The foregoing provisions shall inure to the benefit of any such owner, mortgagee or holder and shall be
self-operative upon any such demand, without requiring any further instrument to give effect to such provisions. 
  
 17.4 Non-Disturbance Protection. Notwithstanding the foregoing provisions of this Article 17, the subordination of this Lease and Tenant’s
obligations attorn to any such mortgagee or holder shall be conditioned upon its receipt of a Subordination, Non-Disturbance and Attornment Agreement (“SNDA”), in form and substance reasonably satisfactory to Tenant and any such mortgagee
or holder, which shall provide, among other things, that: 
  
 (a)
so long as Tenant is not in Default with respect to any of Tenant’s obligations under this Lease, Tenant shall not be joined as a party defendant (unless required by applicable law) (i) in any action or proceeding which may be instituted or
taken by any such holder for the purpose of terminating such underlying leasehold by reason of any default thereunder, or (ii) in any foreclosure action or proceeding which may be instituted by any such mortgagee; 
  
 (b) so long as Tenant is not in Default with respect to any of Tenant’s
obligations under this Lease, Tenant shall not be evicted from the Demised Premises, nor shall Tenant’s leasehold estate or right to possession of the Demised Premises be terminated or disturbed, by reason of any default under any such
underlying leasehold or mortgage; 
  

 30 

 (c) in the event of any act or omission of Landlord which would give Tenant the right, immediately or
after lapse of a period of time, to cancel or terminate this Lease, or to claim a partial or total eviction, Tenant shall not exercise such right: (i) until it has given written notice of such act or omission to each Landlord’s holder or
mortgagee whose name and address shall previously have been furnished to Tenant in writing, and (ii) unless such act or omission shall be one which is not capable of being remedied by Landlord or Landlord’s holder or mortgagee within thirty
(30) days, until a thirty (30) day period for remedying such act or omission shall have elapsed following the giving of such notice, provided Landlord’s holder or mortgagee shall with due diligence give Tenant written notice of its intention
to, and commence and continue to, remedy such act or omission. 
  
 (d) the holder or mortgagee shall not be: (i) liable for any previous act or omission of Landlord; (ii) subject to any defenses which Tenant nay have against Landlord; (iii) subject to any offsets which Tenant may have against any prior
landlord, except to the extent such offsets are expressly provided under the Lease and the holder or mortgagee has received notice thereof and the opportunity to cure within the applicable time periods set forth in the Lease; (iv) bound by any Net
Base Rent which Tenant might have paid for more than one month in advance of its due date under the Lease to Landlord, unless such additional rent is paid in accordance with the applicable provisions of this Lease; or (v) liable for the performance
of Landlord’s covenants and agreements contained in this Lease to any extent other than as successor landlord of the Demised Premises, and no other property of such holder or mortgagee shall be subject to levy, attachment, execution or other
enforcement procedure for the satisfaction of Tenant’s remedies. 
  
 Tenant acknowledges that it would be unreasonable to reject an SNDA which incorporates clauses (a) through (d) above, and otherwise does not result in an increase of Tenant’s monetary obligations under the Lease or materially and
adversely affect Tenant’s non-monetary obligations under the Lease. In addition, any SNDA may also provide that Tenant will, at the option of any such mortgagee or holder, either (x) attorn to such mortgagee or holder and perform for such
mortgagee’s or holder’s benefit all of the terms, covenants and conditions to be performed by Tenant under this Lease, or (y) enter into a new lease with such mortgagee or holder or their respective successors or assigns for the balance of
the Lease Term on the same terms and conditions as are contained in this Lease. Landlord shall have no liability to Tenant if, for any reason whatsoever, Tenant shall not receive an SNDA nor shall the same relieve or release Tenant from any of the
obligations of Tenant under this Lease. 
  
 ARTICLE 18.
ASSIGNMENT AND SUBLETTING 
  
 18.1. Restrictions Upon
Transfer. (a) Subject to the provisions of Section l8.4, Tenant expressly covenants that it shall not by operation of law or otherwise assign, encumber or mortgage this Lease in whole or in part, nor sublet or suffer or permit the Demised
Premises or any part thereof to be used by others, without the prior written consent of Landlord in each instance, which consent will not be unreasonably withheld, conditioned or delayed; provided, however, that (i) Landlord may withhold its consent
for any or no reason to any such transfer requested by Tenant prior to the commencement Date, and (ii) Landlord may withhold its consent for any or no reason to any such at transfer requested by Tenant prior to the l81st day following the Commencement Date except a transfer that involves an assignment of this Lease or a subletting (to one (1)
subtenant) of the entire Demised Premises or a portion of the Demised 

  

 31 

 
Premises containing no less than 150,000 rentable square feet (in which event, Landlord’s consent shall not be unreasonably withheld, conditioned or
delayed, as aforesaid). Any attempt by Tenant to assign, encumber or mortgage this Lease or sublet all or any portion of the Demised Premises without the express consent of Landlord shall he null and void. 
  
 (b) If Tenant’s interest in this Lease is assigned or if the Demised
Premises are sublet to or occupied by, or used by, anyone other than Tenant, whether or not in violation of this Article 18, Landlord may, after the occurrence of a Default by Tenant, accept from any assignee, subtenant or any one who claims a right
to the interest of Tenant under this Lease or who occupies any part(s) or the whole of the Demised Premises the payment of Net Base Rent and Additional Rent and/or the performance of any of the other obligations of Tenant under this Lease, but such
acceptance shall not be deemed to be a waiver by Landlord of the breach by Tenant of the provisions of this Article 18 nor a recognition by Landlord that any such assignee, subtenant, claimant or occupant has succeeded to the rights of Tenant
hereunder, or a release by Landlord of Tenant from further performance by Tenant of the covenants on Tenant’s part to be paid or performed under this Lease; provided, however, that the net amount of Net Base Rent and Additional Rent collected
from any such assignee, subtenant, claimant or occupant shall be applied by Landlord to the Net Base Rent and Additional Rent to be paid hereunder. 
  
 (c) Tenant agrees to pay to Land lord all out-of-pocket fees, costs and expenses (which in no event shall exceed $5,000.00 in any proposed transaction),
including, but not limited to, reasonable attorneys’ fees and disbursements, incurred by Landlord in connection with any proposed assignment of this Lease or any proposed sublease of the Demised Premises. 
  
 18.2. Landlord’s Consent Recapture. (a) If Tenant is required to
obtain Landlord’s consent to an assignment of this Lease or a subletting of all or any part of the Demised Premises (i.e., other than as set forth in Section 18.4 below), Tenant shall submit a request to Landlord and include the following
information: (i) the name of the proposed assignee or subtenant; (ii) the terms of the proposed assignment or subletting, including without limitation the proposed effective date thereof; (iii) the nature of the proposed assignee or subtenant’s
business and its proposed use of the Demised Premises; (iv) copies of the most recently available information regarding the financial responsibility of the proposed assignee or subtenant; and (v) description of any required revisions to the floor
layout of the Demised Premises. 
  
 (b) Provided Landlord receives
such information from Tenant, Landlord shall, within ten (10) business days of its receipt of Tenant’s request to assign or sublet, notify Tenant whether Landlord consents to or rejects the proposed assignment or subletting. 
  
 (c) In lieu of either consenting to or rejecting Tenant’s request,
Landlord shall have the option, to be exercised in writing within said ten (10) business day period, if the request is to assign this Lease or to sublet all of the Demised Premises for a proposed term of sixty (60) months or more (inclusive of
renewal terms in such subletting), to cancel and terminate this Lease, either with respect of such portion of the Demised Premises or, at Landlord’s option, with respect to the entire floor(s) of the building on which such portion(s) of the
Demised Premises is located (or such portion of the entire floor(s) as has been sublet to entities other than Related Entities in accordance with the provisions of this Article 18. The cancellation date shall be the proposed effective commencement
date referred to in Section l8.2(a)(ii) above, and upon such 

  

 32 

 
cancellation date, Tenant shall thereafter be released from all liability hereunder (in the case of a termination of this Lease for the entire Demised
Premises), or from all liability hereunder with respect to the portion of the Demised Premises so recaptured by Landlord (in the case of a termination of this Lease with respect to less than the entire Demised Premises). Landlord and Tenant shall
enter into a written agreement to reflect any Lease termination or Lease modification effected pursuant to this Section; provided, however, that the failure of the parties to execute such agreement shall not vitiate the effect of any cancellation
pursuant to this Section. 
  
 (d) If Landlord shall cancel this
Lease in whole or in part as above provided, Tenant shall surrender possession of the Demised Premises, or the portion of the Demised Premises which is the subject of the recapture, as the case may be, on the proposed effective commencement date
referred to in Section 18.2(a)(ii) above, in accordance with the provisions of this Lease relating to surrender possession of the Demised Premises (including without limitation, Section 33, 1 hereof). If this Lease shall be canceled as to a portion
of the Demised Premises only, (i) the Net Base Rent payable by Tenant hereunder and Tenant’s Proportionate Share of Operating Expenses and the number of parking spaces allocable to Tenant pursuant to Section 32.1 hereof, shall be reduced
proportionately according to the ratio that the portion of space surrendered bears to the entire Demised Premises, and (ii) Landlord, at Landlord’s expense shall make any alterations to the Demised Premises required to make the portion of the
Demised Premises surrendered a self-contained rental unit (including without limitation with access through corridors to the elevators and toilets serving such space). 
  
 (e) if Landlord does not respond to Tenant’s request for consent to assign this Lease or sublet the Demised Premises
within ten (10) business days of Landlord’s receipt thereof, Tenant may send Landlord a second request for consent (the ‘Second Notice”), which Second Notice shall contain in capital letters the following language: “TENANT’S
REQUEST FOR LANDLORD’S CONSENT AS SET FORTH HEREIN, WHICH REQUEST WAS PREVIOUSLY SUBMITTED TO LANDLORD, SHALL HE DEEMED GIVEN BY LANDLORD IF LANDLORD SHALL FAIL TO RESPOND TO THIS SECOND NOTICE WITHIN TEN (10) BUSINESS DAYS FROM RECEIPT
HEREOF.” Should Landlord so fail to respond to the Second Notice within such ten (10) business day period, Landlord’s consent, in such specific instance only, shall be deemed given. 
  
 (f) If Landlord’s consent is given (or deemed given, as aforesaid) and
the assignment or subletting does not become fully binding upon the parties thereto and effective within six (6) months of the proposed effective date referred to in Section l8.2(a)(ii) above, Landlord’s consent to such transaction shall again
be required. 
  
 18.3. Approval of Sublease or Assignment
Requiring Consent. (a) If Landlord shall consent to a sublease or an assignment pursuant to a request from Tenant, or if a sublease or assignment is permitted herein without Landlord’s consent, Tenant shall cause to be executed by its
assignee or subtenant an agreement to perform faithfully and to assume and be bound by all of the terms, covenants, conditions, provisions and agreements of this Lease for the period covered by the assignment or sublease and to the extent of the
space sublet or assigned (and, in the ease of a sublease, the subtenant shall agree to afloat to Landlord in the event this Lease is terminated as a result of a Default by Tenant hereunder and Landlord elects, at its sole option, to recognize such
subtenant as a direct tenant). An executed counterpart of each sublease or assignment and 

  

 33 

 
assumption of performance by the subtenant or assignee, in form and substance approved by Landlord, shall be delivered to Landlord within five (5) days prior
to the commencement of occupancy set forth in such assignment or sublease; no such assignment or sublease shall be binding on Landlord until Landlord has received such counterpart as required herein. In the case of an assignment, the assignor tenant
shall not be relieved or released from the performance of any of Tenant’s obligations under this Lease, nor shall such assignment be construed to impair or discharge any of said obligations. 
  
 (b) With respect to any such assignment of this Lease or to any such sublease
requiring Landlord’s consent, Tenant shall in consideration therefor pay to Landlord as Additional Rent the following amounts: 
  
 (i) in the case of an assignment, an amount equal to fifty percent (50%) of all sums and other considerations paid to Tenant by the
assignee for or by reason of such assignment (after deducting therefrom the out-of-pocket costs incurred by Tenant in connection with such assignment, including without limitation marketing expenses, brokerage commissions and attorneys’ fees),
together with such rental increment paid by such assignee in excess of the Net Base Rent and Recurring Additional Rent items in the same manner as hereinafter provided in subsection (ii); and 
  
 (ii) in the case of a sublease, fifty percent (50%) of any
rents, additional charges or other consideration payable under the sublease to Tenant by the subtenant which is in excess of the Net Base Rent and Recurring Additional Rent Items accruing during the term of the sublease in respect of the subleased
space (at the rate per square foot payable by Tenant hereunder) pursuant to the terms hereof (after deducting therefrom the out-of-pocket costs incurred by Tenant in connection with such sublease, including without limitation marketing expenses,
brokerage commissions and attorneys’ fees. 
  
 The sums payable under this
Section 18.3(b) shall be paid to Landlord as Additional Rent if, as and when paid by the assignee or subtenant to Tenant. 
  
 18.4 Transfers to Related/Successor Entities. (a) Notwithstanding the preceding provisions of this Article 18 of any other provision of this Lease,
Tenant may sublet all or any portion of the Demised Premises or assign this Lease to, or permit occupancy of all or a portion of the Demised Premises by, a Related Entity (as hereinafter defined) without being required to obtain Landlord’s
consent thereto, provided that at the time of any such sublet, assignment or grant of occupancy right no Default by Tenant shall have occurred and be continuing. Not later than ten (10) days after such subletting, assignment or grant of occupancy
right. Tenant shall notify Landlord of the subletting, assignment or grant of occupancy right and, in the case of a sublet or an assignment, deliver to Landlord an executed counterpart of such sublease or assignment and assumption of performance by
the subtenant or assignee. The term “Related Entity” shall mean an Affiliate of Tenant or any joint venture in which Tenant owns a fifty percent (50%) or greater equity interest, in the case of a subletting or grant of occupancy right,
such subletting or grant of occupancy right shall not be deemed to vest in any such Related Entity any right or interest in this Lease or a direct grant by Landlord of any right to occupy the Demised Premises, nor shall it relieve, release, impair
or discharge any of Tenant’s obligations 

  

 34 

 
under this Lease (including the obligation not to allow the Demised Premises to be used for any use or purpose other than the Permitted Use). In the case of
an assignment, the assignor tenant shall not be relieved or released from the performance of any of Tenant’s obligations under this Lease, nor shall such assignment be construed to impair or discharge any of said obligations. 
  
 (b) Notwithstanding the preceding provisions of this Article 18 or any other
provision of this Lease tenant may assign this Lease to a Successor Entity (as hereinafter defined) without being required to obtain Landlord’s consent thereto, provided that at the time of any such assignment no Default by Tenant shall have
occurred. Not later than ten (10) days after such assignment, Tenant shall notify Landlord of the assignment and deliver to Landlord an executed counterpart of such assignment and assumption of performance by the assignee. The term “Successor
Entity” shall mean any of the following: (x) a corporation or other entity into which or with which Tenant shall be merged or consolidated, in accordance with applicable statutory provisions for the merger or consolidation of corporations or
entities, provided that (whether by operation of law or by effective provisions contained in the instruments of merger or consolidation) the liabilities of the corporations participating in such merger or consolidation are assumed by the corporation
or entity surviving such merger or consolidation; or (y) a corporation or other entity acquiring this Lease and the term hereof and the estate hereby granted, the goodwill and all or substantially all of the other property and assets of Tenant, and
assuming all or substantially all of the liabilities of Tenant; or (z) any corporate or other business entity successor to a Successor Entity becoming such by either of the methods described in clauses (x) and (y) above; provided that, in each ease:
(1) such merger or consolidation, or such acquisition and assumption, as the case may be, shall be made for a good business purpose other than (and not principally for) the purpose of transferring the Leasehold estate created hereby, (2) immediately
after giving effect to any such merger or consolidation, or such acquisition and assumption, as the case may be, the corporation or other entity surviving such merger or created by such consolidation or acquiring such assets and assuming such
liabilities, as the ease may be, shall have a net worth, as determined in accordance with generally accepted accounting principles, of no less than One Hundred Million and no/100 Dollars ($100,000,000) and (3) proof reasonably satisfactory to
Landlord of such net worth shall have been delivered to Landlord at least ten (10) days after the effective date of any such transaction. In the case clan assignment, the assignor tenant shall not be relieved or released from the performance of any
of Tenant’s obligations under this Lease, nor shall such assignment be construed to impair or discharge any of said obligations. 
  
 (e) The transfer of the outstanding capital stock of, or interest in, any corporate or partnership tenant shall not he deemed an assignment of this Lease
(and Tenant shall not be required to furnish Landlord with the information described in the last sentence of Subsection 18.1(b) above) if such transfer shall be effected by the sale of such stock or interest through any recognized national stock
exchange. 
  
 18.5. Continuing Liability. In no event shall
any assignment or subletting to which Landlord may consent, release or relieve Tenant from its obligations to fully observe or perform all of the terms, covenants and conditions of this Lease on its part to be observed or performed. 
  
 18.6. No Waiver. Consent by Landlord to any assignment or subletting
shall not constitute a waiver of the necessity for such consent to any subsequent assignment or subletting. 
  

 35 

 18.7. Intentionally Omitted. 
  
 18.8. Restrictions upon Rental Arrangements. In no event shall Tenant assign this Lease or enter into any sublease,
license, concession or other agreement for use, occupancy or utilization of any part of the Demised Premises which provides for a rental or other payment for such use, occupancy or utilization based in whole or in part on the income or profits
derived by any person from the Demised Premises leased, used, occupied or utilized (other than an amount based on a fixed percentage or percentages of gross receipts or sales), and Tenant agrees that aft assignments, subleases, licenses, concessions
or other agreen1ents for use, occupancy or utilization of any part of the Demised Premises shall provide that the
person having an interest in the possession, use, occupancy or utilization of the Demised Premises shall opt enter into any lease, sublease, license, concession or other agreement for use, occupancy or utilization of space in the Demised Premises
which provides for a rental or other payment for such use, occupancy or utilization based in whole or in part on the income or profits derived by any person from the Demised Premises leased, used, occupied or utilized (other than an amount based on
a fixed percentage or percentages of gross receipts of sales) and any such purported assignment, sublease, license, concession or other agreement shall be absolutely void and ineffective as a conveyance of any right or interest in the possession,
use, occupancy or utilization of any part of the Demised Premises. 
  
 18.9. Intentionally Omitted. 
  
 18.10. Further
Subletting and Assignment. My subsequent sublease by an assignee or further sublease by a subtenant shall be subject to the terms and conditions of this Article 18. 
  
 ARTICLE 19. RULES AND REGULATIONS 
  
 19.1. Rules and Regulations. Tenant and Tenant’s Visitors shall at all Limes abide by and observe the rules and
regulations attached hereto as Exhibit “E” and all other rules or regulations that Landlord may promulgate from time to time for the operation and maintenance of the Property or the Complex, provided that notice thereof is given to Tenant,
that such other rules and regulations are not inconsistent with the provisions of this Lease, and that such rules and regulations are reasonable and are not discriminatory. Landlord shall not be liable to Tenant for the violation of any such rules
or regulations by any other tenant or its employees, agents, invitees, or licensees. If there is any inconsistency between this Lease and any rules and regulations promulgated by Landlord, including without limitation those set forth in Exhibit
“E”, this Lease shall govern. Landlord agrees that all such rules and regulations shall be uniformly applied to all similarly situated tenants. 
  
 ARTICLE 20. PERFORMANCE OF OTHER PARTY’S COVENANTS 
  
 20.1. Landlord’s Right to Perform. If Tenant fails to perform any of its respective obligations hereunder within applicable notice and cure
periods (or sooner in the event of an emergency), Landlord may (but shall not be obligated to) perform such obligation, in which event the cost of such performance, including but not limited to reasonable attorneys’ fees in instituting,
prosecuting or defending any action or proceeding, together with interest thereon at the Default Rate from the date of payment and, in addition, in the case of repair or replacement 

  

 36 

 
required to be made by Tenant pursuant to Article 6, an administrative cost recovery charge of five percent (5%) of the cost of such repair or replacement,
shall be reimbursed by Tenant as Additional Rent upon thirty (30) days’ prior demand therefor. The performance of such obligation by Landlord shall not constitute a waiver of any right or remedy of Landlord arising from such failure of Tenant.

  
 20.2. Tenant’s Right to Perform. If Landlord fails
to perform any of its respective obligations under Article 6 or Article 8 hereof, Tenant may, after thirty (30) days’ notice to Landlord and Landlord’s failure to commence to cure such failure within such time flame and thereafter
diligently prosecute such cure to completion (but shall not be obligated to) perform such obligation, in which event the cost of such performance, including but not limited to reasonable attorneys’ fees in instituting, prosecuting or defending
any action or proceeding, together with interest thereon at the Default Rate from the dale of payment and, in the case of repair or replacement required to be made by Landlord pursuant to Article 6, an administrative cost recovery charge of five
percent (5%) of the cost of such repair or replacement, shall be reimbursed by Landlord upon thirty (30) days’ prior demand therefor, Notwithstanding anything contained herein. Tenant shall not make any repairs to the roof or other structural
portions of the Building, or to any plumbing, mechanical, heating, air- conditioning, or electrical systems in the Building. The performance such obligation by Tenant shall not constitute a waiver of any right or remedy of Tenant arising from such
failure of Landlord. Notwithstanding the foregoing, Landlord’s breach, default or non-performance of any of Landlord’s covenants or obligations under this lease shall not excuse Tenant of Tenant’s covenants and obligations under this
Lease, including, without limitation, the obligation to pay Net Base Rent and Additional Rent. 
  
 ARTICLE 21. AIR AND LIGHT 
  
 21.1. Air and Light Rights. This lease does not grant any right to air and light. 
  
 ARTICLE 22. NOTICES 
  
 22.1. Notices to Tenant. Any notice or demand given by Landlord to Tenant (except for invoices) shall be in writing and shall be deemed to have been duly
given if sent by registered or certified mail, return receipt requested, postage prepaid, or sent by a nationally recognized overnight receipted delivery service, with receipt acknowledged, addressed to Tenant as follows: 
  
 Aventis Pharmaceuticals Inc. 
 399 Interpace Parkway 
 Parsippany, New
Jersey 07054 
 Attention: General Counsel 
 Telephone #973-394-6262 
 Facsimile #973-394-7222 
  

 37 

	 with a copy to:
	  	 Aventis Pharmaceuticals Inc.

	 	  	Route 202-206
	 	  	Post Office Box 6800
	 	  	Bridgewater, New Jersey 08807-0800
	 	  	Attention: N.A. Real Estate
	 	  	Telephone # 908-231-3821
	 	  	Facsimile # 908-231-3221

  

	 And a copy to:
	  	 Morgan, Lewis & Bockius LLP

	 	  	 1701 Market Street

	 	  	 Philadelphia, PA 19103-2921

	 	  	 Attention; Robert L. Cooney, Jr., Esq.

	 	  	 Telephone # (215) 963-5000

	 	  	 Facsimile #(215)963-5299

  
 or to such other address as Tenant may
from time to time designate by written notice to Landlord. Notwithstanding the foregoing) invoices may be sent by first-class mail, postage prepaid, addressed to Tenant as follows: 
  
 Aventis Pharmaceuticals Inc. 
 Route 202-206 
 Post Office Box 6800 
 Bridgewater, New Jersey 08807-0800 
 Attention: N.A. Real Estate 
 Telephone #908-231-3821 
 Facsimile 1/908-231-3821 
  
 or to such other address as Tenant may from time to time designate by written notice to Landlord. 
  
 22.2. Notices to Landlord. Any notice or demand to be given by Tenant to Landlord shall be in writing and shall he
deemed to have been duly given if sent by registered or certified mail, return receipt requested, postage prepaid, or sent by a nationally recognized overnight receipted delivery service, with receipt acknowledged, addressed to Landlord as follows:

  

	 	 	 Bridgewater Hines Development LLC

	 	 	 885 Third Avenue, Suite 2701)

	 	 	 New York, NY 10022

	 	 	 Attn: Jeff Spiritos

	 	 	 Telephone # (212) 230-2300

	 	 	 Facsimile # (212) 230-2276

  

	 with a copy to:
	  	 Bridgewater Hines Development LLC

	 	  	 c/o Hines Interests limited Partnership

	 	  	 2800 Post Oak Boulevard, 50th Floor

	 	  	 Houston, TX 77056-6118

  

 38 

	 	 	 Attn: C. Hastings Johnson

	 	 	 Telephone # (713) 621-8000

	 	 	 Facsimile # (713) 966-2636

  

	 and a copy to:
	  	 Sills Cummis Radin Tischman Epstein & Gross, P.A.

	 	  	 One Riverfront Plaza

	 	  	 Newark, New Jersey 07102

	 	  	 Attn:Ted Zangari, Esq.

	 	  	 Telephone # (973) 643-5781

	 	  	 Facsimile # (973) 643-6500

  
 or to such other-address or addresses
as Landlord may from time to time designate by written notice to Tenant, except that payment of Rent shall be to the address set forth in Section 5.13 above, 
  
 22.3. Effectiveness of Notices. Notice sent in compliance with the provisions of this Section shall be deemed given on the business day next
following the day on which notice was sent if sent by overnight mail, or three (3) business days next following the day on which notice was sent if sent by registered or certified mail. The listing of telephone and facsimile numbers above shall not
he construed to mean that notices shall be deemed to have been given if sent telephonically or by facsimile (however, Landlord and Tenant may, for informational purposes, elect to send a copy of any notice by such means). 
  
 ARTICLE 23. INTENTIONALLY OMITTED 
  
 ARTICLE 24. EVENTS OF DEFAULT 
  
 24.1 Matters Constituting a Default. The occurrence of any of the
following shall constitute a “Default” under this Lease: 
  
 (a) if Tenant shall fail to pay any installment of Net Base Rent or Additional Rent when due, or fail to pay when due any other payment required by this Lease, and in each case such failure shall continue for a period often (10) days
following written notice thereof to Tenant; 
  
 (b) If Tenant
shall violate or fail to perform any other term, condition, covenant or agreement to be performed or observed by Tenant (under this Lease and such violation or failure shall continue for a period of thirty (30) days after written notice thereof to
Tenant; provided however, that if such violation or failure is capable of being cured within a reasonable period, but cannot be cured within such thirty (30) day period, then provided Tenant commences to cure such violation or failure within said
thirty (30) day period and thereafter diligently prosecutes same to completion, Tenant shall have such period of time longer than thirty (30) days as is reasonably necessary to cure such violation or failure; 
  

 39 

 (c) If Tenant or any guarantor or surely of this Lease shall generally not pay its debts as they become
due, or shall admit in writing its inability to pay its debts, or shall make a general assignment for the benefit of creditors; 
  
 (d) If Tenant or any guarantor or surely of this Lease shall commence any case, proceeding or other action seeking reorganization, arrangement,
adjustment, liquidation, dissolution or composition of it or its debts under any law relating to bankruptcy, insolvency, reorganization or relief of debtors, or seeking appointment of a receiver, trustee, custodian or other similar official for it
or for all or any substantial part of its property, and such case, proceeding or other action results in the entry of an order for relief against it which remains undismissed for a period of ninety (90) days; 
  
 (e) If any case, proceeding or other action against Tenant or any guarantor
or surety of this Lease shall be commenced seeking to have an order for relief entered against it as debtor, or seeking reorganization, arrangement, adjustment liquidation, dissolution or composition of it or its debts under any law relating to
bankruptcy, insolvency, reorganization or relief of debtors, or seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or any substantial part of its property, and such case, proceeding or other action
results in the entry of an order for relief against it which remains undismissed for a period of ninety (90) days; 
  
 (f) Intentionally Omitted. 
  
 (g) The liquidation or dissolution of any corporate surety or guarantor of this Lease; 
  
 (h) Any event shall occur or any contingency shall arise whereby this Lease or the estate hereby granted or the unexpired
balance of the Lease Term would, by operation of law or otherwise, devolve upon or pass to any person, firm, association or corporation other than Tenant, except as maybe expressly authorized in Article 18 above; and 
  
 (i) Any surety or guarantor of this Lease fails to comply with all the
provisions of the suretyship or guaranty agreement and such failure continues beyond any applicable notice and cure periods contained therein. 
  
 ARTICLE 25. RIGHTS OF LANDLORD UPON DEFAULT BY TENANT 
  
 25.1. Landlord’s Remedies. If any Default occurs, Landlord may, notwithstanding the fact that Landlord may have other remedies hereunder or at
law or in equity by notice to Tenant, designate a date, not less than five (5) business (days after the giving of such notice, on which this Lease shall terminate; and thereupon, the Term of this Lease and the estate hereby granted shall expire and
terminate on such date with the same force and effect as if the date specified in such notice were the Termination Date and all rights of Tenant hereunder shall expire and terminate but Tenant shall remain liable as provided in this Lease, and
Landlord shall have the right to remove all persons, goods, fixtures and chattels from the Demised Premises, by reasonable force or otherwise, without liability or damages to Tenant. If Landlord elects to terminate this Lease, everything contained
in this Lease on the part of Landlord to be done and performed shall cease without prejudice, subject, however, to the right of Landlord to recover 

  

 40 

 
from Tenant all Rent and other sums accrued up to the time of termination or recovery of possession by Landlord, whichever is later, and all Rent remaining
to be paid under this Lease (in the manner hereinafter set forth). 
  
 Whether or not Landlord elects to terminate this Lease, Landlord may re-enter and take possession of the Demised Premises and the provisions of this Article 25 shall operate as a native to quit, any other notice to quit or of
Landlord’s intention to re-enter the Demised Premises being hereunder expressly waived if necessary, Landlord may proceed to recover possession of the Demised Premises under and by virtue of the laws of the State of New Jersey or by such other
proceedings, including re-entry and possession, as may be applicable. Following such taking of possession, Landlord may in its own name, but as agent for Tenant, assign, sublet or relet the Demised Premises for any period equal to or greater or less
than the remainder of the Term hereof for any sum which Landlord may deem reasonable to any lessee Landlord may select, and for any use or purpose which Landlord may designate. If the full rental provided herein plus the costs, expenses and damages
hereafter described shall not be realized by Landlord in any assignment, subletting or reletting, Tenant shall be liable for all damages sustained by Landlord, including, without limitation, (1) the deficiency in Net Base Rent and Additional Rent,
and (ii) the cost of recovering the Demised Premises, reasonable attorneys’ fees and court costs, collection costs, brokerage fees, reasonable rental concessions and/or tenant improvement allowances, and the expense of placing the Demised
Premises in first-class rentable condition (the items in this clause (ii) being collectively Referred to as the “Reletting Expenses”). Landlord shall in no way he responsible or liable for any failure to relet the Demised Premises or any
part thereof, or any failure to collect any Rent due and/or accrued from such retelling, to the end and intent that Landlord may elect to hold Tenant liable for the Net Base Rent, Additional Rent, and any and all other items of cost and expense
which Tenant shall have been obligated to pay throughout the remainder of the Lease Term. Any damages or loss of Rent sustained by Landlord may be immediately recovered by Landlord, at Landlord’s option, at the time of the reletting, or in
monthly payments, or in separate actions, from time to time, as said damages shall have been made more easily ascertainable by successive relettings, or, at Landlord’s option may be deferred until the expiration of the Lease Term, in which
event Tenant hereby agrees that the cause of action shall not be deemed to have accrued until the date of expiration of the Lease Term. 
  
 Alternatively, landlord may, at its sole option, recover from Tenant all damages it may sustain by reason of Tenant’s Default, including the
Reletting Expenses, and, in addition, Landlord shall be entitled to recover from Tenant, as and for liquidated damages, and not as a penalty, an amount equal to the difference between the rents, charges and other sums reserved hereunder or the
period which otherwise would have constituted the balance of the Term from the latest of the date of termination of this Lease, the date of reentry or the date through which monthly deficiencies shall have been paid in full (conclusively presuming
the Recurring Additional Rent items to be 105% of the amount payable for the year immediately preceding such termination or reentry) and the fair market rental value of the Demised Premises (at the time of such election) for such period, discounted
to present value using a discount factor of the “prime rate” then being published by Citibank, NA., all of which shall immediately be due and payable by Tenant to Landlord. 
  

 41 

 The provisions contained in this Section shall he in addition to, and shall not prevent the enforcement
of, any claim Landlord may have against Tenant for anticipatory breach of this Lease. 
  
 25.2. Remedies Cumulative. All rights and remedies of Landlord set forth herein are in addition Lu all other rights and remedies available to Landlord at law or in equity. All rights and remedies available to
Landlord hereunder or at law or in equity are expressly declared to be cumulative. The exercise by Landlord of any such tight or remedy shall not prevent the concurrent or subsequent exercise of any such right or remedy. No delay in the enforcement
or exercise of any such right or remedy shall constitute a waiver of any default by Tenant hereunder or of any of Landlord’s rights or remedies in connection therewith. Landlord shall not be deemed to have waived any default by Tenant hereunder
unless such waiver is set forth in a written instrument signed by Landlord. If Landlord waives in writing any default by Tenant, such waiver shall not he construed as a waiver of any covenant, condition or agreement set forth in this Lease except as
to the specific circumstances described in such written waiver. The rights hereunder granted to Landlord shall also be the rights of Tenant in the same manner as hereinabove provided for Landlord. 
  
 25.3. No Waiver. If Landlord shall institute proceedings against
Tenant and a compromise or settlement thereof shall be made, the same shall not constitute a waiver by Landlord of any future breach or of any other covenant, condition or agreement set forth herein, nor of any of Landlord’s rights hereunder.
Neither the payment by Tenant of a lesser amount than the installments of Net Base Rent, Additional Rent or of any sums due hereunder nor any endorsement or statement on any check or letter accompanying a check for payment of Rent or other sums
payable hereunder shall be deemed an accord and satisfaction, and Landlord may accept such cheek or payment without prejudice to Landlord’s light to recover the balance of such Rent or other sums or to pursue any other remedy available to
Landlord. No re-entry by Landlord, and no acceptance by Landlord of keys from Tenant, shall be considered an acceptance of a surrender of this Lease. 
  
 25.4. Payments to Landlord After Default. If a Default by Tenant under this Lease shall have occurred and be continuing (or sooner in the event of
a breach or other default of this Lease deemed by Landlord to be a bona fide emergency), then Landlord may, but shall not be required to, make such payment or do such act. If Landlord elects to make such payment or do such act, all costs and
expenses incurred by Landlord, plus interest thereon at the rate per annum, which is two percent (2%) higher than the “prime rate” then being published by Citibank, N.A. (the “Default Rate”), at the main branch bank in New York
City, from the date paid by Landlord to the day of payment thereof by Tenant, shall be immediately paid by Tenant to Landlord; provided, however, that nothing contained herein shall be construed as permitting Landlord to charge or receive interest
in excess of the maximum legal rate then allowed by law. The taking of such action by Landlord shall not be considered as a cure of such Default (or breach so deemed an emergency by Landlord, as applicable) by Tenant or prevent Landlord from
pursuing any remedy it is otherwise entitled to in connection with such Default. 
  
 25.5. Tenant’s Waivers. Tenant expressly waives the benefit of any and all laws now made or which may hereafter be made, exempting or releasing goods on said Demised Premises 

  

 42 

 
or elsewhere any property in any way belonging to Tenant, from levy and sale upon distress for Rent or other charges herein reserved or payable as Rent, or
upon an execution on any judgment obtained in an action brought for nonpayment of Rent, or in any and all suits, actions or proceedings, amicable or otherwise, for the collection of Rent or other charges herein reserved or payable as Rent due and in
arrears, for any expense incurred in removing rubbish or refuse matter from said Demised Premises, and for any damage for the non-fulfillment of any of the covenants herein contained. Notwithstanding anything contained herein to the contrary, in no
event shall Landlord be liable for, and Tenant hereby waives any claim for, consequential or speculative damages hereunder. 
  
 25.6 Mitigation of Damages. Any provision of this Article 25 to the contrary notwithstanding, Landlord shall use commercially reasonable efforts to
relet the Demised Premises to mitigate Landlord’s damages following the occurrence of a Default by Tenant and Landlord’s recovering possession of the Demised Premises, provided, however, nothing herein shall be construed to require
Landlord to relet the Demised Premises ahead of other similar office premises owned or managed by Landlord or an Affiliate of Landlord in the Somerset County, New Jersey area which are then available for leasing or are about to become available for
leasing. 
  
 ARTICLE 26. ACCESS 
  
 26.1. Landlord’s Entry. Landlord and its authorized
representatives, upon reasonable advance notice (except in an emergency, in which case no notice shall be required, but Landlord shall exercise its commercially reasonable efforts to notify Tenant), may enter the Demised Premises during Business
Hours (except in the event of an emergency) (i) to inspect, make repairs, replacements and improvements to or installations in the Demised Premises or any Building system or facility which Landlord may deem necessary or reasonably desirable, (ii) to
perform following Tenant’s failure to make repairs or perform under this Lease, (iii) for the purpose of complying with laws, regulations and other directions of governmental authorities, or (iv) to show the Demised Premises to prospective
purchasers, investors, encumbrancers, tenants (during the eighteen (18) months immediately preceding the expiration of the Term then in effect), without the same constituting an eviction. In the event Landlord so enters the Demised Premises, it
shall be escorted through the Demised Premises by Tenant (except in the case of an emergency) and comply with such reasonable privacy limitations as Tenant may impose with respect to access to any security-restricted portions of the Demised Premises
((except in the event of an emergency). If Tenant is not present to open and permit entry into the Demised Premises, Landlord or its authorized representatives may enter the same whenever such entry may be necessary or permissible by master key or
forcibly and provided reasonable care is exercised to safeguard Tenant’s properly and such entry shall nut render Landlord or its agents liable therefor, nor in any event shall the obligations of Tenant hereunder be affected. In all of the
foregoing instances, however, Landlord shall exercise commercially reasonable efforts to minimize interference with Tenant’s operations. Notwithstanding the foregoing or anything else to the contrary contained in this Lease, if Tenant’s
operations are interrupted as a result thereof and such interruption shall continue for more than two (2) consecutive business days after notice from Tenant to Landlord of such interruption, and provided such interruption renders all or any portion
of the Demised Premises untenantable, then as Tenant’s sole remedy with respect 

  

 43 

 
thereto, Net Base Rent shall be proportionately abated hereunder commencing on the third (3rd) business day after notice of such interruption, retroactive to
the commencement of the interruption, to the extent, if any, that the amount of such abatement is actually reimbursed to Landlord under policies of rent interruption insurance maintained by Landlord as an Operating Expense for the Property.

  
 ARTICLE 27. CUSTOM AND USAGE PRESUMPTION OF CONSTRUCTION

  
 27.1. Enforcement of Lease Provisions. Landlord and
Tenant shall have the right at all times to enforce the covenants and conditions of this Lease in strict accordance with the terms hereof despite any conduct or custom on the part of either Landlord or Tenant in refraining from so doing at any time
or times, and despite any contrary law, usage or custom or any failure by either to enforce its rights at any time or times. 
  
 27.2. Presumption of Construction. This Lease shall be construed without regard to any presumption or other rule requiring construction against the
party causing this Lease to be drafted. 
  
 ARTICLE 28. SCOPE
AND INTERPRETATION OF AGREEMENT 
  
 28.1. Sole Agreement:
Governing Law. This Lease is the only agreement between the parties hereto pertaining to the Demised Premises, and all negotiations and oral agreements are included herein. The laws of the state in which the Demised Premises is located shall
govern the validity, interpretation, performance and enforcement of this Lease. 
  
 ARTICLE 29. CAPTIONS 
  
 29.1. Captions. Any headings preceding the text of the several Articles and subparagraphs hereof are inserted solely for convenience of reference and shall not constitute a part of this Lease nor shall they affect its meaning,
construction or effect. 
  
 ARTICLE 30. SEVERABILITY

  
 30.1. Enforcement of Remaining Provisions. If any
provision of this Lease is held to be invalid, the remaining provisions shall not be affected thereby, but shall continue in full force and effect. 
  
 ARTICLE 31. PARTIES, SUCCESSORS AND ASSIGNS 
  
 31.1. Definition Tenant. The term “Tenant” shall refer to each and every person or party mentioned as a Tenant herein, be the same one or
more. If there shall be more than one Tenant, they shall be bound jointly and severally by all of the terms, covenants and agreements of this Lease and any notice required or permitted by the terms of this Lease may be given by or to any one thereof
and shall have the same force and effect as if given by or to all. 
  

 44 

 31.2. Definition of Landlord. The term “Landlord” as used in this Lease shall refer only
to the owner for the time being of Landlord’s estate in the Demised Premises or the Building of which it is a part. Landlord shall be and is hereby relieved of all covenants and obligations of Landlord hereunder after the date of transfer of
Landlord’s estate in the Demised Premises or the Building of which it is a part, and it shall be construed without further agreement between the parties that the transferee has assumed and agreed to carry out any and all covenants and
obligations of Landlord hereunder during such time as said transferee shall own or hold Landlord’s estate or interest in the Demised Premises or the Building of which it is a part. Tenant agrees to attorn to any such purchaser or transferee
upon all terms and conditions of this Lease. The provisions of this Article 31 shall apply to each successive transfer of Landlord’s interest or estate. Notwithstanding anything contained herein, Landlord agrees that it shall not ground lease,
sell, transfer or otherwise convey fee ownership of the Demised Premises, the Property or the Complex to any person or entity, other than an Affiliate of Landlord, prior to the Commencement Date. 
  
 31.3. Extent of Landlord’s Liability. The liability of Landlord
under this Lease shall be and is hereby limited to Landlord’s interest in the Demised Premises and the Building of which it is a part, and the proceeds therefrom (except to the extent any lender has prior rights thereto), and no other asset of
Landlord shall be affected by reason of any liability which Landlord may have to Tenant or to any other person by reason of this Lease, the execution thereof, or the acquisition of Landlord’s interest. In no event shall any member, shareholder,
partner, officer or employees of Landlord be held to have any personal liability for satisfaction of any claims or judgments that Tenant may have against Landlord. 
  
 31.4. Successors and Assigns. Subject to the provisions of Article 18 and Section 31.2 hereof, all rights,
obligations and liabilities hereupon given to or imposed upon the respective parties hereto shall extend to and bind the several and respective heirs, executors, administrators, successors, sub-tenants and assigns of said parties. 
  
 31.5 No Personal Liability. In no event shall any member, shareholder,
partner, officer or employees of Tenant be held to have any personal liability for satisfaction of any claims or judgments that Landlord may have against Tenant. 
  
 ARTICLE 32. PARKING PRIVILEGES 
  
 32.1. Parking Allocation. Tenant, is hereby entitled to utilize, at no additional charge, on an exclusive basis (for
so long as Tenant is in possession of the entire Building; otherwise, on a non-exclusive basis)) one thousand thirty-two (1.032) parking spaces, which parking spaces shall be unassigned; any additional parking spaces required or used by Tenant shall
only be available after obtaining Landlord’s prior approval. Landlord shall have, in its reasonable discretion, the right to assign parking spaces. Subject to Article 19 hereof, Tenant covenants and agrees to comply with all reasonable rules
and regulations which Landlord may from time to time make to assure proper use of parking spaces by permitted users, including but not limited to the prohibition of overnight parking. Landlord’s remedies under such tides and regulations may
include, but shall not be limited to, the right to tow away at owner’s expense any vehicles not parked in compliance with these rules and regulations. Landlord shall not be responsible to 

  

 45 

 
Tenant for the non-compliance or breach by any other tenant of said rules and regulations. Parking may be provided by a parking contractor selected by
Landlord. Tenant shall use good faith, commercially reasonable efforts to require its employees to park in the parking area of the Property dedicated to the Building (and not in the parking area of the Property dedicated to 400 Crossing Boulevard,
as shown on Exhibit A-2 annexed hereto). 
  
 32.2. Designation
of Visitor Parking. Provided that Tenant is in possession of the entire Building, and subject to applicable Legal Requirements, Tenant shall have the right to designate which parking spaces are to be used for visitor parking and, upon
Tenant’s request, Landlord shall install signage identifying such spaces as being for the use of visitors (the cost of which signage shall be included in Operating Expenses). Nothing contained herein shall he deemed to obligate Landlord to
police or otherwise enforce the use of such spaces by visitors, it being agreed that any such enforcement shall be the sole obligation of Tenant. 
  
 ARTICLE 33. SURRENDER OF DEMISED PREMISES 
  
 33.1. Tenant’s Obligations upon Surrender. On the Termination Date, or earlier permitted termination of the Lease Term, Tenant shall quit and
surrender the Demised Premises in good and orderly condition and repair (reasonable wear and tear, and damage by fire or other casualty excepted) and shall deliver and surrender the Demised Premises to Landlord peaceably, together with all
alterations, additions and improvements in, to or on the Demised Premises made by Tenant as permitted under the Lease, except to the extent any of the foregoing are required to be removed pursuant to Sections 6.2 and 7.1 and/or are installed by
Tenant in violation of this Lease. Tenant’s obligations shall survive the surrender and the delivery of the Demised Premises as provided hereunder. Prior to the expiration of the Lease Term, Tenant shall also remove all of its movable property,
equipment and trade fixtures from the Demised Premises without damage, leaving the Demised Premises in broom-clean condition. All such personal property not removed by Tenant shall he deemed abandoned by Tenant and Landlord reserves the right to
charge the cost of such removal to Tenant, which obligation shall survive the Lease termination and surrender hereinabove provided. 
  
 3.2 Holdover. Landlord and Tenant have agreed that in the event of any unauthorized holdover (i) Landlord’s damages shall include but shall
not be limited to a monthly use and occupancy charge to be computed at the rate of 200% of the monthly installment of Net Base Rent due and payable in the last full month of the Term then in effect, and (ii)Tenant’s use and occupancy of the
Demised Premises shall be on the terms and conditions of this Lease, including without limitation the obligation to pay the Recurring Additional Rent Items that become due and payable during such holdover period at the rate of 200% of such amount.
The payment of the use and occupancy charge, in the event of such Tenant holdover, shall not be deemed or construed to create a further relationship of Landlord and Tenant hereunder. In addition, such charge shall not derogate from or diminish the
additional damages resulting from Tenant’s holdover, if any, as provided in the last sentence of this Section 33.2. Notwithstanding the foregoing, provided that no Default by Tenant under this Lease shall have occurred and be continuing as of
the date Tenant notifies Landlord of its election to do so, Tenant may extend the Term hereof as it relates to the Demised Premises for up to six (6) months (and such extension shall not constitute a holdover), provided that (i) Tenant shall notify
Landlord of its election to so 

  

 46 

 
extend the Term by giving Landlord notice thereof not less than eighteen (18) months prior to the expiration of the Term then in effect, TIME BEING STRICTLY
OF THE ESSENCE, (ii) the notice to Landlord specifies the period of time (in whole months), not to exceed six (6) months, by which the Term shall be so extended, (iii) the Net Base Rent for such extension period shall be computed at the rate of 150%
of the monthly installment of Net Base Rent due and payable in the last full month of the Term then in effect) and (iv) Tenant’s use and occupancy of the Demised Premises shall be on the terms and conditions of this Lease, including without
limitation the obligation to pay the Recurring Additional Rent Items that become due and payable during such extension period. In the event Tenant so timely extends the Term, then the Termination Date shall be so extended, and upon the Termination
Date, as so extended, the other provisions of this Article 33 shall immediately and automatically apply. If the Tenant shall so holdover, Tenant shall indemnify Landlord against loss or liability resulting from delay by Tenant in surrendering the
Demised Premises, including, without limitation any claims made by any succeeding tenant founded on the delay. 
  
 ARTICLE 34. BROKERS 
  
 34.1. Tenant’s Representation. Tenant represents that it has not dealt with any other real estate brokerage firm other than the Brokers with regard to the leasing of the Demised Premises pursuant to the
terms of this Lease. Tenant agrees to indemnify and hold Landlord harmless from any and all claims of brokers other than Brokers and expenses in connection therewith arising out of or in connection with the negotiation of or the entering into this
Lease by Landlord and Tenant due to any action of Tenant. 
  
 34.2. Landlord’s Representation. Landlord represents that it has not dealt with any other real estate brokerage firm other than the Brokers with regard to the leasing of the Demised Premises pursuant to the terms of this Lease.
Landlord agrees to indemnify and hold Tenant harmless from any and all claims of brokers (including Landlord’s Broker, but excluding Tenant’s Broker) and expenses in connection therewith arising out of or in connection with the negotiation
of or the entering into this Lease by Landlord and Tenant due to any action of Landlord. 
  
 34.3. Commissions. Landlord shall pay the Brokers their commission pursuant to a separate agreement between Landlord and each Broker.

  
 ARTICLE 35. SIGNAGE AND FIXTURES 
  
 35.1. Signs. (a) No sign, advertisement or notice referring to Tenant
(other than signs located in the interior of the Demised Premises and not visible from the exterior of the Demised Premises) shall be inscribed, painted, affixed or otherwise displayed on any part of the exterior or the interior of the Building
without the prior approval of Landlord, which approval shall not be unreasonably withheld, conditioned or delayed. All of Tenant’s signs that are approved by Landlord shall be installed at Tenant’s cost and expense, in accordance with
Article 7. If any sign, advertisement or notice that has not been approved by Landlord is exhibited or installed by Tenant, Landlord shall have the right to remove the same at Tenant’s expense. Tenant may list the name of its firm, together
with the names of all officers of Tenant located at the Demised 

  

 47 

 
Premises, on the office directory (if any) in the lobby, at no additional charge to Tenant (except that the costs of operating, maintaining, repairing and
replacing such directory may be included in Operating Expenses); 
  
 (b) Provided that Tenant obtains any governmental approvals for a monument sign that is in addition to (and not to the exclusion of) a monument sign that may be erected by the Landlord for the Property, Tenant, at its expense and subject to
obtaining any required governmental permits and approvals, may install (for Tenant’s exclusive use or, at Tenant’s option, for the exclusive use of any subtenantor Tenant), maintain, repair and replace a monument sign (the
“Tenant’s Monument Sign) on the Land in the location at the entrance to the Property to be mutually acceptable to Landlord and Tenant. The design and specifications for the monument to be used for Tenant’s Monument Sign shall be
subject to the prior written approval of Landlord, Which approval shall not be unreasonably withheld, conditioned or delayed. The specifications for the letters and symbols used on Tenant’s Monument Sign shall also be subject to the prior
written approval of Landlord, which approval shall not be unreasonably withheld, conditioned or delayed. In the event that Tenant does not obtain approval for a separate monument sign, Landlord shall make space available on its monument sign, if
any, for Tenant’s use. 
  
 (c) So long as Aventis
Pharmaceuticals Inc., or any Related Entity, or any Successor Entity thereto, taken together, are in possession of, in the aggregate, at least 400,000 rentable square feet in the Complex, Tenant, at its expense and subject to its obtaining any
required governmental permits and approvals, shall have the right to install, maintain, repair and replace a sign on the exterior of the Building (the “Tenant’s Building Exterior Sign”) in a location that is approved by 1andlord,
which approval is not to be unreasonably withheld, conditioned or delayed, and by all governmental authorities having jurisdiction over the installation of Tenant’s Building Exterior Sign. The design and specifications for Tenant’s
Building Exterior Sign (including the specifications for the letters and symbols proposed to be utilized thereon) shall be subject to the prior written approval of Landlord, which approval shall not unreasonably be withheld, conditioned or delayed.
Landlord agrees that during the Term Tenant’s Building Exterior Sign shall he the only sign identifying a tenant on the exterior walls of the Building. 
  
 35.2. Tenant’s Equipment and Fixtures. Landlord shall have the right to prescribe the weight and position of safes, and other heavy equipment
and fixtures, which, if allowed by Landlord, shall be installed in such manner in order to distribute their weight adequately. Tenant, in any event, shall not install any furniture, fixtures or equipment which shall exceed floor loads of the
Building specified in the Work Letter. Any and all damage to the Demised Premises or the Building caused by moving the same in or upon the Demised Premises, shall be repaired by and at the sole cost of Tenant. No furniture, equipment or other bulky
matter of any description will be received into the Building or carried in the elevators, except as approved by Landlord, and all such furniture, equipment and other bulky matter shall be delivered only through the designated delivery entrance of
the Building and the designated freight elevator. Landlord may, but shaft not be obligated to, supervise all moving of furniture, equipment and other materials, but Landlord shall not, however, be responsible for any damage to or charges for moving
the same. Tenant agrees to remove promptly from the sidewalks adjacent to the Building any of Tenant’s furniture, equipment or other material there delivered or deposited. 

  

 48 

 
Tenant agrees that delivery of furniture, fixtures and equipment shall be subject to Landlord’s prior designation of the time of delivery during normal
Business Hours and of the access areas for the entry of such furniture, fixtures and equipment, as Landlord shall direct, except Tenant shall have the right lo move in on weekends, and subject to prior approval of Landlord, during normal working
hours. 
  
 ARTICLE 36. FORCE MAJEURE 
  
 36.1. Effect of Excusable Delay. Whenever a period of time is herein
prescribed for the taking of any action by a party, such party shall not be liable or responsible for, and there shall be excluded from the computation of such period of time, any delays due to Excusable Delay, except as otherwise expressly provided
in this Lease or except where “Severe Excusable Delay” applies. 
  
 ARTICLE 37. COMPLIANCE WITH ENVIRONMENTAL LAWS 
  
 37.1. Tenant’s Compliance. Tenant agrees to comply with all applicable environmental laws, of rules and regulations, including but not limited to the New Jersey Spill Act, N.J.S.A. 58:10-23.11 et
seq., and the Industrial Site Recovery Act (N.J.S.A. 13:1K-6 et seq.), as same may be amended (“ISRA”). Tenant shall not conduct any operations that shall cause the Building or the Demised Premises to be deemed an “industrial
establishment” as defined in ISRA. 
  
 37.2. Obligations
under ISRA. Tenant hereby agrees to execute such documents Landlord reasonably deems necessary and to make such applications as Landlord reasonably requires to assure compliance with ISRA. Without waiving the requirement that Tenant shall engage
in no ISRA applicable operations at the Demised Premises, Tenant shall bear all costs and expenses incurred by Landlord associated with any ISRA compliance resulting front Tenant’s use of the Demised Premises including but not limited to state
agency fees (including oversight costs), consulting and engineering fees, clean-up and monitoring costs, filing fees and suretyship expenses. As used in this Lease, ISRA compliance shall include such applications for determinations of
nonapplicability of ISRA by the appropriate governmental authority as Landlord may reasonably request. The foregoing undertaking shall survive the termination or sooner expiration of the Lease and surrender of the Demised Premises and shall also
survive sale, lease or assignment of the Demised Premises by Landlord. Tenant shall immediately provide Landlord with copies of all correspondence, reports, notices, orders, findings, declarations and other materials pertinent to Tenant’s
compliance and the New Jersey Department of Environmental Protection’s requirements under ISRA as they are issued or received by Tenant. 
  
 37.3. No Hazardous Substances. Landlord nor Tenant shall generate, store manufacture, refine) transport, treat, dispose of, or otherwise cause or
permit to be released or present in, on, under or about the Building (including the Demised Premises) or the Complex, any Hazardous Substances, Tenant acknowledges that it has received and has read a copy of that certain No Further Action letter
issued by the New Jersey Department of Environmental Protection dated June 15, 2000 with respect to ground water under the Land. 
  

 49 

 37.4. Indemnity for Environmental Matters. (a) Tenant agrees to indemnify and hold harmless
Landlord from and against any and all liabilities, damages, claims, losses, judgments, causes of action, costs and expenses (including the reasonable fees and expenses of counsel) which may be incurred by Landlord, or threatened against Landlord,
relating to or arising out of any breach by Tenant of this Article 37, which indemnification shall survive the expiration or sooner termination of this Lease. 
  

(b) Landlord agrees to indemnify and hold harmless Tenant from and against any and all liabilities, damages, claims, losses, judgments, causes of
action, costs and expenses (including the reasonable fees and expenses of counsel) which may be incurred by Tenant, or threatened against Tenant, relating to or arising out of any breach by Landlord of this Article 37, which indemnification shall
survive the expiration or sooner termination of this Lease. 
  
 37.5 Existing Environmental Conditions. Notwithstanding anything else to the contrary contained in this Lease, Landlord acknowledges and agrees that Tenant shall have no obligation to remedy any environmental condition affecting the
Complex as of the Commencement Date. 
  
 ARTICLE 38. ESTOPPEL
CERTIFICATES 
  
 38.1. Delivery of Estoppel Certificates to
Tenant. Tenant shall, from time to time, within ten (10) days of Landlord’s written request, execute, acknowledge and deliver to Landlord a written statement certifying: (i) that the Lease is unmodified and in full force and effect, or that
the Lease is in full force and effect as modified and listing the instruments of modification; (ii) the dates to which the Net Base Rent and Additional Rent and charges have been paid; (iii) whether or not) to the knowledge of Tenant, Landlord is in
default in performance of any of its obligations under this Lease, and if so, specifying each such default of which Tenant may have knowledge; (iv) whether Tenant has received notice that it is in default in performance of any of its obligations
under this Lease, and if so, specifying each such default; and (v) as to any other matters reasonably requested by Landlord as to which Tenant may readily obtain or confirm the information; it being intended that any such certificate delivered
pursuant to this Section 38.1 may be relied upon by a prospective purchaser of Landlord’s interest or a ground lessor or mortgagee of Landlord’s interest or assignee of any mortgage under Landlord’s interest in the Demised Premises.

  
 38.2. Delivery of Estoppel Certificates by
Landlord. Landlord shall, from time to time, within ten (10) days of Tenant’s written request; execute, acknowledge and deliver to Tenant a written statement certifying; (i) that the Lease is unmodified and in full force and effect or that
the Lease is in full force and effect as modified and listing the instruments of modification; (ii) the dates to which the Net Base Rent and Additional Rent and charges have been paid; (iii) whether or not, to the knowledge of Landlord, Tenant is in
default in performance of any of its obligations under this Lease, and if so, specifying each such default of which I and lord may have knowledge; (iv) whether Landlord has received notice that it is in default in performance of any of its
obligations under this Lease, and if so, specifying each such default; and (v) as to any other matters reasonably requested by Tenant as to which Landlord may readily obtain or confirm the information; it being intended that any such certificate
delivered pursuant to this 

  

 50 

 
Section 38.3 may be relied upon by a prospective assignee of Tenant’s interest in this Lease or a prospective subtenant of Tenant’s interest in the
Demised Premises. 
  
 ARTICLE 39. WAIVER OF JURY TRIAL

  
 39.1. Waiver by Landlord and Tenant. Landlord and
Tenant each hereby waive trial by jury in any action, proceeding or counterclaim brought by either of them against the other in connection with any matter arising out of or in any way connected with this Lease, the relationship of Landlord and
Tenant hereunder, Tenant’s use or occupancy of the Demised Premises, and/or any claim of injury or damage. 
  
 ARTICLE 40. TENANT’S ACCESS RIGHTS 
  
 40.1 Roof Rights. Provided Landlord shall have the continued ability to lawfully allow tenants or itself the right to install roof top dish
antennas or other communication devices, Tenant shall have the right, subject to the provisions of Section 7.1 and applicable Legal Requirements, to install communications equipment on Tenant’s Proportionate Share of the roof, provided said
equipment: (i) does not display any name, logo or identity; (ii) is installed in compliance with any and all necessary governmental approvals; (iii) is installed at Tenant’s sole cost and expense. and (iv) is installed by Landlord’s
designated contractor(s) so long as the cost charged by such contractor(s) is commercially competitive in the Somerset County, New Jersey area, Tenant shall be responsible for any damage caused to the roof as a result thereof, and hereby agrees to
indemnify and holds Landlord harmless from all costs, expenses, and claims resulting therefrom. In addition to, and not in lieu of, the criteria set forth in Section 7.1, Landlord shall have the right to impose certain conditions on the installation
of such equipment, including but not limited to requiring Tenant to screen the equipment in such manner as to preserve the aesthetic nature of the Building. Upon die expiration or sooner termination of this Lease Tenant shall, at Landlord’s
option, remove said equipment and repair all injury done by or in connection With the installation or removal thereof. Landlord agrees that in the event Landlord installs any such communications equipment.. Landlord shall comply with the same
criteria as Tenant in connection with maintaining the aesthetic nature of the Building. 
  
 40.2 Conduit Rights. Subject to the provisions of Section 7.1 and applicable Legal Requirements, Tenant shall have the right, without the obligation to pay any Additional Rent therefor, to install a
supplemental HVAC system and/or utilize Tenant’s Proportionate Share of the vertical penetrations, risers and chase areas in the Building, and/or to install additional conduits for the purpose of running Tenant’s wiring or cabling to areas
within the Demised Premises, to the roof of the Building, and/or to the exterior of the Building, and/or between the Building and the Adjacent Building, provided that in all such instances, same is installed by Landlord’s designated
contractor(s) so long as the cost charged by such contractor(s) is commercially competitive in the Somerset County, New Jersey area. 
  
 40.3 Loading Dock Rights. Tenant shall have the non-exclusive right to utilize the Building’s loading dock during the Term of this Lease on a
“first come, first served” basis, provided that Tenant coordinates such usage with Landlord. In addition, Tenant shall have the non-exclusive right lo utilize the loading dock during Tenant’s early access period, on a “first

  

 51 

 
come, first served” basis, provided that such usage does not interfere with or otherwise hinder Landlord’s use thereof. 
  
 ARTICLE 41. SUBMISSION TO TENANT; LEASE COUNTERPARTS 
  
 41.1. Non-Binding Nature. The submission of an unsigned copy of this
document to Tenant for Tenant’s consideration does not constitute an offer to tease the Demised Premises or an option to or for the Demised Premises. This document shall become effective and binding only upon the execution and delivery of this
Lease by both Landlord and Tenant. 
  
 41.2. Tenant’s
Option to Renew. This Lease may be executed in counterparts, each of which shall be deemed an original and all of which shall be considered one and the same agreement. 
  
 ARTICLE 42. RENEWAL OPTION 
  
 42.1. Tenant’s Option to Review. Provided that no Default by Tenant under this Lease shall have occurred and be continuing as of the date
Tenant notifies Landlord of its election to extend the Term or as of the commencement date of the extended term, Tenant may extend the original Term as it relates to the Demised Premises for two (2) periods of five (5) years each, subject to the
following terms and conditions: 
  
 (a) Tenant shall notify
Landlord of its election to extend the Term by giving Landlord notice thereof not more than twenty-four (24) months and not less than eighteen (18) months prior to the expiration of the Term then in effect, if the Demised Premises shall then consist
of fifty percent (50%) or more of the rentable square footage contained hi the Building, or not more than eighteen (18) months and not less than twelve (12) months prior to the expiration of the Term then in effect, if the Demised Premises
shall then consist of less than fifty percent (50%) of the rentable square footage contained in the Building, TIME BEING STRICTLY OF THE ESSENCE. All of the provisions of this Lease (other than the amount of Net Base Rent payable hereunder and the
provisions of the Work Letter) shall apply during the extension period. 
  
 (c) The annual Net Base Rent during the first extension period shall be the greater of (a) the annual Net Base Rent in effect during the twelve (12) month period preceding the commencement of such extension term and (b) the “fair
market rent” (as defined below) for the Demised Premises as at the time of the commencement of the extended term, but not to exceed $33.75 per rentable square foot of the Demised Premises per annum. 
  
 (d) The annual Net Base Rent during the second extension period shall be
ninety-five percent (95%) of the “fair market rent” for the Demised Premises as at the time of the commencement of the second extended term. 
  
 (e) The term “fair market rent” shall be the rent generally payable in Somerset County, New Jersey for equivalent space in an office building of
approximately the saint quality, size and condition as the Building, giving due consideration to the fact that the Building is of first class design, the condition of the Demised Premises as improved, the location of the 

  

 52 

 
Demised Premises in the Building, the length of the Term of the Lease, and all other factors that would be relevant to a third-party tenant desiring to lease
the Demised Premises for the extended term, including without limitation whether Landlord is making an improvement allowance available for the extended term. 
  
 (f) Not later than twelve (12) months (or if the Demised Premises shall consist of less than fifty percent (50%) of the rentable square footage contained
in the Building, not later than nine (9) months) prior to the expiration of the Term then in effect, Landlord shall notify Tenant of Landlord’s determination of the annual Net Base Rent during such extension period. If Tenant desires to dispute
Landlord’s determination, Tenant shall, within thirty (30) days after receipt thereof submit to Landlord a written appraisal of the fair market rent for the Demised Premises by an appraiser who is a member of the American Institute of Real
Estate Appraisers, having at least seven (7) years experience in appraising commercial real estate in Somerset County, New Jersey (a “Qualified Appraiser”). If Landlord disagrees with the fair market rent determined by Tenant’s
Qualified Appraiser, it shall, within thirty (30) days of receipt of such appraisal, submit to Tenant a written appraisal of the fair market rent for the Demised Premises by a Qualified Appraiser selected by Landlord. If Landlord’s and
Tenant’s Qualified Appraisers do not agree upon the fair market rent but are apart by less than live (5%) percent, then the fair market rents determined by both shall be averaged; otherwise, Landlord and the Tenant’s Qualified Appraiser
shall mutually agree upon an independent Qualified Appraiser to determine such fair market rent. If the parties are unable to agree upon such independent appraiser, either party may request the American Arbitration Association in Somerset, New
Jersey, to appoint such independent appraiser. The independent appraiser shall select either Landlord’s Qualified Appraiser’s determination of fair market rent or the fair market rent determined by Tenant’s Qualified Appraiser, which
determination shall be binding upon both Landlord and Tenant. The parties shall be responsible for the cost of their own Qualified Appraiser and shall share equally in the cost of any independent third Qualified Appraiser. Pending resolution of the
issue of fair market rent, Tenant shall pay to Landlord as of commencement of the extension term, the Net Base Rent as determined by Landlord. In the event that it is established that the Net Base Rent is less than the Net Base Rent paid by Tenant
prior to a final determination under the preceding sentence, Landlord shall reimburse Tenant any overpayment of Net Base Rent within thirty (30) days of such final determination. In the event that it is established that the Net Base Rent is more
than the Net Base Rent paid by Tenant prior to a final determination under the preceding sentence, Tenant shall pay to Landlord any deficiency amount of Net Base Rent within thirty (30) days of such final determination. 
  
 (g) Upon final determination of the Net Base Rent to be paid during either
extension period as hereinabove provided, Landlord and Tenant shall enter into a lease amendment to reflect the same. 
  
 ARTICLE 43. SALE OF BUILDING 
  
 43.1. Sale of Building. If Landlord decides to sell the Property or the Complex during the Term, then Landlord will provide to Tenant notice of
Landlord’s potential interest in selling the Property or the Complex (as the case may be) at least thirty (30) days prior to Landlord commencing to publicly market same for sale (“Freeze Period”). At the time of such notice to 

  

 53 

 
Tenant, Landlord will provide Tenant with any marketing materials (which may be in draft form) that Landlord then intends to make generally available to
potential purchasers of the Property or the Complex (as the case may be) following the expiration of the Freeze Period. Nothing contained herein shall be deemed to grant Tenant an option to purchase the Property or the Complex, or a right of first
refusal, it being the intention of the panics that the provision of this Article 43 is for the sole purpose of providing Tenant with notice of Landlord’s intention to market the Property or the Complex (as the case may be) for sale and an
opportunity, to be exercised within the Freeze Period, TIME BEING STRICTLY OF THE ESSENCE, to submit to Landlord for Landlord’s consideration, in Landlord’s sole discretion, a proposal to purchase same. The foregoing notice
requirement shall not apply to any transfer of less than all of the Property, or to any transfer of the Property or the Complex by Landlord to any Affiliate of Landlord, or to any unsolicited offer Landlord may receive. This notice requirement is
for the personal benefit of Aventis Pharmaceuticals Inc., any Related Entity or any Successor Entity thereto, and may not be exercised or assigned, voluntarily or involuntarily, by or to any other person or entity other than Aventis Pharmaceuticals
Inc., any Related Entity or any Successor Entity thereto. 
  
 ARTICLE 44. LEASE GUARANTY 
  
 44.1. Lease
Guaranty. The obligations of Tenant pursuant to this Lease shall be guaranteed by Aventis Pharma AG, a German corporation (“Guarantor”), pursuant to the terms of the Lease Guaranty attached hereto as Exhibit “F’.
Tenant shall deliver to Landlord the executed Guaranty, together with an opinion of Tenant’s counsel as may be required by Landlord confirming the enforceability of the Guaranty, simultaneously with Tenant’s execution and delivery of this
Lease. 
  
 ARTICLE 45. ARBITRATION 
  
 45.1. In any case in which this Lease expressly provides that a matter is to
be determined by arbitration and does not otherwise provide a mechanism for arbitration, such arbitration shall be conducted in the City of Newark, New Jersey, in accordance with the Commercial Arbitration Rules (Expedited Procedures) of the AAA,
except that the provisions oft his Article 45 shall supersede any conflicting or inconsistent provisions of said rules. The party requesting arbitration shall do so by giving notice to that effect to the other party, specifying in said notice the
nature of the dispute, and that said dispute shall be determined in Newark, by a panel of up to 3 arbitrators in accordance with this Article 45. Landlord and Tenant shall each appoint their own arbitrator within 20 days after the giving of notice
by either party. If either Landlord or Tenant shall fail timely to appoint an arbitrator, the appointed arbitrator shall select the second arbitrator, who shall be impartial, within 20 days after such party’s failure to appoint. The arbitrators
so appointed shall meet and shall, if possible, determine such matter within 10 days after the second arbitrator is appointed and their determination shall be binding on the parties. If for any reason such two arbitrators fail to agree on such
matter within such period of 10 days, then either Landlord or Tenant may request the AAA to appoint an arbitrator who shall be impartial within 30 days of such request and both parties shall be bound by any appointment so made within such 30 day
period. The third arbitrator (and the second arbitrator if selected by the other arbitrator as provided above) shall subscribe and swear to an oath fairly and impartially 

  

 54 

 
to determine such dispute. Within 7 days after the third arbitrator has been appointed, each of the first two arbitrators shall submit their respective
determinations to the third arbitrator who must select one or the other of such determinations (whichever the third arbitrator believes to he correct or closest to a correct determination) within 7 days after the first two arbitrators shall have
submitted their respective determinations to the third arbitrator, and the selection so made shall in all cases be binding upon the parties, and judgment upon such decision may be entered into any court having jurisdiction. In the event of the
failure, refusal or inability of an arbitrator to act, a successor shall be appointed within 10 days as hereinbefore provided. The third arbitrator shall be experienced in the issue with which the arbitration is concerned and shall have been
actively engaged in such field for a period of at least 10 years before the date of his or her appointment hereunder. If the second arbitrator is appointed by the first arbitrator as provided above such second arbitrator shall also be experienced in
the issue with which the arbitration is concerned and have been actively engaged in such field for a period of at least 10 years before the date of his or her appointment hereunder. The third arbitrator shall apply the laws of the State of New
Jersey without giving effect to any principles of conflicts of laws. The third arbitrator shall schedule a hearing where the parties and their advocates shall have the right to present evidence, call witnesses and experts and cross-examine the other
party’s witnesses and experts. The losing party shall pay the fees and expenses of all arbitrators acting under this Article 45. 
  

 55 

 IN WITNESS WHEREOF, the parties have caused these presents to be duly executed as a sealed
instrument as of the day and year first above written. 
  

	WITNESS/ATTEST:	  	LANDLORD:
		
	 	  	 BRIDGEWATER HINES DEVELOPMENT LLC

		
	 /s/ (Illegible)

	  	 By:     /s/ Tom Owens

	 	  	 	 	 Name: Tom Owens

	 	  	 	 	 Title:   S.V.P.

		
	 WITNESS/ATTEST:
	  	 TENANT:

		
	 	  	 AVENTIS PHARMACEUTICALS INC.

		
	
	  	 By:

	 	  	 	 	 Name:

	 	  	 	 	 Title:

  

 56 

 IN WITNESS WHEREOF, the parties have caused these presents to be duly executed as a sealed
instrument as of the day and year first above written. 
  

	WITNESS/ATTEST:	  	LANDLORD:
		
	 	  	 BRIDGEWATER HINES DEVELOPMENT LLC

		
	
	  	 By:

	 	  	 	 	 Name:

	 	  	 	 	 Title:

		
	 WITNESS/ATTEST:
	  	 TENANT:

		
	 	  	 AVENTIS PHARMACEUTICALS INC.

		
	 /s/ Owen K. Ball, Jr.

	  	 By:     /s/ Gerald P. Belle

	 	  	 	 	 Name: Gerald P. Belle

	 	  	 	 	 Title:    President

  
  

 57Development and License Agreement, dated September 12, 2003

 Exhibit 10.59 
  
  
 CONFIDENTIAL TREATMENT REQUESTED.

 CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED 
 AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND 
 EXCHANGE COMMISSION.

  
  
 ANTARES PHARMA, INC. 
  
  
 AND 
  
  
 ELI LILLY AND COMPANY 
  
  
  
  
 DEVELOPMENT AND LICENSE AGREEMENT 
  
  
 September 12, 2003 

 DEVELOPMENT AND LICENSE AGREEMENT 
  
 This Development and License Agreement (“Agreement”) is made and entered into as of the 12th day of September,
2003 (the “Effective Date”) by and between Antares Pharma, Inc., a Minnesota corporation, having its principal place of business at 707 Eagleview Blvd., Suite 414, Exton, Pennsylvania 19341 (“Antares”) and Eli Lilly and Company,
an Indiana corporation, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”). Antares and Lilly are sometimes referred to herein individually as a “Party” and collectively as the
“Parties”, and references to “Antares” and “Lilly” shall include their respective Affiliates. 
  
 Recitals 
  
 WHEREAS, Lilly is engaged in discovering, developing and marketing pharmaceutical products. 
  
 WHEREAS, Antares is engaged in the research and development of certain
drug delivery devices, including needleless injector systems. 
  
 WHEREAS, Lilly desires to obtain, and Antares desires to grant to Lilly, an exclusive, worldwide license to Antares’ needleless injector systems for use in certain fields upon the terms and conditions set forth in this
Agreement. 
  
 NOW, THEREFORE, in consideration of the
foregoing and the mutual covenants and promises contained in this Agreement, the Parties hereto agree as follows: 
  
 ARTICLE 1 
 DEFINITIONS 
  
 As used herein, the following terms shall have the following meanings
assigned to them in this Article and shall include the plural as well as the singular: 

 1.1 “Adverse Event” means any untoward happening in a patient or subject during or after
administration of Compound via Device, without regard to a causal relationship between Compound, Device and the event. 
  
 1.2 “Adverse Event Report” means any oral, written or electronically transmitted report of any Adverse Event. 
  
 1.3 “Affiliate” means any Person that directly (or
indirectly through one or more intermediaries) controls, is controlled by, or is under common control with a Party. For purposes of this definition only, the terms “controls,” “controlled,” and “control” means (i) the
direct or indirect ability or power to direct or cause the direction of the management and policies of an entity or otherwise direct the affairs of such entity, whether through ownership of equity, voting securities, beneficial interest, by
contract, or otherwise, or (ii) the ownership, directly or indirectly, of at least 50% of the voting securities (or other comparable ownership interest for an entity other than a corporation) of a Party. 
  
 1.4 “Antares Device Development” means the conduct of all
activities by Antares or on its behalf consistent with the Device Development Plan that are reasonably required to complete development of the Device, including: (i) regulatory affairs, pre-clinical studies and clinical trials in accordance with the
cGLPs, cGCPs and cQSRs or other designated quality standards and Applicable Laws; and (ii) all activities relating to developing the ability to manufacture Devices, including, without limitation, tooling development and delivery technologies related
to Devices and components thereof, industrial and mechanical design, and manufacturing and quality assurance technical support until such time as manufacturing of Devices intended for commercial sale of Product commences and, thereafter, to the
extent required under Applicable Law for continued commercial sale of Product, in the event that the Parties agree that Antares will manufacture the Product. 
  
 1.5 “Antares Device Development Costs” means those costs and expenses incurred by Antares, or for its account, with respect to Antares
Device Development that are consistent with the Device Development Plan. Device Development costs include, but may not be limited to, those costs incurred for Device specific FTEs, Device specific Third Person costs, depreciation of Device specific
capital investments, and depreciation of an allocation of general Device Development equipment directly associated with Device Development. Product specific Third Person costs include, but are not limited to, direct costs to Antares solely related
to the development of Devices 

 
for manufacturing materials, clinical and field trial materials (including, if applicable, those FTE and supply costs for manufacturing the Devices)
professional services, contract research, license fees, clinical studies, consultantships, contract labor and purchased Compounds. 
  
 1.6 “Antares’ Fully Burdened Manufacturing Costs” means those costs actually incurred by Antares for the acquisition of materials
and their conversion into salable Devices. Such costs include: (i) the landed cost of purchased materials, including, without limitation, invoice price, outside processing costs, freight, duties, and brokers fees (volume or trade discounts will be
reflected in the calculation); (ii) conversion costs (including, without limitation, direct labor and direct overhead) directly associated with the manufacturing of a Device; (iii) an appropriate allocation of service and administrative departments
performing functions which support manufacturing operations directly associated with the manufacturing of Devices; (iv) depreciation of Device specific capital investments made by Lilly or Antares through an appropriate method consistent with U.S.
Generally Accepted Accounting Principles (“U.S. GAAP”) and Lilly’s internal depreciation methodology used for other products; (v) depreciation of an allocation of general manufacturing equipment and facilities directly associated with
manufacturing of Devices; and (vi) to the extent attributable to the manufacture of Devices, any other costs considered inventory costs or costs of products sold, less any depreciation paid by Lilly, under U.S. GAAP. Antares’ Fully Burdened
Manufacturing Cost shall specifically exclude: (i) capacity costs not allocable to Devices; (ii) any royalties and/or indemnification that Antares is obligated to pay for under this Agreement; (iii) any item that Antares is financially responsible
for under this Agreement; or (iv) any item that Antares has already been compensated for by Lilly under this Agreement or otherwise. Antares’ Fully Burdened Manufacturing Cost shall be calculated in a manner consistent with U.S. GAAP
consistently applied. Furthermore, the methodology to be used in making the allocations referred to above shall be disclosed by Antares to Lilly and shall be consistent with Antares’ methodology for other products and shall be consistent from
year-to-year. An estimate of the items described above for the *** are attached as Exhibit A hereto. 
  
 1.7 “Antares Indemnities” shall have the meaning set forth in Section 16.2 hereof. 
  
 1.8 “Antares Know-How” means all Information that is owned
or Controlled by Antares at any time during the term of this Agreement, and 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
that is useful or necessary for the development, manufacture, use or commercialization of the Device and/or Product. Antares Know-How does not include
Antares Patent Rights. 
  
 1.9 “Antares Patent
Rights” means all Patent Rights in the Territory that are owned or Controlled by Antares at any time during the term of this Agreement that Cover the Device and/or Product, or that otherwise Cover a method, apparatus, composition or process
necessary or useful for Lilly to proceed with the undertakings envisioned by this Agreement, including without limitation the Patent Rights associated with the patents and patent applications identified in Exhibit B. Antares Patent Rights do
not include Antares Know-How. 
  
 1.10 “Antares
Rights” means Antares Patent Rights and Antares Know-How. 
  
 1.11 “Applicable Laws” means all applicable statues, ordinances, regulations, rules and orders of any kind whatsoever of any Governmental Authority, including, without limitation, the Anti-kickback Statute (42 U.S.C. §
1320a-7b, et. seq.), Prescription Drug Marketing Act, Generic Drug Enforcement Act of 1992 (21 U.S.C. § 3359, et. seq.), the Federal Food Drug and Cosmetics Act, Resource Conservation and Recovery Act, Clean Water Act, Clean Air
Act, the Drug Enforcement Act, Occupational Safety and Health Act, cGMP, cGCP, cGLP, cQSR and any comparable laws of any foreign jurisdiction, all as amended from time to time. 
  
 1.12 “cGCP” means the then current Good Clinical Practice Standards promulgated or endorsed by the FDA (or
in the case of foreign jurisdictions, comparable regulatory standards), including those regulations or guidelines expressed or implied in the regulatory filings made with respect to the Product with the FDA or foreign regulatory agents.

  
 1.13 “cGLP” means the then current Good
Laboratory Practices promulgated or endorsed by the FDA (or in the case of foreign jurisdictions, comparable regulatory standards), including those procedures expressed or implied in the regulatory filings made with respect to the Product with the
FDA or foreign regulatory agents. 
  
 1.14 “cGMP”
means current Good Manufacturing Practices as defined in the U.S. regulations 21 CFR § 210 et. seq., and the EEC Guide to Good Manufacturing Practices for Medicinal Products (Vol. IV Rules 

 
Governing Medicinal Products in the European Community 1992), and foreign equivalents. 
  
 1.15 “cQSRs” means current Quality System Regulations as defined in the U.S. Code of Federal Regulations,
21 CFR Part 820 and, in the case of foreign jurisdictions, comparable regulatory standards. 
  
 1.16 “Calendar Quarter” means a three-month period ending on March 31, June 30, September 30, or December 31. 
  

1.17 “Calendar Year” means the twelve-month period ending on December 31. 
  
 1.18 “Compound” means any of the following: *** compounds,
*** compounds, *** compounds, and *** compounds (any of the foregoing, “Specific Compounds”), and/or any combination of two or more of the Specific Compounds (e.g., ***), and/or any combination of one or more of the Specific Compounds
along with any one or more other therapeutics. 
  
 1.19 “Compulsory License” means a compulsory license under (i) any Antares Patents or Antares Know-How, or (ii) any patent rights that cover a formulation of a Compound specifically formulated and packaged, or packaged for
delivery by a Device, obtained by a Third Person through the order, decree, or grant of a competent Governmental Authority, authorizing such Third Person to manufacture, use, sell, offer for sale or import products in a particular territory.

  
 1.20 “Confidential Information” shall have
the meaning set forth in Section 17.1 of this Agreement. 
  
 1.21 “Controlled” means the ability to grant a license or sublicense as provided for herein without violating the terms of any agreement or other arrangement with any Third Person. 
  
 1.22 “Cover” (including variations thereof such as
“Covering”, “Covered”, and “Coverage”) means that the development, manufacture, use, import, export, offer for sale or sale of the item(s) referred to would infringe a Valid Claim. 
  
 1.23 “Damages” shall have the meaning set forth in Section
16.2 hereof. 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and
Exchange Commission. 

 1.24 “Debenture Letter” shall have the meaning set forth in Section 8.10 hereof.

  
 1.25 “Device” means any device (and any
component thereof) in the Field for the delivery of drugs through injection by means of needle free technology that in whole or in part is invented, designed, developed, acquired and/or manufactured by or for Antares in or outside the Field and at
any time during the term of this Agreement, and further shall include, without limitation, the MJ7 and the ***. 
  
 1.26 “Device Development Plan” shall have the meaning set forth in Section 2.2 of this Agreement. 
  
 1.27 “DHF” means the Design History File that Antares will
establish and maintain for Devices in and outside the Field that will contain or reference all records and submissions necessary to demonstrate that the design was developed in accordance with the approved Device Development Plan. 
  
 1.28 “Diabetes Product” means any Product indicated for the
diagnosis, prevention or treatment of diabetes. 
  
 1.29
“Discontinuance Election” shall have the meaning set forth in Section 12.4 hereof. 
  
 1.30 “DMF” means a Device Master File, or other similar terminology, such as the term is defined in 21 C.F.R. 814.3(d) and is
consistent with FDA Pre-Market Approval Manual (HHS Publication FDA 97-4212, January 1998), or comparable filings accepted by any Regulatory Authority in a country or jurisdiction outside the U.S. The DMF shall include, without limitation, the
specifications for quality testing, design verification, process validation and release of Devices, in addition to any other information necessary for development, manufacture and release of Devices. 
  
 1.31 “Effective Date” shall have the meaning set forth in
the first paragraph of this Agreement. 
  
 1.32
“EMEA” means the European Medicine Evaluation Agency for the European Union (“E.U.”), or any successor agency, having responsibility for Regulatory Approval, or for making recommendations to the European 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
Commission for Regulatory Approval, of a pharmaceutical or biological therapeutic product or device. 
  
 1.33 “E.U. Regulatory Approval” means the first date on
which Lilly shall have received Regulatory Approval for the first Major European Country in the European Union. 
  
 1.34 “E.U. Regulatory Submission” means the first submission and acceptance for filing by the Regulatory Authority of all Regulatory
Materials necessary for the manufacture, marketing and sale of Product in a Major European Country through the E.U. central filing process or through the national approval process of any of the Major European Countries. 
  
 1.35 *** means ***, including analogs, derivatives, fragments,
mimetics, and other peptides that act through the same receptor that *** exerts its effects. 
  
 1.36 “FDA” means the U.S. Food and Drug Administration, or any successor federal agency, having responsibility over Regulatory Approval. 
  
 1.37 “FD&C Act” means the U.S. Food, Drug and Cosmetic Act (21 U.S.C. §301 et. seq.), as
amended from time to time, together with any rules and regulations promulgated thereunder. FD&C Act shall also be deemed to include the Applicable Laws pertaining to the Product in any particular country or region in the Territory. 

 
 1.38 “Failure Credit” shall have the meaning set forth in
Section 8.3 hereof. 
  
 1.39 “Field” means (i)
all uses, including the delivery to humans or animals, of the Compounds, including, without limitation, uses other than diagnosing, treating or preventing diabetes or obesity, and (ii) all uses, including the delivery to humans or animals, of any
pharmaceutical compound indicated for the diagnosis, treatment or prevention of diabetes or obesity, including without limitation, uses other than diagnosing, treating or preventing diabetes or obesity. 
  
 1.40 “FTE” means a full-time equivalent scientific or
technical person year, or a total of 47 weeks or 1,880 hours per year of scientific and/or technical work, on or directly related to the performance of activities under the Device Development Plan, carried out by Antares employees as agreed to

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
by the Joint Coordination Team, exclusive of non-research and development administrative work associated therewith. Antares FTE costs shall initially, and in
the first full Calendar Year of this Agreement be paid at a rate of *** dollars ($***) per FTE. Future year FTE rates will be indexed according to the US Consumer Price Index (US Bureau of Labor Statistics for all urban consumers series ID CUUR0000
SA00) and adjusted on January 1 of each subsequent year. 
  
 1.41 *** means ***, including analogs, derivatives, fragments, mimetics and other peptides that act through the same receptor where *** exert their effects. 
  
 1.42 “Governmental Authority” means any court tribunal, arbitrator, agency, commission, official or other
instrumentality of any federal, state, or other political subdivision, or supranational body, domestic or foreign. 
  
 1.43 “IND” means an Investigational New Drug application (together with all additions, deletions, and supplements thereto) filed with the
FDA or any equivalents of such items in countries within the Territory outside the U.S. 
  
 1.44 “Information” means any and all information, data, items, material and knowledge in the Field including, without limitation, any and all suggestions, descriptions, ideas, inventions (whether or
not patentable), know-how, trade secrets, techniques, strategies, methods, syntheses, processes, practices, skills, experience, documents, apparatus, devices, chemical formulations, compounds, composition of matter, chemical samples, assays,
screens, databases, database structures and data analysis methods in the Field.  
  
 1.45 “Infringed Antares Rights” shall have the meaning set forth in Section 15.1 hereof. 
  
 1.46 *** means ***, including analogs, derivatives, fragments, mimetics, conjugates, and other peptides that act through the same receptor that ***
exerts its effects, including any mixtures thereof. 
  
 1.47
“Intellectual Property Rights” shall have the meaning set forth in Section 13.1, hereof. 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement
with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 1.48 “Japan Regulatory Approval” means the first date on which Lilly shall have received
Regulatory Approval in Japan. 
  
 1.49 “Japan
Regulatory Submission” means the first submission and acceptance for filing by the Regulatory Authority of all Regulatory Materials necessary for the manufacture, marketing and sale of Product in Japan. 
  
 1.50 “Joint Coordination Team” shall have the meaning
set forth in Section 3.1 hereof. 
  
 1.51 “Joint
Invention” shall have the meaning set forth in Section 12.1 hereof. 
  
 1.53 “Lilly Indemnities” shall have the meaning set forth in Section 16.3, hereof. 
  
 1.54 *** means a peptidyl compound that has affinity for and stimulates physiological activity at the ***. 
  
 1.55 “MJ7” means the specific Device described in Exhibit
C, and any improvements or modifications thereof. 
  
 1.56 *** means the specific Device described in Exhibit D, and any improvements or modifications thereof. 
  
 1.57 “Major European Country” shall mean Germany or the United Kingdom.  
  
 1.58 “Major Market” means any of the following
jurisdictions, the U.S., Japan, and the Major European Countries. 
  
 1.59 “Manufacturing Agreement” shall have the meaning set forth in Section 10.1 of this Agreement. 
  
 1.60 “Manufacturing Responsibilities Document” or “MRD” means a document that may contain certain specifications,
procedures, logistics and personal contacts relating to the manufacture for sale and supply of the Product by Antares to Lilly that will be compiled and agreed upon between the Parties. The MRD contains Product information such as information
related to Product quality and regulatory compliance. The MRD also describes how Antares and Lilly will work together in coordinating the 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
forecasting, manufacturing, packaging, ordering, storing and transport of the Device. A nonexhaustive table of contents of a sample MRD is attached hereto as
Exhibit E. 
  
 1.61 “Material Breach”
shall have the meaning set forth in Section 19.3 of this Agreement. 
  
 1.62 “MHLW” means the Japanese Ministry of Health, Labor and Welfare (Ko Seisho), or any successor agency having the administrative authority to regulate the approval for marketing of new human pharmaceutical or biological
therapeutic products or devices in Japan. 
  
 1.63 “Net
Sales” shall mean, with respect to a Product, the gross amount invoiced by Lilly (including a Lilly Affiliate) or any sublicensee thereof to Third Persons, excluding any sublicensee thereof, for the Product in the Territory, less:

  

	 	(a)	 	The aggregate Device cost to Lilly as set forth in Section 10.2(e) hereof (to ease the administration of this deduction, a constant cost amount for each Device sold will be used for
all Net Sales calculations within each Calendar Year. The per unit deduction for any Calendar Year will be equal to Lilly’s average cost of the Device (the amount paid by Lilly to Antares or any other supplier, less Lilly’s share of any
cost savings achieved by Antares as set forth in Section 10.2 of this Agreement), during the month of December of the preceding Calendar Year, unless Lilly did not purchase any Devices during the month of December, in which event the average cost of
the Device for the last Calendar Quarter will be used). 

  

	 	(b)	 	Trade, quantity and cash discounts allowed; 

  

	 	(c)	 	Commissions, discounts, refunds, rebates, chargebacks, retroactive price adjustments, and any other allowances which effectively reduce the net selling price;

  

	 	(d)	 	Actual Product returns and allowances; 

  

	 	(e)	 	Any tax imposed on the production, sale, delivery or use of the Product, including, without limitation, sales, use, excise or value added taxes, with the exception of income taxes;

  

	 	(f)	 	Allowance for distribution expenses equal to 2% of gross sales; and 

  

	 	(g)	 	Any other similar and customary deductions which are properly recorded as a reduction of Net Sales under U.S. GAAP consistently applied. 

 Such amounts shall be determined from the books and records of Lilly or its sublicensee, maintained in
accordance with U.S. GAAP or, in the case of sublicensees, such similar accounting principles, consistently applied. Lilly further agrees that in determining such amounts, it will use Lilly’s then current standard procedures and methodology,
including Lilly’s then current standard exchange rate methodology for the translation of foreign currency sales into U.S. dollars or, in the case of sublicensees, such similar methodology, consistently applied. 
  
 It is the intent of the Parties that Net Sales shall include only sales of
pharmaceuticals specifically formulated and packaged, or packaged by Lilly for delivery by a Device. For example, it is presently contemplated that the Parties will develop a version of the *** for use with existing ***. Those *** are currently sold
for use with ***. It is anticipated that these***, when sold for use in the ***, will be *** together with an *** or with special *** designed to *** the *** for use with the ***. Sales of *** with the *** or *** shall be included in Net Sales.
Sales of *** not *** with the *** or not *** with *** are not specifically *** for use with the *** and shall not be included in Net Sales. 
  
 In the event that the Product is sold as Part of a Combination Product (where “Combination Product” means any pharmaceutical product which
comprises the Product and other active compound(s) and/or ingredients not included in the Field), the Net Sales of the Product, for the purposes of determining royalty payments, shall be determined by multiplying the Net Sales of the Combination
Product (as defined in the standard Net Sales definition) by the fraction, A / (A+B) where A is the weighted average sale price of the Product when sold separately in finished form, and B is the weighted average sale price of the other product(s)
sold separately in finished form. 
  
 In the event that the
weighted average sale price of the Product can be determined but the weighted average sale price of the other product(s) cannot be determined, Net Sales for purposes of determining royalty payments shall be calculated by multiplying the Net Sales of
the Combined Product by the fraction A / C where A is the weighted average sale price of the Product when sold separately in finished form and C is the weighted average sale price of the Combination Product. 
  
 In the event that the weighted average sale price of the other product(s) can
be determined but the weighted average sale price of the 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
Product cannot be determined, Net Sales for purposes of determining royalty payments shall be calculated by multiplying the Net Sales of the Combined Product
by the following formula: one (1) minus (B / C) where B is the weighted average sale price of the other product(s) when sold separately in finished form and C is the weighted average selling price of the Combination Product. 
  
 In the event that the weighted average sale price of both the Product and the
other product(s) in the Combination Product cannot be determined, the Net Sales of the Product shall be deemed to be equal to fifty percent (50%) of the Net Sales of the Combination Product. 
  
 The weighted average sale price for a Product, other product(s), or
Combination Product shall be calculated once each Calendar Year and such price shall be used during all applicable royalty reporting periods for the entire following Calendar Year. When determining the weighted average sale price of a Product, other
product(s), or Combination Product, the weighted average sale price shall be calculated by dividing the sales dollars (translated into U.S. dollars) by the units of active ingredient sold during the twelve (12) months (or the number of months sold
in a partial Calendar Year) of the preceding Calendar Year for the respective Product, other product(s), or Combination Product. In the initial Calendar Year, a forecasted weighted average sale price will be used for the Product, other product(s),
or Combination Product. Any over or under payment due to a difference between forecasted and actual weighted average sale prices will be paid or credited in the first royalty payment of the following Calendar Year. 
  
 1.64 “NDA” means (a) the single application or set of
applications (together with all additions, deletions, and supplements thereto) for Products and/or pre-market approval to make and sell commercially both a formulation of Compound and a compatible commercial Device to be marketed as Product, filed
by Lilly with the appropriate Regulatory Authority within the Territory, and (b) any related registrations with or notifications to the appropriate Regulatory Authority within the Territory. 
  
 1.65 “Obesity Product” means any Product indicated for the
diagnosis, treatment or prevention of obesity. 
  
 1.66
“Patent Right(s)” means (a) patents and patent applications (including provisional applications and applications for certificates of invention); (b) any patents issuing from such patent applications (including certificates of
invention); (c) all patents and patent applications claiming the 

 
priority date(s) of any of the foregoing; (d) any reissues, substitutions, confirmations, registrations, validations, re-examinations, additions,
continuations, continued prosecution applications, continuations-in-part, or divisions of or to any of the foregoing and any patents issuing thereon; and (e) term extensions, supplementary protection certificates and other governmental action which
provide exclusive rights to a product beyond the original patent expiration date. 
  
 1.67 “Permitted Person” shall have the meaning set forth in Section 17.2 hereof. 
  
 1.68 “Person” means a natural person, a corporation, a partnership, a trust, a joint venture, a limited liability company, any
Governmental Authority or any other entity or organization. 
  
 1.69 “Pricing Approval” means such approval, agreement, determination or governmental decision establishing prices for Product that can be charged to consumers and/or will be reimbursed by Governmental Authorities in
countries in the Territory where Governmental Authorities or Regulatory Authorities of such country approve or determine pricing for pharmaceutical products for reimbursement or otherwise. 
  
 1.70 “Product” means any and all Devices and/or components
thereof and/or any and all formulations of a pharmaceutical compound in the Field that are specifically formulated and packaged, or packaged for delivery by a Device pursuant to this Agreement. 
  
 1.71 “Product Development Program” means the program of
development activities set forth in or otherwise contemplated by the Device Development Plan (as amended from time to time) as more fully described in Article 2 of this Agreement. 
  
 1.72 “Product Launch” means the first commercial sale of Product by Lilly or its sublicensees in the
country at issue following Regulatory Approval for Product in such country. 
  
 1.73 “Program Intellectual Property” shall have the meaning set forth in Section 12.1 hereof. 

 1.74 *** means ***, including analogs, derivatives, fragments (e.g., *** and other peptides
thereof that act through the same receptor that *** exerts its effects. 
  
 1.75 “Quality Agreement” or “QA” means the document between the Parties which describes certain quality expectations and responsibilities relating to the development, manufacture, release testing and supply of the
Devices and packaging of the Product. A non-exhaustive table of contents of a sample QA is attached hereto as Exhibit F.            1.76 “Recipient” shall have the
meaning set forth in Section 17.1 hereof. 
  
 1.77
“Regulatory Approval” means (a) in the U.S., approval by the FDA of any one or more of the following, an NDA, 510K or similar application for marketing approval, and satisfaction of any related applicable FDA registration and
notification requirements (if any),together with any other approval necessary to make and sell Products commercially in the U.S.; and (b) in any country other than the U.S., approval by Regulatory Authorities having jurisdiction over such country of
a single application or set of applications comparable to an NDA or similar application for marketing approval and satisfaction of any related applicable regulatory and notification requirements, if any, together with any other approval necessary to
make and sell Products commercially in such country, and the grant of Pricing Approval. 
  
 1.78 “Regulatory Authority” means, in a particular country or jurisdiction, any applicable government regulatory authority involved in granting Regulatory Approval and/or, to the extent required in
such country or jurisdiction, Pricing Approval of Product in such country or jurisdiction, including, without limitation, (a) in the U.S., the FDA, and any other applicable Governmental Authority or Regulatory Authority in the U.S. having
jurisdiction over the Product, and any successor Governmental Authority having substantially the same function, and (b) any foreign equivalent thereof (e.g., the EMEA and the MHLW) and any successor Governmental Authority having substantially the
same function. 
  
 1.79 “Regulatory Material”
means regulatory correspondence, submissions, notifications, registrations, approvals and/or other filings, to the extent such material is generated under the terms of this Agreement and is solely related to the Field, made to or with a Regulatory
Authority that may be necessary to develop, manufacture, market, sell or otherwise commercialize Product, including, without limitation, clinical trial data, 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
toxicology studies, IND, NDA, 510K, clinical trial exemption, Pricing Approvals, and any other foreign equivalents. 
  
 1.80 “Royalty Period” means the period commencing on Product
Launch of a particular Product in the particular country at issue until the later of either: (i) the expiration date of the last-to-expire of a Valid Claim of any relevant Antares Patent Rights existing in such country at issue which cover the
manufacture, use, sale, offer to sale, or import of the particular Product at issue in such a manner that the manufacture, use, sale, offer to sale, or import of such Product by Lilly in such country would constitute infringement of such Antares
Patent Rights but for the license granted to Lilly under Section 5.1 hereof, and such Antares Patent Rights provides effective market exclusivity, or (ii) five (5) years from Product Launch; provided, however, in no event shall the
Royalty Period extend beyond the date of expiration or termination of this Agreement.  
  
 1.81 “Safety Information Document” shall have the meaning set forth in Section 4.3 hereof. 
  
 1.82 “Serious Adverse Event” means any Adverse Event with the following conditions: death, life-threatening, hospitalization, permanent
disability, congenital anomaly/birth defect or cancer. 
  
 1.83
“Serious Adverse Event Report” means any oral, written or electronically transmitted report of any Serious Adverse Event. 
  
 1.84 “Sole Invention” shall have the meaning set forth in Section 12.1 hereof. 
  
 1.85 “Technical Failure” shall have the meaning set forth in
Section 19.2 hereof. 
  
 1.86 “Territory” means
the entire world. 
  
 1.87 “Third Person” means
any Person or entity other than Lilly, Antares, or a sublicensee of either of them. 
  
 1.88 “Third Person Claim” shall have the meaning set forth in Section 16.2 hereof. 
  
 1.89 “Third Person Rights” shall have the meaning set forth in Section 8.2 hereof. 

 1.90 “United States” or “U.S. “ means the United States of America, including
its territories and possessions. 
  
 1.91 “U.S. Regulatory
Approval” means the first date on which Lilly shall have received Regulatory Approval in the U.S. 
  
 1.92 “U.S. Regulatory Submission” means the first submission and acceptance for filing by a Regulatory Authority of all Regulatory
Materials necessary for the manufacture, market and sale of Product in the U.S. 
  
 1.93 “Valid Claim” means any claim in any issued, unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent
jurisdiction following exhaustion of all possible appeal processes, and which has not been admitted to be invalid or unenforceable through reissue, reexamination or disclaimer. If in any country there should be two or more such decisions conflicting
with respect to the validity of the same claim, the decision of the higher or highest tribunal shall thereafter control; however, should the tribunals be of equal rank, then the decision or decisions upholding the claim shall prevail when the number
of decisions of such authority are equal in number, and the majority of decisions shall prevail when the conflicting decisions are unequal in number. 
  
 ARTICLE 2 
 PRODUCT DEVELOPMENT
PROGRAM 
  
 2.1 Purpose and Scope of Development. In
accordance with, and subject to, the terms described herein, the Parties agree to collaborate in the research and development of Devices for the ultimate purpose of commercializing Products (“Product Development Program”). 

 2.2 Preparation of Device Development Plan. The Parties shall develop and prepare a Device
Development Plan which shall include Antares’ budgeted costs and project timelines for work to be performed by the Parties. The Parties may from time to time amend the Device Development Plan or create additional Device Development Plans to
provide for the development of additional Products. The scope of the initial Device Development Plan shall include development of the *** for use with Lilly ***, and the redesign of the needle free syringe as more fully described in Section 2.3
below. 
  
 2.3 Responsibilities of the Parties. 

 
 (a) General. Each Party shall have responsibility for development
activities as set forth in the Device Development Plan. 
  
 (b)
Lilly’s Responsibilities. Lilly shall be responsible for overseeing implementation of the Device Development Plan, addressing fully the appropriate strategy for development and Regulatory Approval of Products, developing the
responsibilities of the Parties and the procedures for handling any and all regulatory issues related to Products and Product complaints, determining the Products for which Devices will be developed, and for development of Devices, including
clinical development through to the achievement of Regulatory Approval for Product in accordance with the Device Development Plan and for addressing all issues that develop during the course of the Product Development Program, provided that Lilly
may request that Antares undertake regulatory aspects of Device development as set forth in this Agreement. With respect to the ***, Lilly will manage, fund, and resource all activities within Lilly and with Third Persons including, but not limited
to, working with a Third Person design firm to optimize device ergonomics, functionality, and robustness of the Device, and consult with such Third Person design firm regarding clinical trials, regulatory submissions, and marketing activities.
Further, Lilly shall have responsibility for obtaining and maintaining (including, without limitation, satisfying regulatory reporting obligations) all necessary Regulatory Approvals required to conduct the activities contemplated by this Agreement
and to commercialize Product. Lilly, or its sublicensees, shall hold legal title to any and all Regulatory Approvals related to the use of Devices in the Field, as well as any equivalents of such items in countries within the Territory. Lilly shall
assume full responsibility for the clinical protocols to be developed pursuant to and in support of such applications. 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of
this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 (c) Antares’ Responsibilities. Antares shall be responsible for arranging and leading a
meeting with *** to discuss the development and *** of an initial Product, and preparation of a *** development plan for use in such meeting as specifically provided in Section 8.1 hereof. At Lilly’s request, Antares shall be responsible for
(i) redesign of the *** for the ***, such that the life of a *** shall meet or exceed the total days of therapy for a ***, assumed to be ***, (ii) activities associated with manufacturing, manufacturing development, and tooling development, (iii)
regulatory matters relating to the Device, including prosecution of appropriate regulatory applications, (iv) cooperating with Lilly in the investigation and handling of Product complaints, and (v) assisting Lilly with the redesign and optimization
of the *** for *** and to improve ***. 
  
 2.4 Development
Expenses. Except as expressly provided in this Agreement, each Party shall be responsible for all expenses related to its activities under the Agreement unless otherwise provided in the Device Development Plan. Lilly intends to fund
manufacturing development and tooling expenses with the understanding that tooling paid for by Lilly will be owned by Lilly. In addition, Lilly only intends to fund Antares’ portion of the manufacturing development expenses to the extent such
expenses were previously agreed to by the Parties in the Device Development Plan. Antares shall provide technical advice, consulting and other information as Lilly may reasonably request. Lilly shall pay Antares for such manufacturing development
expenses, including Antares Device Development Costs, on a quarterly basis in arrears for the expenses accumulated by Antares during the previous Calendar Quarter. Antares shall submit an invoice for such expenditures to Lilly within fifteen (15)
days after the end of such Calendar Quarter, and Lilly shall pay such invoices net forty-five (45) days after Lilly’s receipt of the invoice. 
  
 2.5 Antares FTEs. Lilly agrees to pay Antares for work performed by Antares under the Device Development Plan according to the FTE rate set forth
in Section 1.40 of this Agreement. 
  
 (a) Antares FTE
Funding. Within fifteen (15) days following the end of each Calendar Quarter, Antares shall provide Lilly with a report and invoice detailing the actual time spent by Antares personnel (including a breakdown of the names of each employee working
on the Product Development Program and the number of hours billed on the Product Development Program by each employee, along with a brief description of the work performed) during such Calendar Quarter. Such information will be 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
provided for each Device Development Plan. Lilly, or its representatives, shall have the right to audit (with financial and scientific representatives)
Antares’ records with respect to such reports, in accordance with Section 11.2 of this Agreement. Lilly shall be entitled to any tax credits due on account of research and development expenses, to the extent permitted by law, for such payments
made by Lilly to Antares under this Section 2.5 of this Agreement. 
  
 (b) Payments. Lilly shall make the payments due under this Section 2.5 on a Calendar Quarter basis due to Antares net forty-five (45) days after Lilly’s receipt of the invoice and report as described in Section 2.5(a) above.

  
 2.6 Transfer of Antares Know-How. As soon as reasonably
practicable, and to the extent reasonably necessary or useful to facilitate Lilly’s furtherance of its responsibilities under the Product Development Program, Antares shall furnish all Antares Know-How to Lilly that is in Antares’
possession, including, without limitation, and to the extent legally permissible, transferring possession and legal ownership to all appropriate Regulatory Materials submitted by Antares to the FDA or other Regulatory Authorities outside the U.S.
related to the use of Devices in the Field, if any, and shall cause any subcontractor used by Antares to provide services hereunder to transfer possession and legal ownership to all such Regulatory Materials, if any, except for legal title to
Regulatory Materials submitted by Antares to Regulatory Authorities prior to the Effective Date, and legal title to DHFs and DMFs related to the Device, and the *** outside the Field, owned by Antares, if any, which shall be handled in accordance
with Section 4.1 of this Agreement. 
  
 ARTICLE 3

 GOVERNANCE AND ADMINISTRATIVE MATTERS 
  
 3.1 Joint Coordination Team. No later than forty-five (45) days after the Effective Date, the Parties shall form a Joint Coordination Team for the
Product Development Program. The Joint Coordination Team shall be responsible for overall direction and management of the Product Development Program. The operation and authority of the Joint Coordination Team shall be as follows: 
  
 (a) Responsibilities. The primary objectives of the Joint
Coordination Team shall include the preparation, modification (if 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
appropriate) and implementation of one or more development plans to address fully, consistent with the terms of this Agreement, the key elements reasonably
necessary for the research, development, manufacture and clinical testing of Devices, and any formulation of a pharmaceutical compound specifically developed for use with a Device, through Regulatory Approval (each a “Device Development
Plan”). The Joint Coordination Team shall from time to time review and, if appropriate, recommend revisions to the Device Development Plan. The Joint Coordination Team also shall monitor the progress of the Product Development Program and
periodically review the results of the Product Development Program and make recommendations as appropriate. In addition, no later than ninety (90) days after the Effective Date, the Joint Coordination Team shall prepare and adopt the Safety
Information Document. 
  
 (b) Representation. Antares shall
appoint two (2) representatives and Lilly shall appoint three (3) representatives to serve on the Joint Coordination Team. The representatives of a Party may be changed from time to time at the discretion of each Party upon written notification by
the Party making such change to the other. 
  
 (c)
Meetings. The Joint Coordination Team shall meet from time to time as determined by the Joint Coordination Team members. It is expected that the Joint Coordination Team shall meet at least four (4) times per Calendar Year or as otherwise
agreed by the Joint Coordination Team members. Such meetings may be in person, via videoconference or via telephone conference at such times and places as are agreeable to the members of the Joint Coordination Team. Consultants and non-member
employees of the Parties may attend meetings of the Joint Coordination Team as required to further the Product Development Program. Minutes of all such meetings setting forth decisions of the Joint Coordination Team relative to the Product
Development Program will be prepared by the Party hosting the meeting. Such minutes will become official when agreed to by all members of the Joint Coordination Team. Each Party will bear all expenses associated with attendance of its employees and
consultants at such meetings. 
  
 (d) Decisions. Decisions
of the Joint Coordination Team shall be made by unanimous vote, with each Party having one vote regardless of its number of representatives on the Joint Coordination Team. If the Joint Coordination Team is unable to resolve any issue or dispute,
then the issue shall be referred to the President of Antares (or successor position), and the Vice President of Product/Process Development of Lilly (or successor position) 

 
for further discussion and resolution and, thereafter, if any matter arising under, and consistent with, the terms of this Agreement remains unresolved,
Lilly shall have the final decision-making authority with respect to such matter. 
  
 3.2 Quarterly Status Report. During the Product Development Program, each Party shall provide the Joint Coordination Team with a quarterly status report that generally summarizes research and development
efforts conducted by such Party under the Product Development Program during such Calendar Quarter at issue. Such report shall include, without limitation, a general summary of important events and/or milestones achieved, personnel changes, learning
points and other matters that the Joint Coordination Team may deem appropriate. 
  
 3.3 Subcontracting Permitted. The Parties acknowledge and agree that portions of the work involved in the Product Development Program may be performed on behalf of the Party responsible for such work thereunder
by Third Persons provided that the Joint Coordination Team shall have previously approved using such Third Person.  
  
 3.4 Meeting Expenses. Each Party will be responsible for its expenses associated with the attendance of its employees and consultants at meetings
related to the activities contemplated by this Agreement. 
  
 ARTICLE 4 
 REGULATORY 
  
 4.1 Regulatory Filings. As of the Effective Date, and pursuant to the terms of this Agreement, Lilly will assume responsibility for all regulatory
filings related to Products, and Lilly shall be responsible for preparing, filing and maintaining the Regulatory Material relating to Product as set forth below. Lilly shall own all Regulatory Material relating to the *** in the Field and any future
Devices, including but not limited to variants of ***, developed under the terms of this Agreement.  
  
 (a) Preparation, Maintenance and Ownership. Lilly, or its sublicensees, shall be responsible for the preparation of any Regulatory Materials,
including regulatory filings and/or suitable applications required in order to conduct clinical trials and achieve Regulatory Approval (including, without limitation, achievement of marketing approval) for the Product and 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
shall be the owner and party of record for all such Regulatory Materials, including, to the extent permitted by Applicable Laws, all C.E. Markings for
Devices and/or Products. Lilly shall have the right to request that Antares take responsibility for preparation of any Regulatory Materials required to conduct clinical trials to obtain valid scientific evidence to support a determination that there
is reasonable assurance that the Device is safe and effective for its conditions of use and is approved for marketing. Antares will have the right to compensation for such services. Lilly, or its sublicensees, shall further be responsible for
managing all interactions regarding such Regulatory Materials with all Regulatory Authorities in the Territory. Antares shall cooperate with Lilly as Lilly reasonably requires in preparing such Regulatory Materials or in managing such interactions
with Regulatory Authorities. Lilly, or its sublicensees, shall determine those countries of the Territory where marketing is intended. Upon reasonable request to Lilly, Antares shall have a right of access to such Regulatory Materials, as long as
Antares has contributed thereto and Lilly has a right to redact its Confidential Information. 
  
 (b) Access to Device Files. After the Effective Date, Lilly shall own the DMFs and DHFs related to the *** in the Field. With respect to any DMFs and DHFs of Antares related to the Device, including the ***
outside the Field, for so long as the licenses granted to Lilly hereunder remain in full force and effect, Antares hereby grants to Lilly access to, and a right of reference to, such DMFs and DHFs. For the avoidance of doubt, Lilly’s right to
access such DMFs and DHFs shall include Lilly’s right to incorporate information otherwise contained in Antares’ DMFs and DHFs into any Lilly regulatory submission or Regulatory Material submitted to a Regulatory Authority in the Territory
pursuant to the terms of this Agreement.. 
  
 4.2 Quality
Assurance Audit. Lilly, at its own expense, shall have the right to conduct quality assurance audits with respect to all facilities, operations, and laboratories where work under this Agreement is conducted by Antares, or on its behalf by
subcontractors, (including, without limitation, work conducted by Antares related to the Device Development Plan) and to verify Antares’ conformance with applicable cGMP, cGLP, cGCP, cQSRs and other regulatory requirements including, without
limitation, verifying appropriate inventory control and material accountability systems with respect to the Device. Such audits shall only be conducted upon reasonable notice during business hours. Antares shall make necessary changes as required by
such audit based on an action plan agreed to by the Parties. 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted
information intact has been filed separately with the Securities and Exchange Commission. 

 4.3 Adverse Event Reporting. During the Product Development Program and thereafter, Lilly will
report Adverse Events and Serious Adverse Events which occur during the development of Product to Antares and the relevant Regulatory Authorities promptly according to the applicable regulations. Antares will cooperate and provide Lilly with
all information and assistance necessary or desirable for Lilly to carry out and comply with any regulatory requirements of such Regulatory Authorities. In addition, Antares will report to Lilly Adverse Events and Serious Adverse Events which occur
during the development of the Product and, after Product Launch, Antares will report to Lilly Serious Adverse Events and spontaneously reported Adverse Events of which it becomes aware and has the right to disclose, as such events relate to the use
of Devices for other products, within two (2) working days of Antares’ initial receipt of such information, in order that Lilly can fulfill its obligations to the appropriate regulatory authorities. Finally, Antares will supply specially
formatted safety information to Lilly upon request, with reasonable notice, in order that Lilly can comply with FDA requirements for annual reports and safety updates. The specific details concerning the type of safety information, the appropriate
format for such safety information, and the process for exchange of such information will be developed by the Joint Coordination Committee consistent with the requirements of the then current Lilly adverse reporting policies and consistent with
those policies of the relevant Regulatory Authority (“Safety Information Document”). 
  
 4.4 Product Complaints. Antares shall refer any complaints (including medical complaints) which it receives concerning the Product to Lilly within forty-eight (48) hours of Antares’ receipt of such
complaint; provided that all complaints concerning suspected or actual Product tampering, contamination or mix-up (e.g., wrong ingredients) shall be delivered within twenty-four (24) hours of Antares’ receipt thereof. Antares shall not take any
further action in connection with any such complaints without the consent of Lilly, but shall cooperate in the investigation of any such complaints at the request of Lilly. 
  
 4.5. Regulatory Inspections. Antares shall promptly advise Lilly of any notice of regulatory inspection or other
regulatory action related to this Agreement or any Product and shall permit Lilly to be present during any inspection and to participate in the preparation of any response thereto. 

 ARTICLE 5 
 LICENSE 
  
 5.1
Exclusive License to Lilly. Antares hereby grants to Lilly a sole and exclusive license in the Territory, with a license to sublicense, under Antares Rights to develop, make, use, sell, offer for sale and import and export Devices and Products
in the Field; provided, however, such licenses shall be non-exclusive to the extent necessary to allow the pre-*** technology related distribution referenced in Article 13.1(d) and Section 8.7. Such licenses in practice may be limited for at least a
finite time period by the two issues expressly acknowledged by Lilly in Section 13.1(b) of this Agreement. Notwithstanding the foregoing exclusive license grant to Lilly, Antares shall retain during the Product Development Program nonexclusive
rights to Antares Rights described in this Section 5.1 but only to the extent useful or necessary to fulfill its obligations under the Product Development Program. 
  
 5.2 Assistance. Antares shall promptly provide Lilly with all Information included in Antares Rights, reasonably
useful or necessary for Lilly to exploit the exclusive licenses granted in Section 5.1 of this Agreement. Moreover, Antares shall provide Lilly with reasonable technical assistance in connection with such disclosure of Information. 
  
 5.3 Right to Intellectual Property. The Parties agree that all rights
and licenses granted under or pursuant to Article 5 and Article 12 of this Agreement are, and shall be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, as such section may be amended, licenses to rights to “intellectual
property” as defined in the Bankruptcy Code. The Parties agree that Lilly, as licensee of such rights, shall retain and may exercise all of its rights and elections under the Bankruptcy Code, including, without limitation, Section 365(n). The
Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Antares under the Bankruptcy Code, Lilly will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual
property and all embodiments of such intellectual property, which, if not already in Lilly’s possession, will be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon Lilly’s written request therefor,
unless Antares continues to perform all of its obligations under this Agreement or (b) if not delivered under clause (a) above, following the rejection of this Agreement by or on behalf of Antares upon written request therefor by Lilly. 

 

 ***-Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 5.4 Maintenance of Patent Rights. During the term of this Agreement, and absent express written
prior authorization from Lilly to the contrary, Antares shall further prosecute and/or maintain all Antares Patent Rights listed on Exhibit B. Upon request, Antares shall in a timely fashion provide Lilly with such information as Lilly reasonably
requests in order to allow Lilly to monitor the prosecution of such Antares Patent Rights. In addition, within thirty (30) days of the Effective Date, Antares shall record at the U.S. Patent and Trademark Office the exclusive licenses to Lilly with
respect to the Antares Patent Rights granted herein. A copy of such notice provision to be filed with the U.S. Patent and Trademark Office with respect to each of the patents and applications listed on Exhibit B is attached hereto as
Exhibit L. Antares further agrees to similarly record such notice for any future patents or applications that become part of the Antares Patent Rights. 
  

ARTICLE 6 
 *** OPTION

  
 *** Option. From the Effective Date of this
Agreement until one (1) year after the Effective Date, Lilly shall have an exclusive option to obtain a license under Antares Rights to develop *** for delivery through the Device outside the Field. Terms for such a license agreement shall include,
without limitation, the use of the Device for the field of treatment or prevention of ***. The terms of such license agreement will be subject to negotiation by the Parties, but such terms shall not in the aggregate be more favorable to Antares than
those terms contained herein. 
  
 ARTICLE 7 
 COMMERCIAL RIGHTS 
  
 7.1 Marketing and Commercialization. Subject to the terms described in this Agreement, Lilly shall have the sole right, at its own expense, to
obtain Regulatory Approval, and to market, sell, promote, distribute and otherwise commercialize Products in the Field, including, without limitation, preparation of promotional materials, direct-to-consumer advertising, samples, and sales
representatives, in each country in the Territory that Lilly elects to market the Product as Lilly may deem appropriate. Lilly shall control the marketing plans for Product in the Field, including, but not limited to, branding of Devices and
packaging materials 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
which, unless Lilly determines otherwise, shall be sold solely under Lilly trademarks, trade dress and logos. 
  
 7.2 Accessories. In the event that Antares develops accessories for
Devices including, without limitation, carrying cases, the licenses granted to Lilly pursuant to Article 5 of this Agreement shall be deemed to include such accessories, and the Parties shall negotiate in good faith the terms of a definitive
agreement governing Lilly’s purchase of such accessories from Antares. 
  
 ARTICLE 8 
 COMPENSATION TO ANTARES 
  
 8.1 Up-Front Payments. Lilly shall make an initial payment to Antares
in the amount of *** dollars ($***) within *** of the Effective Date of this Agreement. 
  
 In addition to the initial payment provided in the preceding sentence of this Section 8.1, Lilly shall make a non-refundable *** dollar ($***) payment to Antares if Lilly, in its sole discretion, decides to continue
development of the Product upon completion of a meeting between Antares, Lilly and *** to discuss a *** for the Product which shall include, without limitation, the *** required by *** for ***. Antares shall be primarily responsible for preparing
the *** and leading the discussion with ***. While the decision to continue development of the Product will be at Lilly’s sole discretion, it is anticipated that a positive decision by Lilly will be based at least in part upon acceptance in
principle by *** that the presented ***, or a reasonable variant of it, would meet ***. In the event of a positive decision by Lilly, which decision shall be made not later than *** following the meeting with *** referred to above, then payment of
the $*** referenced above will be made to Antares within *** of the date on which Lilly decides to continue development of the Product. 
  
 8.2 Royalties. 
  
 (a) Royalty Rates. Subject to the provisions of this Agreement, during the Royalty Period, Lilly (except to the extent previously paid by a
sublicensee thereof) shall pay Antares a royalty on Net Sales of Product in the Territory sold by Lilly or its sublicensee, as applicable, in accordance with the following: 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under
Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

	 Annual Product Net Sales (U.S. dollars/year)

	  	Royalty

	 The portion that is less than $***
	  	***%
	 The portion that is between $***- $***
	  	***%
	 The portion that is greater than $***
	  	***%

  
 (b) Royalty
Calculations. Royalties shall be calculated on a Product-by-Product and a Device-by-Device basis from the Net Sales of each individual Product. For example, royalties due on a *** Product administered via the *** shall be calculated distinctly
from royalties due on a *** Product administered via the *** (e.g., distinct Compounds). Also, for example, royalties due on an Obesity Product administered via the *** shall be calculated distinctly from royalties due on the same Obesity Product
administered via the next generation Device (e.g., distinct Devices). 
  
 The increments of the Annual Product Net Sales tiers set forth in Section 8.2(a) will be adjusted for the immediately preceding Calendar Year. Such tiers will be adjusted upward on a Calendar Year basis commencing January 1, 2004 (and on
January 1 of each year thereafter during the term of this Agreement) using the U.S. Consumer Price Index (U.S. Bureau of Labor Statistics for all urban consumers series ID CUUR0000 SA0 (Update: April 2002. equals 179.8). 
  
 (c) Multiple Patents. Royalties payable under this Section 8.2 will be
payable only once with respect to a particular sale of Product regardless of there being more than one Antares Patent Right applicable to such Product. 
  
 (d) Credit Against Future Royalties. In consideration of Lilly’s agreement to fund Antares’ manufacturing development and prototype
tooling costs as set forth in the Device Development Plan, Lilly shall be entitled to a credit against future royalties due Antares. The credit will equal the amount paid by Lilly for such manufacturing development and prototype tooling expenses
plus a *** annual interest rate of *** percent (***%). Such credit shall be applied at the rate of *** percent (***%) of future royalties due Antares by Lilly until the credit is fully utilized. 
  
 (e) Compulsory License. If in any country a Third Person obtains a
Compulsory License, then Lilly and/or Antares, as applicable, shall promptly notify the other Party, and the royalty payable by Lilly to Antares under the terms of this Agreement shall be reduced to zero (0) in that country as a result of
Lilly’s loss of exclusivity. 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 (f) Access to Third Person Rights. If, after the Effective Date, access to a Third Person’s
intellectual property rights becomes necessary, advantageous or reasonably useful to make, use, sell, offer for sale and/or import Product in the Field (“Third Person Rights”), Lilly shall have the right to acquire access to such Third
Person Rights via license or otherwise. Any decision to access such Third Person Rights will be discussed by the Joint Coordination Team. Upon acquisition of such Third Person Rights, fifty percent (50%) of the acquisition cost paid by Lilly
(i.e., 50% of all consideration paid by Lilly in connection with such acquisition including, without limitation, signing-fees, milestone payments and royalties) for access to Third Person Rights, via license or otherwise, shall be credited
against future royalties owed to Antares by Lilly under this Agreement, such credit to be applied at the rate of fifty percent (50%) of future royalties due Antares by Lilly until the credit is fully utilized. Any access to such Third Person Rights
shall be shared by the Parties (i.e., joint access). 
  
 (g) Current Royalty Obligations (as of Effective Date). Notwithstanding anything to the contrary in this Agreement (including, without limitation, Section 8.2(e)), both Parties acknowledge and hereby agree that each is solely
responsible for any and all royalty obligations that have accrued or may accrue in the future with respect to any agreements and/or arrangements that such Party may have agreed to prior to the Effective Date. 
  
 (h) Royalty Payments. Lilly shall pay royalties owed to Antares under
this Section 8.2 as follows: 
  
 (1) Duration
of Royalties Paid for Products. During the Royalty Period (such period being determined for each Product on an individual Product basis and country-by-country basis), royalty payments hereunder shall be paid by Lilly to Antares on Net Sales of
each Product for the particular country and Product at issue. 
  
 For the avoidance of doubt, upon expiration of the Royalty Period, with respect to a particular Product in a particular country, Lilly shall have no further obligation to pay royalties under the terms of this
Agreement. 
  
 (2) Payment Terms.
Royalty payments due Antares under this Section 8.2 will be paid by Lilly for Net Sales made by Lilly not later than ninety (90) days following the end of each Calendar Quarter 

 
and each such royalty payment shall be accompanied by a report in writing showing the Calendar Quarter for which such royalty payment applies on a
Product-by-Product and Device-by-Device basis, the amount of Net Sales during such Calendar Quarter for which a royalty payment is due on a country-by-country basis and the total royalty payment due. Notwithstanding the foregoing, with respect to
any sublicensee’s sales of Product, Lilly shall report its sublicensee’s Net Sales to Antares (and pay any royalties on such sublicensee’s Net Sales to Antares not previously paid by Lilly’s sublicensee) as of the next Calendar
Quarter payment from the time Lilly receives such information from its sublicensee. Antares or its representatives shall have the right to audit Lilly’s records with respect to such reports in accordance with Section 11.2 of this Agreement.

  
 8.3 Milestones. In addition to the royalty payments
provided in Section 8.2 above, Lilly shall make the following non-refundable milestone payments to Antares with respect to, but only with respect to, the first Diabetes Product, and the First Obesity Product, subject to the Failure Credit defined
below, within sixty (60) days following the first occurrence of each of the following events: 
  

	 Milestone Events

	  	Payment (U.S. Dollars)

	 ***
	  	$	***
	 ***
	  	$	***
	 ***
	  	$	***
	 ***
	  	$	***
	 ***
	  	$	***
	 ***
	  	$	***
	 Total Milestone Payments
	  	$	***

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 If after reaching any of the milestones listed above, the development of a Product is terminated, the milestones that
have already been paid by Lilly to Antares will be credited against future milestones due Antares (the “Failure Credit”) that are applicable to a subsequent Product in the Field. 
  
 Such milestone payments shall be made by Lilly to Antares only once for a Diabetes Product
and only once for an Obesity Product, regardless of how many times such milestones are reached by the Parties during the term of this Agreement. Under no circumstance shall Lilly make aggregate milestone payments to Antares under this Agreement in
excess of *** dollars ($***). For the avoidance of doubt, Lilly shall not make more than *** dollars ($***) in milestone payments for any Diabetes Product, or more than *** dollars ($***) for any Obesity Product. 
  
 The Parties agree that milestone payments are not, and shall not be deemed to
be, royalties for purposes of Section 365(n) of the U.S. Bankruptcy Code. 
  
 8.4 Currency of Payment/Exchange Rates. All payments to be made under this Agreement shall be made in U.S. Dollars. 
  
 8.5 Taxes. Any and all taxes levied on account of royalties or milestone payments accruing under this Article 8 shall be paid by Antares. If laws
or regulations require withholding of taxes, such taxes will be deducted by Lilly or its sublicensee from such remittable royalties or milestone payments and will be paid by Lilly or its sublicensee to the proper taxing authority. Proof of each
payment shall be sent to Antares within ninety (90) days following December 31st of each reporting year.  
  
 8.6 Status of Antares Patent Rights. Within 60 days after each Calendar Year-end, Antares shall provide Lilly with a report describing the status
of the Antares Patent Rights. Such report shall include, at a minimum, the patent country, patent and application numbers, filing date, issue date, expiration date and any other relevant information. Such report shall be mailed to: 
  

 ***-Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 Eli Lilly and Company 
 Attention: General Patent Counsel, D.C. 1104 and 
 Royalty Administration, D.C. 1064 
 Lilly Corporate Center 
 Indianapolis, IN 46285 
  
 8.7 Compensation Relating to MJ7. Notwithstanding any provision of
this Agreement to the contrary, Antares shall not be entitled to any royalty payment or other compensation from Lilly for any use of Lilly products in the MJ7, unless Lilly develops a Product that is specifically formulated and packaged, or packaged
for use with the MJ7. 
  
 Antares currently sells or causes to be
sold through distributors the MJ7 for use with insulin provided in conventional vials. Lilly acknowledges that Antares intends that promotion and sales of the MJ7 will continue by Antares during the term of this Agreement until it is determined that
the availability of an alternate Device as a product of this Agreement can be provided to patients currently dependent on the Antares MJ7, and that such a transition would not significantly negatively impact Antares revenue flow, at which time
Antares shall discontinue promotion of the MJ7. Antares will not enter into any agreement with any other pharmaceutical company to promote use of the MJ7 in the Field itself, or on behalf of itself by the use of a Third Person acting on behalf of
Antares, to enter into any agreement in the Field with a pharmaceutical company. 
  
 8.8 Warrants to Purchase Antares Common Stock. Concurrently with the execution of this Agreement, Antares has issued to Lilly certain warrants to purchase common stock of Antares by Lilly pursuant to the terms
of the Warrant Agreement of even date herewith. The Warrant Agreement is attached hereto as Exhibit G. 
  
 8.9 Registration of Common Stock. Concurrently with the execution of this Agreement, the Parties have executed a Registration of Rights Agreement,
of even date herewith, governing the registration of certain common stock of Antares to be issued to Lilly upon exercise of the warrants as provided in the Warrant Agreement. The Registration of Rights Agreement is attached hereto as Exhibit
H. 

 8.10 Antares Corporate Financing. 
  
 (a) Balance Sheet. Antares has previously furnished to Lilly its unaudited financial statements as at August 31,
2003. Such statements fairly present the financial position of Antares as at the date thereof and the results of its operations and statements of cash flow for the period then ended, subject to normal year end audit adjustments and recognizing that
the results of operations for interim periods are not necessarily indicative of Antares’ operations for any other periods. 
  
 (b) *** Concurrently with the execution of this Agreement, Antares has received letters from authorized representatives of *** (as defined in each such
letter) wherein the *** have agreed to ***. The *** are attached hereto as Exhibit I. 
  
 (c) Effect on Agreement. Notwithstanding the Effective Date of this Agreement, the Parties agree that this Agreement will not be effective, and Lilly shall not pay Antares the *** dollar ($***) initial payment
pursuant to the first paragraph of Section 8.1 of this Agreement, unless *** has been completed pursuant to such *** and evidence thereof provided to Lilly; and further, if the foregoing events have not been completed within two (2) days of the
Effective Date of this Agreement, Lilly may, at its sole option, declare this Agreement void. 
  
 8.11 No Surviving Royalties. For clarification, notwithstanding any applicable continuation of the licenses provided in Article 5 of this Agreement, Lilly shall have no further obligation to make royalty
payments following the expiration or termination of this Agreement. 
  
 ARTICLE 9 
 USE OUTSIDE FIELD 
  

If Antares, in the exercise of its sole discretion, uses or licenses to any Third Person any Joint Inventions outside of the Field, Antares shall pay to Lilly ten
percent (10%) of all revenue received from such use or licensing of any item incorporating such Joint Invention. To the extent any Device or Product distributed for sale by Lilly embodies a Sole Invention of Lilly, Lilly shall negotiate in good
faith the terms upon which Antares may obtain a non- 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
exclusive license under such Sole Invention for use outside the Field, which license shall in no event be available prior to such distribution by Lilly. In
the event Antares markets itself or licenses to any Third Person the right to market any Device for use outside the Field, Antares shall ensure that cosmetic or other changes are made to the Device such that the Device is readily distinguishable
from any Device marketed by Lilly. 
  
 ARTICLE 10

 SUPPLY OF DEVICES 
  
 10.1 Manufacturing of ***. Following the Effective Date of this Agreement, the Parties shall meet to discuss manufacturing arrangements
related to the ***. If the Parties agree that Antares shall be the supplier, or be responsible for the manufacture through a Third Person, of the ***, they shall enter into a mutually acceptable manufacturing agreement providing for manufacture and
supply of the *** (the “Manufacturing Agreement”). The Manufacturing Agreement shall include those terms set forth in Section 10.2 below, and such other terms as the Parties may agree. To the extent Antares utilizes any Third Person to
perform some or all of its obligations under the Manufacturing Agreement, such Third Person, and the terms upon which it shall provide services for Antares, shall be subject to approval by Lilly in its sole discretion. If Lilly elects not to have
the *** manufactured by or for Antares, and if such determination has not been based upon Lilly’s good faith belief that Antares or its designee is unable or unwilling to provide a reliable supply, then Lilly shall for a period of *** years
from the Effective Date pay to Antares a royalty of *** percent (***%) of Net Sales of Product in the Territory sold by Lilly or its sublicenses and not manufactured by or on behalf of Antares. This royalty shall be in addition to any royalty
payable pursuant to Section 8.2 of this Agreement, and is in lieu of any other compensation to Antares (i.e., the Device cost margins pursuant to Section 10.2(e) hereof) on account of Lilly’s decision not to have Product manufactured by or for
Antares. The royalty shall be payable quarterly in a manner consistent with Section 8.2(h)(2). Notwithstanding the foregoing, in no event shall the royalty payable by Lilly to Antares pursuant to Sections 10.1 and 8.2 hereof exceed *** percent
(***%) of Net Sales of Product. 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 In the event the Parties do not agree upon the terms upon which Antares will manufacture the *** for
Lilly, Lilly shall be free to manufacture the *** itself or through any Third Person Lilly may choose in its sole discretion. 
  
 In the event Lilly elects to commercialize any Device other than the ***, the provisions above shall apply to the manufacture of any such Device.

  
 10.2 Manufacturing Agreement. If the Parties agree that
Antares shall manufacture Devices for Lilly, or be responsible for manufacture of Devices for Lilly through a Third Person, the Manufacturing Agreement shall provide for the following terms, in addition to other terms typically included in
manufacturing agreements for devices in the medical device industry. 
  
 (a) Responsibilities of the Parties. At Lilly’s request, Antares will be responsible for Device manufacturing, and any portion of such Device manufacturing performed by Third Persons on Antares’
behalf, including, without limitation, activities such as maintaining the DHF and DMF, complaint investigation, and the oversight of production. Lilly will be responsible for manufacture of any Compound delivered by a Device. At Lilly’s
request, Antares will work with Lilly to integrate the Device and any Compound for commercial sale. Antares and Lilly will together identify appropriate Third Persons for various aspects of Device manufacturing. While it is anticipated that Antares
and Lilly will make any decision for such Third Person selection jointly, Lilly will have final decision-making authority regarding the use of a Third Person to manufacture any aspect of the Device, and Lilly shall have the right to specify the
final packaging for Product, including the combination of the components thereof. 
  
 (b) Development of MRD and QA. At the time of Product Launch, the Parties shall prepare and adopt the MRD. No later than six (6)
months after the Effective Date, the Parties shall prepare and adopt the QA. The Parties shall, at least annually, review the MRD and QA and shall modify it from time to time as necessary through issuance of a revised section signed on behalf of
each of the Parties by an authorized representative incorporating the modification and stating the effective date and revision number of the modification. 
  
 (c) Manufacturing. Subject to the terms and conditions of the Manufacturing Agreement, Antares, or the Third Person acting on

  

 ***-Denotes
portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission.

 (d) its behalf, will manufacture Devices for Lilly at the times and in the quantities set
forth by Lilly in purchase orders as more specifically provided in the Manufacturing Agreement. Antares, and the Third Person acting on its behalf, will ensure that each shipment of Devices: (i) will have been manufactured in accordance with the
specifications, cGMP, and cQSR, in effect at the time of Manufacture, (ii) will not be adulterated or misbranded within the meaning of the FD&C Act by Antares, the Third Person acting on its behalf, or their agents, and (iii) will not have been
manufactured or sold in violation of any Applicable Laws in any material respect. 
  
 (d) Manufacturing Decisions. Lilly shall have final decision-making authority with respect to any
manufacturing issue related to manufacture of Devices. 
  
 (e) Device Cost. As long as Antares is responsible for manufacturing the ***, the cost to Lilly of the *** will be as follows: 
  

	 	(i)	 	Cost of each power unit to Lilly will be Antares’ Fully Burdened Manufacturing Cost for the power unit (currently estimated at *** U.S. dollars ($***) less any Antares’
estimate of depreciation from capital investments if such capital investments are paid by Lilly) plus *** U.S. dollars ($***). 

  

	 	(ii)	 	Cost of each needle free syringe per unit to Lilly (assuming *** of life) will be Antares’ Fully Burdened Manufacturing Cost for the needle free syringe (currently estimated at
***less any Antares’ estimate of depreciation from capital investments if such capital investments are paid by Lilly) plus ***. 

  

	 	(iii)	 	Cost of each cartridge adapter unit to Lilly will be Antares’ Fully Burdened Manufacturing Cost for the cartridge adapter cost (currently estimated at *** less any
Antares’ estimate of depreciation from capital investments if such capital investments are paid by Lilly) plus ***. 

  
 Antares warrants that the costs to manufacture the *** listed above are best estimates based upon volume projections provided by Lilly of 
  

 ***-Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 
*** up to *** units per year. Any cost savings achievable with respect to the initial Device cost estimates will be shared *** by Antares and Lilly ***. Any
changes in the projected Device cost that could occur owing to factors including, but not limited to, increased raw material costs, labor costs, and shipping costs, will be discussed by the Joint Coordination Team. 
  
 The cost for the *** will be handled as described above. As
long as Antares is responsible for the manufacture of any other Device, the cost to Lilly will not exceed Antares’ Fully Burdened Manufacturing Costs plus *** percent (***%). 
  
 (f) Back-up Supplier. At Lilly’s request, Antares will qualify at least one back-up supplier for
each critical component of the Device as determined to be appropriate as part of the Device Development Plan. Lilly shall bear the cost associated with a second set of tooling for such back-up supplier, and other qualification costs associated
therewith. 
  
 (g) Most Favored
Supplier. The Device and/or components thereof shall be sold by Antares to Lilly at prices no less favorable to Lilly than the most favorable prices Antares offers to any Third Person for the supply of comparable devices and/or components
thereof for comparable volumes and terms, excluding any cost savings that Antares achieves as described in this Agreement. As part of the Manufacturing Agreement between Lilly and Antares, Lilly and Antares shall agree upon a mechanism to allow
Lilly, through a Third Person, to monitor Antares’ compliance with this clause. 
  
 (h) Capital Expenditures. It is anticipated that Lilly will fund certain tooling costs and may decide to fund other capital
expenditures with the understanding that any capital expenditures funded by Lilly shall be owned by Lilly and shall not be used for any purpose other than manufacture of Product for Lilly. Prior to any decision by Lilly not to fund certain capital
expenditures required to supply the Device, the matter which is the subject of such decision shall be discussed by the Joint Coordination Team. The cost of any capital expenditure not funded by Lilly shall be borne by Antares. If Lilly subsequently
manufactures any Device itself or through any Third Person, or if this Agreement expires as described in Section 19.1 hereof, or is terminated for any reason other than default by Antares pursuant to Section 19.3 hereof, Lilly shall pay to Antares
the amount 

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
of all capital expenditures made by Antares as approved by the Parties in the Device Development Plan as required to supply Devices, less any depreciation of
such capital investments that Lilly has previously paid as part of the cost of the Device as described in Section 10.2(e) of this Article 10; provided, however, that in no event shall Lilly pay Antares for such capital expenditures made by Antares
if Antares is deemed to be in Material Breach of this Agreement or if Lilly terminates Antares’ manufacturing obligations based upon the good faith belief that Antares or its designee is unable or unwilling to provide reliable supply.

  
 (i) Product Recall. Lilly, after
consultation with Antares, shall have the right and responsibility to determine whether Product must or should be recalled. Lilly shall also be responsible for managing such recalls and Antares will cooperate with Lilly as Lilly may reasonably
requests. Antares shall be responsible for all costs incurred due to a recall that are the result of the manufacture of the Device. Product recall costs incurred by Antares shall be specifically excluded from Antares Fully Burdened
Manufacturing Cost. 
  
 (j)
Subcontracting. To ensure that the quality of Product (and/or major components thereof) is maintained, the Parties agree that any subcontracting of the manufacture of Product (and/or major components thereof) by Antares is permissible only
provided such subcontract, and the business terms related thereto, are first preapproved in writing by Lilly. 
  
 (k) Alternative Suppliers. Lilly shall have the right at any time to qualify and utilize back-up or alternative suppliers of
Devices, including Lilly itself. Antares shall cooperate in such efforts by making available to any alternative supplier manufacturing documents, including but not limited to, standard operating procedures, manufacturing tickets, and quality control
and assurance documentation for manufacture of Devices and shall permit Lilly to have unrestricted access to Antares’ DMFs and DHFs and, if necessary, utilize any information in the DMFs and DHFs to manufacture, and obtain any regulatory
approval to manufacture, Product royalty-free. Should Lilly assume the manufacture of Product itself and/or utilize the services of a Third Person as described herein, Lilly shall bear all reasonable costs incurred by Antares related to any
technology transfer and manufacturing set-up by Antares necessary to 

 
enable Lilly or such Third Person to perform such manufacturing, but Antares shall not be entitled to any other compensation. 
  
 ARTICLE 11 
 RECORD-KEEPING AND AUDITS 
  
 11.1 Records Retention. The Parties shall keep complete and accurate records pertaining to the development, use and sale of Products in sufficient detail to permit the other Party to confirm, in the case of
Antares, its research, development and manufacturing efforts hereunder, and in the case of Lilly, its development and commercialization efforts, and the accuracy of calculations of all payments due hereunder. 
  
 11.2 Audit Request. Each of the Parties shall have the right to
request in writing an audit of the records described in Section 11.1, at its own expense, once on an annual basis, to determine, with respect to any of the two (2) preceding Calendar Years, the correctness of any report or payment made under this
Agreement. If a Party desires to audit such records, it shall utilize Lilly’s independent, certified public accountant (i.e., currently Ernst & Young LLP auditors), to examine financial records and may utilize an independent scientist
reasonably acceptable to the other Party to audit scientific records. Such accountant/scientist shall be instructed to provide the Party desiring the audit a report on the findings of the agreed upon procedures which verifies any previous report
made, payment submitted, or work performed by the audited Party during such period. The expense of such audit shall be borne by the auditing Party; provided, however, that if an error in favor of the auditing Party of more than ten percent (10%) is
discovered, then such expenses shall be paid by the audited Party. If the audit determines that additional amounts are owed to Antares, or that amounts were overpaid to Antares, during the audit period, Lilly shall pay Antares the additional amount
owed to Antares, or Antares shall pay Lilly the overpaid amount, within forty-five (45) days of the date on which the paying Party receives the audit report. Any Information received by a Party pursuant to this Section 11.2 shall be deemed to be
Confidential Information hereunder. 
  
 11.3 Survival. This
Article 11 shall survive any termination of this Agreement for a period of two (2) years. 

 ARTICLE 12 
 PROGRAM INTELLECTUAL PROPERTY 
  
 12.1 Ownership of Program Intellectual Property. Any and all information, data, items, material and knowledge including, without limitation, any and all suggestions, descriptions, ideas, inventions (whether or not patentable),
know-how, trade secrets, techniques, strategies, methods, syntheses, processes, practices, skills, experience, documents, apparatus, devices, chemical formulations, compounds, composition of matter, chemical samples, assays, screens, databases,
database structures and data analysis methods discovered, generated or developed within the scope and during the course of the Product Development Program solely by the employees or independent contractors of a Party (“Sole Invention”) or
jointly by employees or independent contractors of the Parties (“Joint Invention”, and collectively with “Sole Invention” referred to as “Program Intellectual Property”) shall be the property of the Parties as follows:

  
 (a) Program Intellectual Property Relating to
Compound. Program Intellectual Property that relates to Compound (e.g., including, without limitation, uses for Compound, methods or processes for manufacturing Compound, formulations applicable to Compound, analogs, derivatives, fragments,
mimetics, conjugates and any excipients thereof) shall be the sole property of Lilly. Antares hereby assigns all of its rights to such Program Intellectual Property to Lilly. 
  
 (b) Other Program Intellectual Property. The U.S. laws of inventorship shall govern the ownership of all other
Program Intellectual Property that is not assigned to Lilly pursuant to the ownership provisions of Sections 12.1(a) hereof. 
  
 (c) Trademarks and Logos. Lilly shall solely determine and own all logos, trademarks, tradedress or trade names used in connection with Devices
and/or Products in the Field. 
  
 12.2 Cooperation.
Each Party shall cooperate with the other in completing any patent applications relating to both Sole and Joint Inventions that will be owned by the other Party. Each Party shall also cooperate with the other in executing and delivering any
instrument required to assign, convey or transfer to such other Party its interest should such assignment, conveyance or transfer be required by the terms of this Agreement. 

 12.3 Ownership Review. No Party shall file a patent application on Program Intellectual Property
until ownership as described in Section 12.3 is reasonably determined by the Parties after such Parties have had a reasonable opportunity to review and discuss the particular Program Intellectual Property at issue. 
  
 12.4 Patent Filings. Each Party may, in the exercise of its sole
discretion and at its own cost, prepare, file, prosecute and/or maintain patent applications for its own Sole Inventions and shall be responsible for related interference proceedings. The Parties shall utilize an outside law firm acceptable to both
Parties to prepare, file, prosecute and/or maintain patent applications for Joint Inventions and shall be responsible for related interference proceedings. The Parties shall share equally the costs associated with the use of such outside law firm in
accordance with the terms of this Section 12.4. 
  
 Should any
Party not wish to file, prosecute, maintain or issue any patent application for a Joint Invention, or Antares not wish to prosecute, maintain or issue any other Antares Patent Rights, in any particular country, that Party, or Antares as the case may
be, will so notify the other Party, or Lilly as the case may be, of its intentions (“Discontinuance Election”). Upon receipt of such Discontinuance Election, the other Party, or Lilly as the case may be, may elect to have the right to
file, prosecute, maintain or issue any such patent or patent application at its own expense by providing written notice of the same within thirty (30) days of its receipt of the Discontinuance Election. Upon such election: (i) the discontinuing
Party shall grant the other Party any necessary authority to file, prosecute, issue and maintain such patent application and/or patent at issue; and (ii) shall assign such patent or patent application to the other Party. Until such assignment is
complete, the discontinuing Party shall take reasonable efforts to maintain or otherwise ensure that patent protection will not be lost with respect to such patent and/or patent application provided the other Party does not unreasonably delay the
assignment thereof. Finally, upon any such assignment by Antares, the patent and/or patent application at issue shall no longer be considered an Antares Patent Right. 
  
 12.5 Public Disclosure. Each Party agrees to make every reasonable effort to delay any public disclosure of the
subject matter of any patent application related to Program Intellectual Property of which it is aware until after the filing of such patent application. 

 ARTICLE 13 
 REPRESENTATIONS, AND WARRANTIES AND COVENANTS 
  
 13.1 Antares Representations. Antares hereby represents, warrants and covenants to Lilly as follows: 
  
 (a) Intellectual Property. Antares has the requisite legal and/or beneficial title and ownership under the Antares Rights, and including its
Intellectual Property Rights (defined below), necessary for it to fulfill its obligations under this Agreement, including, without limitation, the granting of the exclusive licenses in Article 5. There is no pending or threatened litigation,
arbitration, government proceeding, or government investigation (and Antares has not received any communication relating thereto) which alleges or would allege that Antares’ past activities, or activities proposed under this Agreement,
including, without limitation activities with respect to the Antares Patent Rights, infringe or misappropriate any of the Intellectual Property Rights of any Third Person. There is no Patent Right or other Intellectual Property Right of any Third
Person that would be infringed or misappropriated by this Agreement, including, without limitation Lilly’s activities under this Agreement with respect to developing, making, using, selling, offering for sale, importing or exporting Device and
Product. For purposes of this Section 13.1, the term “Intellectual Property Rights” means all intellectual property rights, including, without limitation all patent rights, copyrights, trademarks, trade secret rights and know-how rights.

  
 (b) No Prior License. Antares represents and warrants
that as of and prior to the Effective Date, it has not granted any license under Antares Rights to develop, make, use, sell, offer for sale and import and export Device and Product in the Field; provided, however, Lilly acknowledges that (a) Becton
Dickinson and Company jointly owns with Antares the Patent Rights for U.S. Patent Application Serial Nos. 08/773,660, 08/773,659, 60/094,163, and 60/094,167, and (b) until Antares modifies its *** with *** pursuant to Section 13.1(c) of this
Agreement, Lilly’s right to *** may be limited to ***, including, without limitation, ***, and ***. Lilly shall have no liability on account of amounts due to any Person under any agreements of Antares. Antares has previously provided to Lilly
true and correct copies of its agreements with Becton Dickinson and ***, redacted to delete certain information not relevant to the scope of the license. 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities
Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 (c) ***. Antares represents and warrants that within *** of the Effective Date, Antares shall (a)
*** with *** in writing the *** between Antares and *** effective ***, specifically including ***, to limit any and all *** to *** to being ***, as such term is defined in such ***, and (b) provide a true, unredacted copy of such *** to Lilly for
verification. Failure of Antares to comply with the terms of this provision shall be deemed a Material Breach of this Agreement by Antares. Upon request of Lilly, Antares shall provide to Lilly periodic updates of the status of Antares’
progress with respect to such foregoing events. 
  
 (d)
Exclusivity. During the term of this Agreement, Antares shall work exclusively with Lilly and shall not enter into commercial development and/or marketing agreements with Third Persons other than mere distributors for the Device in the Field.
Antares hereby represents that as of the Effective Date, it does not have a commercial development and/or marketing agreement with any Third Person for the Device in the Field, with the exception of the distribution agreements that are identified in
Exhibit K, which is complete and accurate in all respects. Antares shall have the right to replace or supplement such distributors of the MJ7 in the Field at its sole discretion provided that any such future distributor is merely a
distributor, and is not a pharmaceutical company or a biotechnology company. Failure of Antares to comply with the terms of this provision shall be deemed a Material Breach of this Agreement by Antares. 
  
 (e) Full Disclosures. Antares represents and warrants that it has
provided Lilly with all information that Lilly has requested for deciding the merits of entering into this Agreement and all information that, to the best of Antares’ knowledge, could be reasonably useful or necessary to enable Lilly to make an
informed decision regarding entering into this Agreement including, without limitation, all material information that potentially could have an impact on this Agreement and/or rights granted hereunder. 
  
 (f) Employee Obligations. Antares hereby represents and
warrants that all of its employees, officers and consultants who will work on the Product Development Program have legal obligations requiring, in the case of employees and officers, assignment to Antares of all inventions made during the course of,
and as a result of, their association with Antares and obligating the individual to maintain as confidential the confidential information of Antares, as well as the confidential information of a Third Person which Antares may receive. 
  

 ***-Denotes portions omitted
pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 (g) Compliance with Laws. Antares hereby represents and warrants that in carrying out its work
under the Product Development Program such work shall be carried out in compliance with any Applicable Laws including, without limitation, federal, state, or local laws, regulations, or guidelines governing the work at the site where such work is
being conducted. Moreover, Antares represents and warrants that in connection with carrying out its work under the Product Development Program, as applicable, based on the specific work to be conducted, it will carry out such work under the Product
Development Program in accordance with current cGLP, cGCP, cGMP and cQSRs. 
  
 (h) No Debarment. Antares hereby represents and warrants that it will comply at all times with the provisions of the Generic Drug Enforcement Act of 1992, and will upon request certify in writing to
Lilly that none of it, its employees, or any person providing services to Antares in connection with the collaboration contemplated by this Agreement have been debarred under the provisions of such Act. 
  
 13.2 Lilly Representations. Lilly hereby represents and warrants to
Antares as follows: 
  
 (a) Employee Obligations.
Lilly hereby represents and warrants that all of its employees, officers and consultants have legal obligations requiring, in the case of employees and officers, assignment to Lilly of all inventions made during the course of, and as a result of,
their association with Lilly, and obligating the individual to maintain as confidential the confidential information of Lilly, as well as the confidential information of a Third Person which Lilly may receive. 
  
 (b) Compliance with Laws. Lilly hereby represents and warrants
that in carrying out its work under the Product Development Program such work shall be carried out in compliance with any Applicable Laws including, without limitation, federal, state, or local laws, regulations, or guidelines governing the work at
the site where such work is being conducted. Moreover, Lilly represents and warrants that in connection with carrying out its work under the Product Development Program, as applicable based on the specific work to be conducted, it will carry out
such work under the Product Development Program in accordance with cGLP, cGCP, cGMP. 
  
 (c) No Debarment. Lilly hereby represents and warrants that it will comply at all times with the provisions of the Generic Drug Enforcement Act of 1992, and will upon request certify in writing to
Antares that neither 

 
it, nor its employees, or any person providing services to Lilly in connection with the collaboration contemplated by this Agreement have been debarred under
the provisions of such Act. 
  
 ARTICLE 14 
 INFRINGEMENT OF THIRD PERSON RIGHTS 
  
 14.1 Notice. If any activity relating to this Agreement, including, without limitation, the development, manufacture, use, sale, offer for sale or
import/export of Products results in a claim for patent infringement, the Party to this Agreement first having notice shall promptly notify the other Party in writing. The notice shall set forth the facts of the claim in reasonable detail.

  
 ARTICLE 15 
 INFRINGEMENT BY THIRD PERSONS 
  
 15.1 Notice. If any of the Antares Rights licensed under this Agreement (“Infringed Antares Rights”) is infringed and/or misappropriated
by a Third Person, the Party first having knowledge of such infringement/misappropriation shall promptly notify the other in writing. The notice shall set forth the facts of such infringement and/or misappropriation in reasonable detail. 

 
 15.2 Prosecution of Actions. 
  
 (a) Lilly shall have the primary right, but not the obligation, to institute,
prosecute and control any action or proceeding with respect to any infringement/misappropriation of any of the Infringed Antares Rights by counsel of its own choice. Antares shall cooperate with Lilly at Lilly’s request in the prosecution of
such action or proceeding. If Lilly reasonably determines that Antares is an indispensable party to the action, Antares hereby consents to be joined. In such event, Antares shall have the right to be represented in that action by counsel of its own
choice and at Antares’ expense. 
  
 (b) If Lilly fails to
bring an action or proceeding within a period of ninety (90) days after receiving written notice from Antares or otherwise having knowledge of such infringement/misappropriation of Infringed Antares Rights, Antares shall have the right to bring and
control any such action by counsel of its own choice and expense. If Antares reasonably 

 
determines that Lilly is an indispensable party to the action, Lilly hereby consents to be joined. In such event, Lilly shall have the right to be
represented in that action by counsel of its own choice and at Lilly’s expense. 
  
 (c) No settlement, consent judgment or other voluntary final disposition of a suit under this Section 15.2 may be entered into without the joint consent of Lilly and Antares (which consent shall not be unreasonably
withheld or delayed). 
  
 (d) If Lilly brings action, any damages
or other monetary awards recovered by Lilly shall be applied first to defray the reasonable costs and expenses incurred in the action by both Parties. If any balance remains, Lilly shall pay Antares an amount equal to ten percent (10%) of such
remaining balance. 
  
 (e) If Lilly fails to bring action and
Antares brings action, any damages or other monetary awards recovered by Antares shall be applied first to defray the reasonable costs and expenses incurred in the action by both Parties. If any balance remains, Antares shall pay Lilly an amount
equal to ten percent (10%) of such remaining balance. 
  
 15.3
Infringement of Antares Rights Outside Field. In the event that any Antares Rights that have application outside the Field are infringed and/or misappropriated outside the Field by a Third Person, the Party first having knowledge of such
infringement and/or misappropriation shall notify the other as set forth above and the Parties shall consult with each other as to how they should proceed, but each Party shall be free to pursue or protect its own respective interests to the extent
it is legally entitled to do so. Antares hereby agrees to use commercially reasonable efforts to diligently enforce such Antares Rights that have application outside the Field. 
  
 ARTICLE 16 
 MUTUAL INDEMNIFICATION 
  
 16.1 Responsibility
and Control. Lilly and Antares shall each be solely responsible for the safety of its own employees, agents, licensees or sublicensees with respect to Product development, manufacturing, marketing, selling and detailing the Products, and each
shall hold the other harmless with regard to any liability for damages or personal injuries resulting from acts of its respective employees or agents. 

 16.2 Antares’ Right to Indemnification. Lilly shall indemnify each of Antares, its successors
and assigns, and the directors, officers, employees, and agents thereof (the “Antares Indemnitees”), defend and hold each Antares Indemnitee harmless from and against any and all liabilities, damages, losses, settlements, claims, actions,
suits, penalties, fines, costs or expenses (including, without limitation reasonable attorneys’ fees) (any of the foregoing, “Damages”) incurred by or asserted against any Antares Indemnitee of whatever kind or nature, including,
without limitation, any claim or liability based upon negligence, warranty, strict liability, violation of government regulation or infringement of patent or other proprietary rights, but only to the extent arising from or occurring as a result of a
claim or demand made by a Third Person (a “Third Person Claim”) against any Antares Indemnitee because of (a) breach of any warranty made by Lilly pursuant to Section 13.2 hereof; (b) the safety or dosage of the Product, unless
attributable to an item identified in Section 16.3 below which is under the responsibility of Antares; (c) the distribution or detailing of any Product by or on behalf of Lilly or its sublicensees, or (d) any breach of this Agreement by Lilly,
except, in each such case, to the extent that such Damages are finally determined to have resulted from the negligence or misconduct of Antares. Antares shall promptly notify Lilly of any Third Person Claim upon becoming aware thereof, and shall
permit Lilly, at Lilly’s cost, to defend against such Third Person Claim and to control the defense and disposition (including, without limitation, all decisions to litigate, settle or appeal) of such claim, and shall cooperate in the defense
thereof. Antares may, at its option and expense, have its own counsel participate in any proceeding that is under the direction of Lilly and shall cooperate with Lilly and its insurer in the disposition of any such matter. 
  
 16.3 Lilly’s Right to Indemnification. Antares shall indemnify
each of Lilly, its successors and assigns, and the directors, officers, employees, and agents thereof (the “Lilly Indemnitees”), defend and hold each Lilly Indemnitee harmless from and against any and all Damages incurred by or asserted
against any Lilly Indemnitee of whatever kind or nature, including, without limitation, any claim or liability based upon negligence, warranty, strict liability, violation of government regulation or infringement of patent or other proprietary
rights, but only to the extent arising from or occurring as a result of a Third Person Claim against any Lilly Indemnitee because of (a) breach of any warranty made by Antares pursuant to Section 13.1 hereof; (b) any alleged defect in the design or
functionality of the Device; (c) the failure of Antares or its agents to manufacture, process, test or package Devices according to specifications; (d) the failure of Antares to knowingly fail to disclose any material information in Antares’
possession to Lilly regarding 

 
any Product; (e) the labeling, warehousing or distribution of a Product by Antares; (f) any allegation that the Device or any delivery system including the
Device violates patent or other proprietary rights of any Person; or (g) any breach of this Agreement by Antares, except, in each such case, to the extent that such Damages are finally determined to have resulted from the negligence or misconduct of
Lilly or a sublicensee of Lilly. Lilly shall promptly notify Antares of any Third Person Claim upon becoming aware thereof, and shall permit Antares at Antares’ cost to defend against such Third Person Claim and to control the defense and
disposition (including, without limitation, all decisions to litigate, settle or appeal) of such Third Person Claim and shall cooperate in the defense thereof. Lilly may, at its option and expense, have its own counsel participate in any proceeding
that is under the direction of Antares and will cooperate with Antares or its insurer in the disposition of any such matter. 
  
 ARTICLE 17 
 CONFIDENTIALITY

  
 17.1 Confidentiality; Exceptions. Unless otherwise
set forth in this Agreement, with respect to all Information disclosed or provided by, or on behalf of, either Party to the other or its designees in connection with this Agreement, whether provided orally, visually, electronically, in writing or in
any other form, (“Confidential Information”), the Party receiving such Confidential Information (“Recipient”) shall maintain the confidential and proprietary status of such Confidential Information, keep such Confidential
Information and each part thereof within its possession or under its control, use all its reasonable efforts to prevent the disclosure of any Confidential Information to any other person, and use all its reasonable efforts to ensure that such
Confidential Information is used only for those purposes specifically authorized by this Agreement. These mutual obligations of confidentiality shall apply until five (5) years following the later of expiration or termination of the Agreement, but
such obligations shall not apply to any Information to the extent that such Information is: 
  
 (a) independently developed by such Party outside the scope and not in violation of this Agreement, as evidenced by such Party’s contemporaneous written records; 
  
 (b) in the public domain at the time of its receipt or thereafter becomes
part of the public domain through no fault of or breach of this 

 
Agreement by the Recipient or by any person to whom the Recipient disclosed such Confidential Information; 
  
 (c) received without an obligation of confidentiality from a Third Person
having the right to disclose such information; or 
  
 (d) released
from the restrictions of this Section 17.1 by the express written consent of the disclosing Party. 
  
 Notwithstanding the provisions of Section 17.1 hereof, the Parties may, to the extent necessary, disclose and use Confidential Information (i) to secure
patent protection for an invention developed as a result of the Product Development Program or, to obtain regulatory clearance or institutional or government approval to clinically test or market Product, or (ii) as required by law, statute, rule or
court order to be disclosed (the disclosing Party shall, however, use reasonable efforts to obtain confidential treatment of any such disclosure, and consult with the other Party and permit the other Party to participate in seeking an appropriate
protective order). 
  
 17.2 Authorized Disclosures of
Confidential Information. 
  
 (a) Permitted Persons.
Each Party may disclose Confidential Information of the other Party, without such Party’s prior written consent, to its directors, employees, agents, consultants, permitted suppliers, and other person or entities (“Permitted Person”)
who need to know such Confidential Information to assist the Party in fulfilling its obligations or exploiting its rights hereunder. As a result of Antares non-performance of its obligations under this Agreement, Lilly may disclose such Confidential
Information to Third Persons as necessary for such Third Person to perform such obligations of Antares, provided Lilly ensures that such Third Person is bound by an appropriate confidentiality agreement prior to disclosure of Confidential
Information. The Party making such disclosure shall be responsible for any confidentiality breaches of this Agreement by any Permitted Person to the same extent as if the confidentiality breach was made by the Party. 
  
 (b) Legally Required or Necessary. Each Party may also disclose the
Confidential Information of the other Party, without such Party’s prior written consent, to any person, entity, or government or regulatory authority to the extent that the law requires such disclosure. 
  
 Notwithstanding the foregoing, prior to disclosing the other Party’s Confidential
Information under this Subsection, the disclosing Party, to the 

 
extent practicable, will give the other Party a copy of the Confidential Information to be disclosed and provide such Party a reasonable opportunity to
comment on the necessity and the text of the proposed disclosure. The disclosing Party agrees to consider such comments in good faith and to reasonably avail itself of available means under the applicable law to minimize the disclosure of such
Confidential Information. 
  
 (c) Court Orders. Each Party
may also disclose the Confidential Information of the other Party, without such Party’s prior written consent, pursuant to an order of a Regulatory Authority or court of competent jurisdiction, provided that it promptly notifies the other Party
of the required disclosure in order to provide such Party an opportunity to take legal action to prevent or limit such disclosure and, if asked, reasonably assists the other Party in pursuing such action. 
  
 (d) Legal Actions. Each Party may also disclose the Confidential
Information of the other Party, without such Party’s prior written consent, as is necessary to pursue or defend against a legal or regulatory action by one Party against the other with respect to this Agreement. A Party disclosing the other
Party’s Confidential Information, pursuant to this Subsection, will use reasonable efforts to minimize the disclosure of the other Party’s Confidential Information, including, without limitation, by seeking to file pleadings under seal.

  
 ARTICLE 18 
 PUBLICITY 
  
 18.1 Disclosure of Agreement. Neither Party to this Agreement may release any information to any Third Person regarding the terms or existence of
this Agreement without the prior written consent of the other Party. This prohibition applies to press releases, educational and scientific conferences, promotional materials, governmental filings and discussions with public officials and the media.
Notwithstanding the foregoing, however, this provision does not apply to any internal publications, or disclosures regarding this Agreement or related information to regulatory agencies such as the U.S. Food and Drug Administration, Securities and
Exchange Commission, Federal Trade Commission and/or the Department of Justice which may be required by law, including requests for a copy of this Agreement or related information by tax authorities. Subject to the limitation set forth in the
immediately preceding sentence, if any Party to this Agreement determines a release of information regarding the existence or terms of this Agreement is 

 
required by law, that Party will notify the other Party as soon as practical and give as much detail as possible in relation to the disclosure required. The
Parties shall then cooperate with respect to deciding what information will actually be released. The Parties shall have the right to review and comment on any such information to be included in such governmental filing, including any redactions of
Confidential Information required by the governmental agency requiring the release of information. The Parties shall cooperate with respect to any filings under the Hart-Scott-Rodino Antitrust Improvements Act, 15 U.S.C. §18a et. seq.,
as appropriate. The Parties hereby agree that release of a press release upon complete execution of this Agreement is appropriate. Such press release shall not in any way mention the financial terms or the pharmaceutical compounds governed by this
Agreement. A copy of such press release is attached hereto as Exhibit J of this Agreement. 
  
 18.2 Terminations. Both Parties agree that if this Agreement is terminated, neither Party will disclose its reasons for not proceeding to
any Third Person without the express written consent of the other Party. 
  
 18.3 Publications. Except as otherwise provided in Section 18.1, neither Party shall disclose any information in the Field or derived under this Agreement to any Third Person without the prior written
consent of the other Party, and for information outside the Field, neither party shall disclose any information derived under this Agreement to any Third Person without the prior written consent of the other Party, such consent for information
outside the Field may not be unreasonably withheld. Furthermore, subject to and in addition to the consent requirement set forth above in this Section 18.3, each Party shall provide the other with an opportunity to review and comment upon any
proposed abstracts, manuscripts or proposed presentations that relate to the Field at least sixty (60) days prior to their intended submission for publication and agrees, upon request, not to submit such an abstract or manuscript for publication
until the other Party is given a reasonable period of time to secure patent protection for any material in such publication which it believes to be patentable. 
  

ARTICLE 19 
 TERM AND TERMINATION

  
 19.1 Term. This Agreement shall commence as of the
Effective Date and, unless sooner terminated in whole or in part as specifically provided in 

 
this Agreement, shall continue in effect and will not expire until the earlier of either (i) fifteen (15) years or (ii) the date on which Lilly ceases to
develop or sell Product. Upon expiration of this Agreement by any means other than termination pursuant to Sections 19.2 and 19.3 below, Lilly shall have a non-exclusive license in the Territory, with a license to sublicense, under Antares Rights to
develop, make, use, sell, offer for sale and import and export Devices and Products in the Field, which licenses shall be irrevocable and royalty-free. 
  
 19.2 Termination By Lilly. 
  
 (a) Termination Right. Lilly may terminate this Agreement for any reason at any time provided Lilly furnishes Antares with forty-five (45) days
written notice of such termination. 
  
 (b) Consequences of
Termination under Section 19.2(a). In addition to the provisions set forth in Sections 19.4 and 19.5 below, in the event that Lilly terminates this Agreement pursuant to this Section 19.2, upon the effective date of such termination, the
following shall occur: 
  
 (1) License.
All of the licenses granted to Lilly under this Agreement shall convert to non-exclusive licenses, as applicable, and shall otherwise continue in full force and effect, except that such licenses shall be limited to any Product for which Lilly has
invested in its development under the Product Development Program. Such licenses shall survive the termination of this Agreement, shall be royalty-free, except as described below, and shall be irrevocable. Following the termination of this Agreement
pursuant to Section 19.2, but only until the *** year anniversary of the Effective Date, Lilly shall pay to Antares *** percent (***%) of the royalties that would be due Antares pursuant to Section 8.2, but for the termination of this Agreement
pursuant to Section 19.2. For the avoidance of doubt, if such termination occurs *** years after the Effective Date, then no royalties shall be payable by Lilly. If Antares decides that it desires to manufacture Devices for Lilly following
termination of this Agreement under this Section 19.2, it shall submit a request to Lilly for consideration. If the Parties agree that Antares will manufacture Devices, the Parties shall negotiate in good faith the terms upon which Antares shall
manufacture, or have manufactured on its behalf, Devices for Lilly. The terms of any such manufacture and supply agreement shall be mutually acceptable to the Parties and include those terms set forth in Article 10 of this Agreement, in addition to

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 
other terms typically included in manufacturing and supply agreements for devices in the medical device industry. 
  
 (2) Access to Device-Specific Information. Lilly
shall, to the extent that it is legally entitled to do so, negotiate with Antares, in good faith the terms and conditions under which Lilly would provide Antares access to Information generated by Lilly specifically related to the Device in the
Field, (e.g., Device ergonomics and design information) (and shall cause any subcontractor used by Lilly to do the same), at a cost to be negotiated by the Parties, provided that the cost Antares pays to Lilly at least shall equal Lilly’s fully
burdened costs incurred in developing such Device-specific Information. 
  
 Notwithstanding the foregoing, if Lilly terminates this Agreement under this Section 19.2 because of Product safety concerns, or unacceptable clinical trial results, or if after the meeting with the FDA pursuant to Article 8.1 of this
Agreement, Lilly reasonably believes that Regulatory Approval of the Product is unlikely, or for any other significant technical failure as to the suitability of using Product in the Field (“Technical Failure”), Lilly shall be under no
obligation to provide access to Lilly’s Device-specific Information to Antares under this Section 19.2. 
  
 19.3 Termination for Default. This agreement may also be terminated as follows, (a) if either Party believes the other is in default of any of its
material obligations under this Agreement or the Manufacturing Agreement (“Material Breach”); (b) if a change occurs to Antares which Lilly reasonably believes leaves Antares unable to perform its obligations under this Agreement; (c) if
Antares is in breach or default under any financing arrangements; or (d) if Antares is declared insolvent or bankrupt by a court of competent jurisdiction, or a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by
Antares, or an involuntary petition for relief under the United States Bankruptcy Code is filed in a court of competent jurisdiction against Antares which is not dismissed within thirty (30) days of its filing, or Antares makes or executes any
assignment for the benefit of its creditors, either Party, or Lilly, as applicable, may give notice of such default to the other Party, which Party shall have forty-five (45) days in which to remedy such default. Such forty-five (45) day period
shall be extended, if such extension is agreed to by the Parties, in the case of a default not capable of being remedied in such forty-five (45) day period so long as the defaulting Party uses diligent efforts to remedy such default and is pursuing
a course of action that, if successful, will effect such a remedy. If any alleged default under this Section 19.3 is not remedied in the time period set forth above, the Party alleging such default shall refer the matter to the President 

 
of Antares (or successor position) and the Vice President of Product/Process Development of Lilly (or successor position) who shall meet and confer within
fifteen (15) days after notice from the nondefaulting Party of its desire for such a meeting. If the Parties are unable to resolve any dispute in such meeting, the nondefaulting Party may give notice of termination pursuant to this Section 19.3. In
the event of a dispute regarding royalty payments owing hereunder, all undisputed amounts shall be paid when due and the balance, if any, shall be paid promptly after settlement of the dispute. In addition to the foregoing, the following provisions
shall apply: 
  
 (a) Lilly’s Termination of
Agreement. If Lilly terminates this Agreement under this Section 19.3, the licenses granted to Lilly pursuant to this Agreement, including the exclusive licenses of the Antares Patent Rights, shall survive such termination, shall be
royalty-free, shall be irrevocable, and shall continue in full force and effect. In accordance with Section 19.5 of this Agreement, the remedy set forth in this Section 19.3(a) shall not be an exclusive remedy and, therefore, shall neither preclude
nor prejudice any other rights or remedies available to Lilly, including, without limitation, any rights and remedies that may be available under law or equity. 
  

(b) Antares’ Termination of Agreement. If Antares terminates this Agreement under this Section 19.3 because of Lilly’s Material
Breach, all license rights granted to Lilly under this Agreement shall terminate forthwith. In accordance with Section 19.5 of this Agreement, the remedy set forth in this Section 19.3(b) shall not be an exclusive remedy and, therefore, shall
neither preclude nor prejudice any other rights or remedies available to Antares as a result of Lilly’s Material Breach including, without limitation, any rights and remedies that may be available under law or equity. 
  
 19.4 Surviving Rights. Termination of this Agreement shall not
terminate Lilly’s obligation to pay all milestone payments, royalties and other payments that shall have accrued hereunder (including any milestone payments then accrued but not yet due under Section 8.3). The obligations of the Parties under
Article 5 (License), Article 6 (PTH Option), Article 9 (Payments to Lilly), Article 11 (Record-Keeping and Audits), Article 12 (Program Intellectual Property), Article 14 (Infringement of Third Person Rights), Article 16 (Mutual Indemnification),
Article 17 (Confidentiality), Article 19 (Termination), Section 8.8 (Warrant Agreement), Section 8.9 (Registration of Rights Agreement), and Section 8.11 (No Surviving Royalties), of this Agreement will survive the termination or expiration of this
Agreement. 

 19.5 Accrued Rights, Surviving Obligations. Termination, relinquishment or expiration of the
Agreement for any reason shall be without prejudice to any rights which shall have accrued to the benefit of either Party prior to (or as a result of, including, without limitation, rights available under law and equity) such termination,
relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement. 
  
 ARTICLE 20 
 MISCELLANEOUS 
  
 20.1 Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer or legal representative of the other Party for any purpose. Neither Party shall be entitled to enter into any contracts
in the name of, or on behalf of the other Party, nor shall either Party be entitled to pledge the credit of the other Party in any way or hold itself out as having the authority to do so. 
  
 20.2 Assignment. Except as otherwise provided herein, neither this Agreement nor any interest hereunder shall be
assignable by any Party without the prior written consent of the other (which consent shall not be unreasonably withheld); provided, however, that either Party may assign this Agreement to any wholly-owned subsidiary or to any successor by merger or
sale of substantially all of its business unit to which this Agreement relates in a manner such that the assignor (if it continues as a separate entity) shall remain liable and responsible for the performance and observance of all its duties and
obligations hereunder. This Agreement shall be binding upon the successors and permitted assignees of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns.
Any assignment not in accordance with this section shall be void. 
  
 20.3 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

  
 20.4 Force Majeure. Neither Party shall be liable to
the other for loss or damages or shall have any right to terminate this Agreement for any 

 
default or delay attributable to any force majeure event, including, but not limited to, acts of God, acts of government, war, fire, flood, earthquake,
terrorist acts, strike, labor dispute and the like, if the Party affected shall give prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby
disabled from performing for so long as it is so disabled and for sixty (60) days thereafter; provided, however, that such affected Party commences and continues to take reasonable and diligent actions to cure such cause. 
  
 20.5 Notices. All notices and other communications hereunder shall be
in writing and shall be deemed given if delivered personally or by facsimile transmission (receipt verified), telexed, mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the
Parties at the following addresses (or at such other address for a Party as shall be specified by like notice; provided, that notices of a change of address shall be effective only upon receipt thereof): 
  

	 If to Lilly, addressed to:
	 	 Eli Lilly and Company

	 	 	 Lilly Corporate Center

	 	 	 Indianapolis, Indiana 46285

	 	 	 Attn: General Counsel

		
	 If to Antares, addressed to:
	 	 Antares Pharma, Inc.

	 	 	 707 Eagleview Blvd., Suite 414

	 	 	 Exton, Pennsylvania 19341

	 	 	 Attn: Chief Executive Officer

  
 20.6 Amendment.
No amendment, modification or supplement of any provision of the Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
  
 20.7 Waiver. No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents
or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. 
  
 20.8 Counterparts. The Agreement may be executed simultaneously in two counterparts, either one of which need not contain the signature of 

 
more than one Party but both such counterparts taken together shall constitute one and the same agreement. 
  
 20.9 Descriptive Headings. The descriptive headings of this Agreement
are for convenience only, and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. 
  
 20.10 Governing Law. This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of New York, without
regard to its choice of law rules. 
  
 20.11 Severability.
Whenever possible, each provision of the Agreement will be interpreted in such manner as to be effective and valid under Applicable Law, but if any provision of the Agreement is held to be prohibited by or invalid under Applicable Law, such
provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of the Agreement. In the event of such invalidity, the Parties shall seek to agree on an alternative enforceable provision that
preserves the original purpose of this Agreement. 
  
 20.12
Entire Agreement of the Parties. This Agreement, including the Exhibits attached hereto, constitutes and contains the complete, final and exclusive understanding and agreement of the Parties hereto, and cancels and supersedes any and all prior
negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof. In the event there is a discrepancy between the Exhibits and the Agreement, the Agreement shall control.

  
 20.13 Jointly Prepared. This Agreement has been
prepared jointly by both Parties and shall not be strictly construed against either Party. 
  
 20.14 Limitation of Liability. No Party shall be liable to another for lost profits or for indirect, incidental, consequential or special damages, arising from or relating to any breach of this Agreement,
regardless of any notice of the possibility of such damages. Nothing in this section is intended to limit or restrict the indemnification rights or obligations of any Party. 
  
 20.15 Essential Personnel. Antares agrees to use reasonable efforts to retain personnel essential for the
Parties’ performance of this Agreement for the duration of this Agreement. Essential personnel shall include *** and *** from Antares. 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act
of 1934. A copy of this agreement with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 IN WITNESS WHEREOF, the Parties hereto have as of the Effective Date duly executed this Agreement.

  

	 ELI LILLY AND COMPANY
	 	 	 	 ANTARES PHARMA, INC.

					
	By:	 	 /s/    ROGER G.
HARRISON        

	 	 	 	By:	 	 /s/    JOHN C.
LECHLEITER        

	 Name:
	 	Roger G. Harrison	 	 	 	 Name:
	 	John C. Lechleiter
	 Title:
	 	Chief Executive Officer	 	 	 	 Title:
	 	Executive Vice President

 EXHIBIT A (Redacted in Entirety) 
 ANTARES FULLY BURDENED MANUFACTURING COST ESTIMATE 
  
 *** 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted
information intact has been filed separately with the Securities and Exchange Commission. 

 EXHIBIT B 
  
 ANTARES PATENTS 
  

	 Application

	 PLUNGER FOR NOZZLE ASSEMBLY

	 EP 97953437.7

	 Japan 10-529066

	 China 97181944.0

	
	 Application

	 MEDICAL INJECTOR AND MEDICAMENT LOADING SYSTEM FOR USE THERE WITH

	 US 09/692,487

	 EP 00976612.2

	 Japan 2001-532840

	 Canada 2,387,893

	 China 00814658.6

	 Australia 14358/01

	 India IN/PCT/2002/00585/CHE

	
	 Application.

	 ADMINISTRATION OF INSULIN BY JET INJECTION

	 US 10/219,757

	PCT/US02/026049
	
	 Patent/Application

	 PLUNGER FOR NOZZLE ASSEMBLY

	 US 5,921,967(Patent)

	 Taiwan NI-102209

	
	 Patent/Application

	 NOZZLE AND ADAPTER FOR LOADING MEDICAMENT INTO AN INJECTOR

	 US 5,769,138(Patent)

	 EP 97917716.9

	 Japan 9-535486

	 Taiwan NI-089822

	 China 97194934.4

	Korea 707827/98
	
	 Patent

	 COUPLING DEVICE FOR MEDIAL INJECTION SYSTEM

	 US 5,846,233

	
	 Patent

	 SAFETY MECHANISM FOR INJECTION DEVICES

	 US 5,865,795

	
	 Patent

	 INJECTION-ASSISTING PROBE FOR MEDICAL INJECTOR ASSEMBLY

	 US 6,309,371

 EXHIBIT C 
  
 MJ7 Device 
  
 *** 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted
information intact has been filed separately with the Securities and Exchange Commission. 

 EXHIBIT D 
  
 *** 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement
with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 EXHIBIT E 
  
 TABLE OF CONTENTS GUIDELINE FOR MRD 
  

	
	 I. Introductions

	
	 A. Explanation of Document

	
	 B. Purpose of Document

	
	 C. Implication on other Documents

	
	 II. Administration

	
	 A. Document modification requirements

	
	 B. Review and Revision Coordination

	
	 C. Abbreviations and Definitions

	
	 III. Primary contacts for the MRD

	
	 IV. Customer Satisfaction Measurement

	
	 A. Purpose

	
	 B. Expectations

	
	 C. Measurement

	
	 D. Communication / Meeting Process

	
	 V. Key Contacts (Direct and Support Personnel)

	
	 • Antares

	
	 • Name, Title, Phone, and Fax

	
	 • Lilly

	
	 • Name, Title, Phone, and Fax

	
	 VI. Organizational Charts

	
	 A. Antares including support group charts

	
	 B. Lilly including support group charts

	
	VII. Supply Chain Diagram (Physical flow of device, subassembly, and components including subcontracts as required)
	
	 VIII. Material Planning, Forecasting, and Inventory Policy

	
	 A. Product Identification Details

	
	 B. Itemized Bill of Material Details

	
	 C. Market Shelf Life

	
	 D. Production Planning

	
	 E. Capacity Planning

	
	 F. Inventory Commitments

	 a) Lilly

	 b) Antares

	
	 G. Manufacturing and Printed Material

	
	 IX. Shipping and Receiving of Finished Goods

	
	 A. Time and Location Details

	
	 B. Storage and Shipping Requirements

	
	 C. Temperature Monitoring Requirements

	
	 D. Receiving Requirements of Finished Goods

	
	 E. Shipping Package Design

	
	 F. Shipping Terms

	
	 X. Financial

	
	 A. Financial Flow Chart of Device

	
	 B. Final Device Invoicing Process

	
	 C. Financial Responsibility for Destroyed Materials

	
	 D. Receipt of Damaged Devices and Returns

	
	 E. Shipping Terms

	
	 Attachments/Appendix

	 Lilly Packing List (Example)

	 MRD Reason for Revision Log

	 MRD Signatures

	 MRD Distribution Process

	 MRD Change Control Process

	 Device Specifications

	 Transport Packaging Design and Notification

	 Receiving Requirements

 EXHIBIT F 
  
 TABLE OF CONTENTS GUIDELINE FOR QA 
  

		
	 1.
	  	 Quality Statement (Vision)

		
	 2.
	  	 Purpose

		
	 3.
	  	 Definitions

		
	 4.
	  	 Responsibilities

		
	 5.
	  	 Implication to Other Documents

		
	 6.
	  	 Reason for Revision

		
	 7.
	  	 Expectations

		
	 8.
	  	 Metrics

		
	 9.
	  	 Documenting Quality Responsibilities

		
	 10.
	  	 Organizational Charts

		
	 11.
	  	 Regulatory Compliance

		
	 12.
	  	 Quality Audits

		
	 	  	 (i) Internal

	 	  	 (ii) External

		
	 13.
	  	 Manufacturing Facilities

		
	 14.
	  	 Training/Qualification

		
	 15.
	  	 Notification of Regulatory Inspections

		
	 16.
	  	 Notification of Device Recalls

		
	 17.
	  	 Holder of Submissions

		
	 18.
	  	 Device Withdrawal

		
	 19.
	  	 Product Inquiries

		
	 20.
	  	 Certificate of Conformance/ Certificate of Analysis

		
	 21.
	  	 Analytical Methods

		
	 22.
	  	 Latent Defects

		
	 23.
	  	 Product Specifications

		
	 24.
	  	 Design Control

		
	 25.
	  	 Process Change and Validations

		
	 26.
	  	 Material Control / Traceability

		
	 27.
	  	 Storage Requirements

		
	 28.
	  	 Inspection / Testing

		
	 29.
	  	 Lot Documentation / Quality Records

		
	 30.
	  	 Equipment Calibration

		
	 31.
	  	 Corrective and Preventative Actions

		
	 32.
	  	 Documentation and Record Retention

		
	 33.
	  	 Labeling/Printed Packaging Materials

		
	 34.
	  	 Packaging Components

		
	 35.
	  	 Sample Retention

		
	 36.
	  	 Regulatory Update Process

		
	 37.
	  	 Sub-contracting

		
	 38.
	  	 Transportation/Storage

			
	 	 	 39.
	  	 Product Returns

			
	 	 	 40.
	  	 Sort / Rework

			
	 	 	 41.
	  	 Deviations

			
	 	 	 42.
	  	 Nonconforming or Rejected Material

			
	 	 	 43.
	  	 Device Complaint Handling

  
 Attachments/Appendix 

 EXHIBIT G 
  
 [form of Warrant Agreement] 

 EXHIBIT H 
  
 [form of Registration Rights Agreement] 

 EXHIBIT I 
  
 *** 
  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement
with the omitted information intact has been filed separately with the Securities and Exchange Commission. 

 EXHIBIT J 
  
 [form of press release] 

 EXHIBIT K 
 Distribution Agreements 
  

	1. Comar Cardio Technology
		
	Type of Contract:	  	International Distribution Agreement
	Products:	  	Medi-Jector Vision® (MJ7)
	Term of Contract:	  	*** from May 1, 2000. May be renewed for successive *** periods upon mutual agreement. Either party may terminate with 90 days’ notice.
	Field & Territory:	  	For the insulin diabetes market in Italy.
	
	2. Direct Trading
		
	Type of Contract:	  	International Distribution Agreement
	Products:	  	Medi-Jector Choice® (MJ6B) – Product discontinued
	Term of Contract:	  	*** from October 1, 1997. Automatically renews for additional *** periods if not terminated at least 60 days prior to the anniversary date. Can be terminated by mutual agreement,
or upon 30 days’ notice following the anniversary date if revised quotas and pricing cannot be agreed to.
	Field & Territory:	  	For the insulin diabetes market in the Czech Republic.
	
	3. Drugstore.com
		
	Type of Contract:	  	U.S. Distribution/Vendor Agreement – Internet sales
	Products:	  	Medi-Jector Vision® (MJ7).
	Term of Contract:	  	***
	Field & Territory:	  	For the administration of insulin in the U.S.
	
	 4. Diabetic Express (Care Services)

		
	Type of Contract:	  	U.S. fulfillment and distribution services
	Products:	  	Medi-Jector Vision® (MJ7) and all currently marketed replacement supplies
	Term of Contract:	  	*** from March 14, 2001. Automatically renews for additional *** periods until terminated. Either party may terminate with 30 days’ notice.

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

	Field & Territory:	  	For the insulin diabetes market in the U.S.
	
	5. SciGen
		
	Type of Contract:	  	Non-Exclusive International Distribution Agreement
	Products:	  	Medi-Jector Vision® (MJ7).
	Term of Contract:	  	*** from October 1, 2001. May be renewed for successive *** periods upon mutual agreement..
	Field & Territory:	  	For the insulin diabetes market in Australia, Bangladesh, Brunei, Cambodia, China, Hong Kong, India, Indonesia, Laos, Malaysia, Myanmar, New Zealand, Pakistan, The Philippines,
Singapore, South Korea, Thailand, Taiwan, and Vietnam.
	
	6. McKesson Corporation
		
	Type of Contract:	  	Buying Terms Regarding Distribution of Product
	Products:	  	Medi-Jector Vision® (MJ7)
	Term of Contract:	  	***
	Field & Territory:	  	For the insulin diabetes market in the U.S.

  

 ***-Denotes portions omitted pursuant to a request for confidentiality under Rule 24b-2 of the Securities Exchange Act of 1934. A copy of this agreement with the omitted information intact has been filed separately
with the Securities and Exchange Commission. 

 Exhibit L 
  
 Notice Provision 
  
 Antares Pharma and Eli Lilly and Company have entered into an exclusive license agreement for development and use of Antares Pharma’s needle-free drug delivery
technology in the fields of diabetes and obesity.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]